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to"describe"an"endophenotypic" gradient"between"healthy" controls," siblings"of"people"with"
MS"and"people"with"MS."Siblings"of"people"with"MS"are"at"increased"risk"of"developing"MS;"
this" is" thought" to" be" a" result" of" genetic" and" environmental" contributions." Epidemiological"









MS" risk" score" generated." Preliminary" studies" enabled" an" evaluation" of" the" potential"
association"between"selected"biomarkers"and"CSF"oligoclonal"bands."




trigger" for" clinically" apparent" disease." " The" findings" of" this" research" have" the" potential" to"






































































































































































































































































































































































































































































































































































































































































































































Multiple" sclerosis" (MS)" is" the"most" common"nonZtraumatic" cause"of"neurological"disability"
affecting"young"people" in" the"developed"world" (1),"with"a"UK"prevalence"of"approximately"
0.4%"(MS"Society)."No"single"factor"appears"to"precipitate"the"development"of"MS;"instead"a"
complex" interplay" of" risk" factors" contributes" towards" overall" risk" (2)." Epidemiological" data"
implicates" both" genetic" and" environmental" factors" in" influencing" disease" development."
There"is"no"cure"for"MS,"and"treatment"is"centred"on"the"modification"of"disease"course."At"
present,"there"is"no"single"diagnostic"test"for"MS."The"diagnosis"is"based"on"clinical"findings,"
supported" by" paraclinical" tests." NonZimaging" biomarkers" are" of" limited" use" in" MS," with"
outcomes"in"clinical"trials"predominantly"based"around"clinical"or"imaging"findings.""
The" dogma" that" MS" results" from" environmental" influences" in" a" genetically" susceptible"
individual" is" a" popular" one." To" date," there" is" no" evidence" to" conclusively" contradict" this"
hypothesis,"and"a"number"of"potential"environmental"contributors"to"disease"development"






with" genetic" and" environmental" influences." It" provides" a" framework" through" which" the"
population"at"risk"of"a"complex"disease"can"be"described;"potentially"enabling"preventative"
studies." Identifying" and" studying" individuals" at" high" risk" of" developing" MS" provides" a"
powerful" opportunity" to" understand" the"MS" causal" cascade" and" is" highly" relevant" to" the"
development"of"strategies"to"prevent"this"chronic"disorder."The"endophenotype"is"a"concept"





variety" of" forms," including" neurophysiological," biochemical," cognitive" or" neuroanatomical."
One"key"feature"is"that"it"coZlocalises"with"the"disease"in"question."An"additional"feature"of"
an"endophenotype" is" that" it" is"more"common" in" the" siblings"of"people"with" the"disease" in"
question,"highlighting"the"genetic"underpinning"of"a"complex"trait."
Siblings"of"people"with"MS"have"an"increased"risk"of"developing"MS"(3)."However,"it"is"likely"






By"studying"the"unaffected"siblings"of"people"with"MS"within" this" framework," I"hope"to"be"
able" to" demonstrate" a" gradient" of" MS" risk." The" presence" of" cerebrospinal" fluid" (CSF)"
oligoclonal"bands"in"unaffected"siblings"would"provide"a"powerful"endophenotypic"maker"of"
disease" risk;" however" CSF" analysis" of" unaffected" siblings" could" not" be" performed" due" to"
ethical"constraints."As"part"of"this"work"it"was"therefore"important"to"examine"the"validity"of"
potential" biomarkers" in" a" group" of" patients" undergoing" lumbar" puncture," in" order" to"
ascertain"whether"there"was"a"suitable"surrogate"marker"for"CSF"oligoclonal"bands.""
The"validity"of" the"endophenotype"construct" in"MS"can"be"assessed"using"MRI."Unaffected"
siblings" can" be" assessed" for" radiological" abnormalities" in" keeping"with" demyelination;" i.e."




to" those" thought" to" be" at" low" risk," this" provides" powerful" evidence" in" support" of" the"
endophenotypic"gradient"in"MS."
This"thesis"therefore"sets"out"to"examine"the"validity"of"a"number"of"biomarkers"as"surrogate"
markers" for" CSF" oligoclonal" bands," and" then" attempts" to" both" define" and" validate" an" risk"
score"for"MS,"which"will" in"turn"be"examined"using"the"endophenotype"construct."Markers"
such"as"lesions"seen"on"T2"weighted"MRI"and"peripheral"markers"of"immune"activation"will"













be"used" in"both" the"diagnosis"and" longitudinal"monitoring"of"MS."Although"biomarkers"do"
not"necessarily"have"a"causal"relationship"with"the"disease"in"question,"they"often"reflect"the"
underlying" disease" pathogenesis" to" some" degree." In" complex" diseases" such" as" MS," a"
biomarker"may"represent"only"a"single"facet"of"disease"pathogenesis"(5).""
CSF"biomarkers"have"been"extensively"investigated"in"multiple"sclerosis."CSF"IgG"oligoclonal"
bands" (OCBs)" (figure" 2.1;" courtesy" of" Prof." G" Giovannoni)" represent" IgG" unique" to" the"
cerebrospinal" fluid" (CSF)," i.e."without"corresponding" IgG" in" the"serum."They"are"commonly"





using" additional" CSF" and/or" clinical" findings." OCBs" provide" evidence" of" intrathecal" IgG"




























pattern" of" oligoclonal" bands" (11)." Additionally," repeated" CSF" analysis" remains" an" invasive"
method" of"monitoring." Despite" improvements" in" lumbar" puncture"method" and" technique"
there"is"significant"resistance"from"patients"to"repeated"lumbar"puncture."The"absence"of"a"







The"precise"prevalence"of"OCB"positivity" in"MS" is"not"known."There"are"a" large"number"of"
studies" examining" this" as" either" a" primary" or" secondary" research" question." The" largest" of"




(and" negativity)" when" assessing" a" patient" with" a" clinically" isolated" syndrome" (CIS)." The"
presence" or" absence" of" OCBs" can" give" important" information" regarding" the" likelihood" of"







probability" of" that" patient" being"OCB"positive" (13)." The" reasons" behind" this" variability" are"
unclear,"and"this"finding"requires"replication."
Given"the"volume"of"literature"that"has"previously"been"published"surrounding"OCBs"and"MS"






Given" the" lack"of"precise" information"surrounding" the"prevalence"of"OCB" in"MS,"a"primary"
aim" was" to" calculate" the" most" accurate" estimate" of" OCB" prevalence" in" both"MS" and" CIS"
produced"to"date."Through"a"systematic"review"of"the"literature"and"a"metaZanalysis"of"the"
results"contained"within" this"domain," the"prevalence"of"OCBs" in"both"clinically"definite"MS"
and" CIS" are" clarified." The" relationship" between" OCB" positivity" and" MS" disease" type,"











sclerosis" and" OCBs”," “multiple" sclerosis" and" OCB”," “clinically" isolated" syndrome" and"
oligoclonal"bands”,"“clinically"isolated"syndrome"and"OCB”"and"“clinically"isolated"syndrome"
and" OCBs”" on" 22nd" October" 2012." The" resulting" abstracts" were" handZsearched" for"







as" IEF" with" immunofixation" was" not" in" widespread" use" before" this" time." In" order" to" be"
included," papers" had" to" include" CSF" data" on" a" minimum" of" 10" patients" with" either" MS,"
suspected" MS," or" CIS." Those" papers" that" specified" the" inclusion" of" patients" with"
neuromyelitis"optica"(NMO;"Devic’s"disease)"were"excluded."Studies"including"patients"with"
“Asian"opticoZspinal"MS”"were"not"excluded"from"the"initial"analysis,"as"this"diagnostic"entity"




technique" used" to" determine" OCBs" was" recorded." For" those" studies" initially" used" to"
determine" the" prevalence" of" OCB" in" MS," the" study" had" to" specify" that" OCBs" were"
determined"by"IEF"with"immunofixation;"studies"using"alternative"techniques"were"excluded"
from" this" main" analysis." A" supplementary" analysis" where" all" papers" were" included,"
regardless"of"method"of"OCB"detection"were" included"was"also"performed." " Those" studies"
that"used"a"small"number"(<20)"of"patients"with"the"primary"aim"of"comparing"methods"for"
detecting"OCBs"were"rejected"at"this"stage.""
In" order" to" be" included" in" the" prognosis" data" analysis," papers" had" to" give" data" regarding"
both"the"number"of"OCB"positive"and"negative"patients"who"met"a"preZdefined"clinical"end"
point."Data"regarding"all"end"points"were"gathered."Data" from"studies"using"all" techniques"







Prevalence," sensitivity" and" specificity," and" positive" and" negative" predictive" values" were"
calculated"using" standard" formulae." The" odds" ratio" (OR)" of" clinical" outcomes" according" to"
OCB" status" was" calculated" using" the" generic" inverse" variance" model" in" RevMan" 5.1"
(Cochrane"collaboration)."A"random"effects"model"was"applied"unless"I2"was"≤25%;"in"which"
case"a"fixed"effects"model"was"used"(15).""BetweenZstudy"heterogeneity"was"assessed"using"
Cochran's"Q"chiZsquare"test"and" I2" (16)."Bias"was"assessed"using"visual" inspection"of" funnel"
plots"and"quantified"using"an"Egger"pZvalue"(17)."
When" examining" clinical" outcomes," those" studies" using" IEF" with" immunofixation" were"
initially"studied"in"isolation."Studies"using"other"techniques"were"then"added"to"the"cohort"in"
order" to" increase" the"number"of"patients"analysed."Separate"analyses"were"performed" for"
MS"and"CIS."When"examining"outcomes"in"CIS"two"analyses"were"performed"–"one"with"all"
patients"with"CIS," and" a" subgroup"analysis" of" patients" presenting"with"optic" neuritis" (ON)."
Fisher’s" exact" test" was" used" to" compare" the" proportion" of" OCB" positive" and" negative"
patients"reaching"the"clinical"outcomes."Linear"regression"(modelled"using"PASW"v18"(SPSS))"







the" latitude" determined" using"Google"maps" (www.maps.google.com)."Where" samples" had"
been"taken"from"a"regional"or"national"cohort,"the"latitude"of"the"midpoint"of"that"country"
or" area" was" used" for" the" analysis." Papers" describing" samples" taken" from" international"
collaborations"were"excluded"from"this"analysis."MS"and"CIS"were"analysed"separately.""
A" linear" regression"model"was"used" for" this"analysis" (PASW"v18" (SPSS))."The"proportion"of"
CSF" samples" found" to" be" OCB" positive" were" regressed" on" the" population" latitude." The"
dependent" variable" was" the" proportion" of" OCB" positive" samples," and" the" independent"
variable"latitude,"and"the"contribution"of"latitude"to"the"equation"O:E)≈(latitude*X)+constant)









of" these" papers" were" then" hand" searched" for" papers" meeting" the" inclusion" criteria." 71"
articles"were"selected"for"inclusion"in"the"final"analysis"(see"supplementary"appendix"2)."The"
reasons"for"rejecting"papers"at"this"stage"were"varied,"but"most"commonly"included"papers"
that" selected" small" numbers" of" patients" for" methodological" studies" (n=58)," papers" that"







48" studies" were" used" to" assess" the" prevalence" of" OCB" in" MS" and" CIS," 36" were" used" to"
calculate"the"association"between"OCB"and"clinical"outcomes,"and"14"papers"gave"qualitative"
information" regarding" the" relationship" between" clinical" outcomes" and" OCB" status" (see"
supplementary"appendix"2)."Of"the"36"papers"used"to"calculate"outcomes,"18"used"IEF"with"
immunofixation,"in"12"the"technique"was"not"specified,"and"the"remaining"6"used"a"specified"













population" and" technique" used" to" detect" OCB," 16,678/19,773" MS" patients" were" OCB"
positive" (84.3%)." " A" conservative" analysis," where" only" those" papers" using" IEF" with"
immunofixation" were" included," and" all" papers" possibly" using" duplicate" cases" (i.e." those"
originating"from"the"same"centre)"and"the"Asian"studies"were"excluded"showed"5495/6118"
(89.8%)"patients"with"MS"were"OCB"positive."""
There"were"OCB"data"meeting"the" inclusion"criteria" in"a" total"of"2685"patients"with"CIS,"of"
whom"1841"were"OCB"positive"and"844"OCB"negative;"overall"68.6%"patients"with"CIS"were"
OCB" positive." There" were" no" studies" examining" OCBs" in" CIS" in" Asian" patients." When" all"
studies" were" included" regardless" of" technique," 3580/5154" (69.5%)" patients" were" OCB"





2.2.2.3. Relationship( between( oligoclonal( band( status( and( clinical(
outcomes(in(MS(
10"studies"gave"data"regarding"clinical"outcomes" in"patients"with"MS."Of" these,"4"used" IEF"
with"immunofixation"(21Z24)."In"all"of"the"studies"using"IEF"with"immunofixation,"expanded"
disability" status" score" (EDSS)" related" outcome" measures" were" used" to" define" clinical"
outcomes;" one"used" EDSS"of" 4" at" 10" years" disease"duration" (21)," two"used" EDSS"6"during"
follow"up"(22,"23),"and"one"an" increase"of"≥1"EDSS"point" in"5"years" (24)."When"the"results"
were" combined," 667/1764" (37.8%)" OCB" positive" patients" reached" the" specified" disability"
outcome"compared"to"42/154"(27.2%)"OCB"negative"patients"(p<0.0001,"Fisher’s"exact"test)."
When" the" metaZanalysis" was" performed" this" gave" an" odds" ratio" (OR)" of" reaching" the"
disability"outcome"of"1.96"(95%CI"1.31Z2.94;"p=0.001)"with"no"between"study"heterogeneity"
(I2=0%;"Χ2=2.95,"df=3,"p=0.40)"(figure"2.3)."There"was"no"significant"publication"bias"(Egger"pZ
value=0.12)." A" subgroup" analysis" of" the" two" studies" using" EDSS" 6" as" an" endpoint" (22," 23)"
















not" significantly"different" from"the" result"obtained"when"only" those" studies"using" IEF"with"
immunofixation"were"included.""
13"studies"gave"narrative"results"without"absolute"numbers."One"study"found"a"significantly"
lower" relapse" rate" in" OCB" negative" patients" (relapse" rate" 1.45±0.69" in" OCB" positive" and"







14" studies" examined" the" relationship" between" OCB" detected" by" IEF" with" immunofixation"
and"outcomes"in"CIS."2"of"these"studies"specified"ON"(33,"34),"and"one"a"brainstem"syndrome"
as" the" CIS" (35)." 12" studies" used" conversion" to" CDMS" as" the" outcome," 1" used" radiological"
conversion"to"MS"(33)"and"one"used"the"number"of"patients"reaching"EDSS"6"at"5"years"(13)."
The" study" using" EDSS" 6" as" the" outcome"measures" was" excluded" given" the" very" different"
outcome" measure," leaving" 13" studies" in" the" analysis" (see" supplementary" appendix" 2)."
733/1143"(64.1%)"OCB"positive"patients"converted"to"MS"compared"to"139/616"(22.6%)"OCB"
negative" patients" (p<0.0001," Fisher’s" exact" test)." This" gave" a" sensitivity" of" 0.84" and" a"




5.44Z17.94;" p<0.00001)" in" the" OCB" positive" patients" (figure" 2.4)." However" there" was"
significant"between"study"heterogeneity"(I2=71%;"Χ2=40.79,"df=12,"p<0.0001)."There"was"no"
evidence" of" publication" bias" (Egger" pZvalue=0.20)." Excluding" the" study" using" radiological"






When" all" of" the" studies" examining" the" relationship" between" OCB" and" conversion" to" MS"
(regardless"of"the"technique"used"to"detect"OCB)"were"considered"(an"additional"12"studies;"
see" supplementary" appendix" 2)," 973/1584" (61.4%)"OCB"positive" CIS" patients" converted" to"
MS"compared"to"173/927"(18.7%)"OCB"negative"CIS"patients"(p<0.0001,"Fisher’s"exact"test)."
This" gave" an" OR" of" conversion" to" MS" of" 9.99" (95%CI" 6.54Z15.27;" p<0.00001)" in" the" OCB"
positive" patients" (data" not" shown)." There" was" significant" between" study" heterogeneity"
(I2=57%;"Χ2=56.27,"df=24,"p=0.0002)"which"proved" impossible" to"eliminate."This" result"was"
not" significantly" different" from" that" obtained" when" only" those" studies" using" IEF" with"
immunofixation"were"used.""
Given" the" large" number" of" studies" examining" outcomes" in" optic" neuritis," a" subZgroup"









of" OCB" positive" patients" converting" to" CDMS" and" the" duration" of" follow" up" (using" linear"
regression," p=0.042," R2=0.1833)" (figure" 2.5)." However," when" only" those" studies" using" IEF"
with" immunofixation"were" included"this" relationship"was"no" longer"significant." It" therefore"
remains" unclear" if" all" OCB" positive" patients"would" convert" to" CDMS" if" followed" up" for" an"
infinite" amount" of" time." Additionally,"MRI" data" was" not" examined" as" a" covariable" in" this"
study." There" was" no" relationship" between" the" proportion" of" OCB" negative" patients"
converting"to"CDMS"and"the"duration"of"follow"up."Given"the"low"conversion"rate"in"the"OCB"











28" studies"with" data" on"OCB" in"MS"were" used" to" determine" the" effect" of" latitude" on" the"
proportion" of"MS" samples" positive" for" OCBs" (see" supplementary" appendix" 2)." Only" those"
studies"using" IEF"with" immunofixation"were" included" in" this" section"of" the"analysis." Linear"
regression"revealed"a"significant"relationship"between"OCB"positivity"and"latitude"(p=0.002,"
figure"2.6)"with"a"correlation"coefficient"(R2)"of"0.31."This"relationship"was"maintained"when"

















this" study" is"able" to" inform"clinicians" regarding" the"clinical" significance"of"OCBs" in"patients"
with"both"suspected"and"definite"MS."Just"under"90%"patients"with"MS"and"around"68%"CIS"
patients" are"OCB"positive." In"my"opinion," this" supports" the"hypothesis" that" “OCB"negative"
MS”"is"a"disease"entity"separate"to"the"majority"of"people"with"MS,"and"indeed"may"well"not"
represent" MS" as" we" pathologically" understand" it" at" the" present" time." The" increasing"
recognition" of" neuromyelitis" optica" (NMO)" as" a" separate" disease" to" MS," with" different"






actually" have"MS" remains" unclear." It" is" likely" that" at" least" some"of" these" patients"will" not"
actually" have" pathologically" definite"MS;" 95%" surveyed"US" neurologists" felt" that" they" had"
evaluated" a" misdiagnosed" patient" in" the" past" year" (36)." The" most" common" suspected"
alternative"diagnoses"included"nonspecific"white"matter"abnormalities"on"MRI,"small"vessel"
ischaemic" disease" and"migraine" (36)." All" of" these" conditions" can" cause"MRI" abnormalities"
that"may"be"mistaken" for"MS;" however"none" are" associated"with"CSF"OCB." Solomon"et" al"
(36)"argue"that"the"inappropriate"use"of"imaging"criteria"for"diagnosis"may"play"an"important"
role"in"misdiagnosis."Given"the"high"rate"of"OCB"positivity"in"this"metaZanalysis,"it"is"clear"that"






length" of" followZup" and" publication/reporting" bias" clouding" the" analysis."Whilst" the" initial"
analysis"would"suggest"that"those"patients"with"MS"who"are"OCB"positive"have"an"OR"of"1.96"
of" reaching" specified" disability" outcomes" at" followZup" compared" to" those" who" are" OCB"
negative," this"must"be"qualified"by"examining" the"studies"giving"narrative"negative" results."





a" clinical" diagnosis" of" MS" actually" have" MS." However," if" one" assumes" that" the" incorrect"
diagnosis"of"MS,"leading"to"a"diagnosis"of"“OCB"negative"MS”"is"one"of"the"major"causes"of"
OCB"negative"MS;"and"this" is" in" turn"dependent"on" the"prevalence"of"MS," then"this"would"
have"a"greater"effect"on"the"perceived"OCB"prevalence"in"those"countries"with"lower"rates"of"
MS."Thus"a"potential"factor"underlying"the"relationship"between"OCB"positivity"and"latitude"
would" be" a" higher" rate" of" MS" misdiagnosis" relative" to" absolute" MS" prevalence" in" those"
countries"where"MS"is"rarer.""
MS" severity" is" unlikely" to" underly" the" trend" in" OCB" positivity" rates" varying" with" latitude."
There" is"no"convincing"evidence"that"OCB"positive"MS"confers"a"worse"prognosis"than"OCB"
negative"MS"(if"such"an"entity"exists)"–"whilst"the"meta"analysis"suggested"that"this"might"be"







incidence," of" MS" varies" in" a" latitudinal" manner" (37)." The" reasons" for" this" difference" are"
unclear," but" may" reflect" changing" cultural" habits," including" attitudes" to" sunbathing" and"
sunscreen,"which"in"turn"affect"population"vitamin"D"levels"(37)."The"latitudinal"variation"in"
OCBs"may" therefore" reflect"a" shared"underlying"aetiology"with" the"variation" in"prevalence"
rates,"and"it"will"be"interesting"to"see"if"this"gradient"changes"or"disappears"altogether."""
Further"studies"are"therefore"required"in"order"to"determine"why"latitude"appears"to"affect"
OCB" status" in" this"way." The" relationship"between"OCB" status" and" clinical" outcomes" in"MS"
remains"unclear,"and"large"scale"prospective"studies"are"required"in"order"to"overcome"the"













Urine" provides" a" valuable" fluid" readily" available" for" serial" sampling" in" MS," but" it" is"
understudied" and" underutilised" (38)." Urine" has" the" distinct" advantage" of" being" easy" to"






been" extensively" studied" and" validated." The" reasons" behind" this" are" unclear;" concerns"
regarding" frequent"urinary" tract" infections" in"people"with"MS" limiting" the"utility"of"urinary"
markers"may"be"one"explanation."However,"with" the"ready"availability"of"bedside"tests" for"
urinary"tract"infection"(such"as"the"presence"of"nitrites),"samples"can"be"easily"evaluated"for"
evidence" of" asymptomatic" infection" prior" to" further" analysis." To" date" there" are" no"
longitudinal" studies"evaluating" the"use"of"urinary"biomarkers"as" surrogate"markers"against"
other" disease" outcome"measures" in" MS." There" remains" a" need" for" sensitive" and" reliable"
surrogate"markers"for"the"monitoring"of"disease"activity"in"MS,"and"it"may"well"be"that"the"
time"has"come"to"revisit"urine"as"a"potential"source"of"such"biomarkers."The"second"part"of"












have" been" shown" to" correlate" with" disability" progression" (42)." However," FLC" cannot" be"
detected" in" the" serum" of" people" with"MS" (43," 44)," either" as" a" result" of" dilution" or" rapid"
fractional"excretion"by"the"kidneys.""
It"has"been"known" for"many"years" that"FLC"are"present"at" increased"concentrations" in" the"
urine" of" people"with"MS" (41," 43," 45)," and" these" can"be" detected"with" either" a" spot" urine"
sample" or" 24Zhour" urine" collection" (43)." Urinary" FLC" are" significantly" increased" in" people"
with"clinically"isolated"syndrome,"relapsing"remitting"and"progressive"MS,"with"no"significant"
difference"between"these"groups"(41)."The"elevated"levels"of"urinary"FLC"seen"in"MS"are"not"
a" disease" specific" phenomenon;" levels" are" also" increased" in"HIV," rheumatoid" arthritis" and"
posterior"uveitis" (41)."There"does"appear" to"be"a"change" in"urinary"FLC" levels"with"disease"
modifying" treatment." When" urinary" FLC" were" determined" in" a" cohort" of" patients" with"
primary" progressive" multiple" sclerosis" participating" in" a" trial" of" interferonZβ" in" primary"
progressive"MS,"those"patients"who"completed"24"months"of"treatment"with"interferonZβ1a"
had"lower"urinary"FLC"at"15"and"24"months"than"those"receiving"placebo"(46)."There"was"a"
statistically" significant" relationship" between" percentage" change" in" spinal" cord" volume" and"
change"in"urinary"FLC"between"12Z24"months,"however"no"significant"relationships"between"
urinary"FLC"and"any"clinical"or"other"radiological"outcome"measures"were"determined"(46)."
To" date," the" presence" of" urinary" free" κ" and" λ" free" light" chains" has" not" been" studied" in"













Neopterin" is" a" product" of" interferonZγ" activated" macrophages" (47)," and" its" formation" is"
augmented" by" the" presence" of" TNFZα" (48)."Neopterin" has" been" extensively" studied" in" the"
context"of" systemic" infections,"HIV,"malignancies"and"autoimmunity" (49)." In"MS," increased"
neopterin"levels"have"been"found"in"the"CSF"(50Z52)"and"serum"(51)."Serum"neopterin"levels"
have" been" used" to" monitor" the" biological" effect" of" interferonZβ" (53," 54);" levels" peak"
approximately"2"days"postZdose" (54," 55)."No" studies"have"examined"a"possible" correlation"
between" CSF" and" urinary" neopterin" levels." A" correlation" has" not" been" found" in" other"
disorders,"although"in"these"studies"urine"concentration"was"not"controlled"for,"making"the"
results"difficult"to"interpret"(56).""
Neopterin" is"a"stable"compound"in"vivo,"which" is"excreted" in"the"urine."When"measured" in"
urine"it"should"be"expressed"as"a"ratio"to"creatinine"(or"total"protein)"in"order"to"control"for"
urine" concentration" (57)." It" can" be" measured" using" high" pressure" liquid" chromatography"







with" relapsing" remitting"MS," 218" μmol/l" (164–517)" in" secondary" progressive"MS" and" 187"




than" a" given" threshold" have" not" been" calculated." There" is" a" lack" of" specificity" in" raised"
urinary"neopterin"–" levels"rise" in"the"context"of"a"systemic" inflammatory"response,"such"as"
viral" infection" (57)." In" addition," neopterin" levels" show" increased" dayZtoZday" variability" in"
people" with"MS," which" is" thought" to" reflect" fluctuations" in" inflammatory" activity,"making"
single"readings"difficult"to"interpret"(57).""
As" individual" neopterin" levels" fluctuate" in" response" to" stimuli" such" as" infection" and"
inflammation," there" is" utility" in" repeated" measurements" in" the" context" of" MS." In" a"
longitudinal" study," 29/31" (94%)"MS" patients" demonstrated" increased" neopterin" excretion"
compared" to" healthy" controls" during" the" course" of" the" study" (57)" as" opposed" to" 39/106"
(37%)"when" levels"were"measured"at" a" single" time"point" in" a" crossZsectional" study" (60)."A"
possible" trend" for"people"with" secondary"progressive"MS" to"have"both"higher"mean"urine"
neopterin" and" greater" intraZpatient" variability" than" those"with" relapsing" remitting"MS" has"




MS,"and" this" increase"appears" to"be"of"a"greater"magnitude" than" the"“normal”"dayZtoZday"
variability"in"MS"(57)."However,"this"did"not"reach"statistical"significance"when"compared"to"
the"background"variability,"possibly"due"to"the"small"number"of"patients"that"had"a"clinical"
relapse" in" the" single" study" examining" this" relationship" (57)." There" was" no" correlation"











use," although" it" may" well" be" possible" to" overcome" these" through" repeated" sampling." In"
addition,"correlation"with"existing"clinical"and"MRI"outcome"measures"is"required,"together"









(61Z64)" and" serum" (62," 65)" of" people" with" MS." NO" is" neurotoxic," and" it" has" been"








expressing" levels" of" NO" metabolites" as" a" ratio" to" protein," urine" concentration" can" be"
controlled"for"(57).""
Urinary" NO" metabolites" are" significantly" elevated" in" people" with" MS" (60)" compared" to"
healthy"controls,"however,"they"are"also"elevated"in"patients"with"rheumatoid"arthritis"and"
HIV"(60)."There"is"no"significant"difference"in"urinary"NO"metabolites"between"different"MS"
















stable," small" protein" of" neuronal" origin" with" a" molecular" weight" of" 24.5kDa" (72)." UCHL1"
levels"are" increased" in"both" serum"and"CSF" following" traumatic"brain" injury" (73),"and" they"
correlate" with" both" severity" of" injury" and" long" term" outcomes" (73," 74)." CSF" UCHL1" is"
elevated"for"a"number"of"days"following"aneurysmal"subZarachnoid"haemorrhage"(72),"with"
dynamics"mirroring"those"of"CSF"heavy"chain"neurofilament"(NFh)."As"the"molecular"weight"
of"UCHL1" is" <30kDa," it" is" likely" to" be" freely" filtered" at" the" glomerulus;" hence" it" should" be"
detected" in"urine"when"serum" levels"are"elevated."However," there"have"been"no"previous"
attempts"to"detect"or"quantify"this"protein"in"the"urine.""
A"single"paper"has"examined"heavy"metal"excretion"in"MS"(75)."Urinary"iron"was"significantly"
higher" in"MS" than" controls." On" subgroup" analysis," people"with" secondary" progressive"MS"
had"significantly"higher"levels"of"urinary"aluminium"and"iron"than"controls,"however"patients"




lower" levels" of" silicon" excretion" in" MS" is" unknown," and" these" changes" have" not" been"
correlated" with" other" markers" of" disease" severity" (75)." These" findings" have" been" neither"
replicated"nor"refuted."






Elevated" serum" levels" of" β2Zmicroglobulin" are" thought" to" reflect" increased" lymphocyte"
turnover" (77)," and" β2Zmicroglobulin" can" be" detected" in" the" urine" using" ELISA" (78)." " Some"
have"found"elevated"CSF"(79)" levels"of"β2Zmicroglobulin" in"MS,"although"this"result"has"not"
been"consistently"replicated"(51,"80)."ILZ1,"ILZ2,"ILZ6"and"ILZ8"can"also"be"detected"in"the"urine"





















This" project" had" ethical" approval" from" the" Outer" North" London" Ethics" Committee" (Ref"
10/H0724/36)."Patients"(n=39)"were"recruited"from"the"Neurology"dayZcase"unit"at"the"Royal"
London" Hospital." Patients" who" were" undergoing" a" diagnostic" and/or" therapeutic" lumbar"
puncture" which" included" an" assessment" for" CSF" OCBs" as" part" of" their" routine" care" were"
approached" about" the" study." Patients" who" had" received" recent" (within" 3" months)"
corticosteroid"treatment"were"excluded"from"this"study."All"patients"who"had"OCBs"present"








the" same" day." All" samples" were" collected" in" sterile" containers" with" no" additives." Urine"
samples"were"assessed"for"the"presence"of"nitrites"(in"order"to"exclude"bacterial"infection)"at"
the"time"of"sampling."Samples"were"coded"and"anonymised,"divided"into"aliquots"and"stored"
at" Z80oc"on" the"day"of" sampling." Care"was" taken"not" to" expose" samples" to"direct" light" for"
































CSF" samples" were" assessed" for" the" presence" of" oligoclonal" bands" in" the" immunology"
department" at" the" Royal" London"Hospital" using" IEF"with" immunofixation" (figure" 2.1," page"
19)."κ"and"λ"FLC"levels"were"assessed"in"CSF"and"urine"using"a"commercially"available"ELISA"
(BioVendor," Brno" Czech" Republic)." The" assay" was" carried" out" to" the" manufacturers’"
instructions,"with"CSF"diluted"1:10"prior"to"the"assay."Neopterin"levels"were"measured"using"
a" commercially" available" ELISA" (IBL," Hamburg," Germany)" according" to" the"manufacturer’s"
instructions." Samples" had"not" been" exposed" to" light" for" prolonged"periods," and" the" assay"
was" performed" in" the" dark." " UCHL1" levels"were"measured" using" a" commercially" available"
ELISA"(USCN,"Wuhan"China)"without"prior"dilution"of"samples."""
Urinary" protein" and" creatinine" were"measured" using" commercially" available" kits" (protein:"
SigmaAldrich," St" Louis"MO"USA;" creatinine:" R+D" Systems,"Minneapolis" USA)." These" assays"
were" performed" according" to" the" manufacturers’" instructions." Urinary" FLC" levels" were"
expressed" as" a" ratio" to" total" protein," and"neopterin" and"UCHL1" as" a" ratio" to" creatinine" in"
order"to"correct"for"urine"concentration"and"glomerular"protein"loss.""
Protein"was"used" as" the" calibrator" for" FLC"primarily" because" FLC" are" themselves"proteins."
FLC"are"renally"excreted"as"22kDa"monomers,"44kDa"dimers,"as"fragments"or"as"multimers"–"
this" can" be" unpredictable" in" individual" patients" (81)." Whilst" the" immunoassay" has" been"
designed" to" measure" all" of" these" eventualities," the" forms" excreted" will" depend" on" the"
glomerular"filtration"to"various"protein"sizes"in"a"given"individual."This"variation"is"controlled"
for" by" measuring" total" protein" –" if" an" individual" has" heavy" proteinuria" they" would" be"
expected"to"excrete"increased"FLC"overall"compared"to"an"individual"with"normal"glomerular"











Statistical" analysis" was" performed" using" PASW" v18" (SPSS)." Variables" were" tested" for"
normality" using" a" ShapiroZWilk" test." Variables" which" were" not" normally" distributed" were"

















































CSF" FLC"were" higher" in" the"MS" group" (p<0.001)" (Figure" 3.1a)." There"was" no" difference" in"
urinary"FLC"between"the"MS"and"control"groups"(Figure"3.1b),"and"no"relationship"between"






















(correlation" coefficient=0.588," p=0.016;" borderline" significance" on" conservative" testing;"
Figure" 3.3a)." There"was" a" strong" correlation" between" CSF" λ" FLC" and" CSF" neopterin" in"MS"















There" was" a" strong" significant" correlation," maintained" on" conservative" testing," between"
urinary" neopterin:creatinine" levels" and" urinary" total" FLC:protein" levels" (correlation"
coefficient=0.452," p=0.004," Figure" 3.4)." This" relationship" was" also" seen" with" urinary" λ"
FLC:protein" (correlation" coefficient=0.419," p=0.009)." The" relationship" between" urinary"




















There"was" no" difference" in" CSF" or" urinary" neopterin" between" the"MS" and" control" groups"
(data" not" shown)." There" was" no" correlation" between" CSF" and" urinary" neopterin" overall,"
although" when" the" MS" cases" were" selected" there" was" a" trend" towards" a" significant"
















This" study" confirms" the" relationship" between" CSF" OCBs" and" CSF" FLC," indicating" the"




this" group." I"was"not"able" to" confirm"an" increase" in"urinary"FLC" in" the"OCB"positive"group"
(41)," indicating" that" urinary" FLC" are" not" a" suitable" surrogate"marker" for" CSF"OCBs." This" is"
potentially"due"to"the"large"difference"in"the"concentrations"of"FLC"between"the"CSF"and"the"
urine," indicating" a" significant" potential" dilutional" effect" during" FLC" excretion." The"
relationship" between" CSF" and" urinary" neopterin" levels" in" MS" was" not" significant" when" a"
Bonferroni"correction"was"applied."
Both" CSF" FLC" and" CSF" neopterin" have" previously" been" shown" to" be" increased" in" MS;"
however," no" correlation" between" the" levels" of" these" biomarkers" has" previously" been"
demonstrated."The"implication"of"this"finding"is"that"those"patients"with"higher" levels"of"BZ"
and"plasmaZcell" activity" in"MS"also"have"higher" levels"of"TZcell" activation."This" finding"may"
reflect"disease"activity"in"individual"patients,"or"possibly"reflect"disease"stage;"however"this"
study"was"not"of"sufficient"power"to"examine"this.""
The" low" levels"of"CSF"UCHL1"seen"may"reflect" the" fact" that" the"patients" in" this" study"have"
relatively" early" stage" disease." UCHL1" correlates" with" NFh" in" subZarachnoid" haemorrhage"
(72),"and"levels"of"NFh"are"increased"in"late"stage"RRMS"and"SPMS,"reflecting"chronic"axonal"
degeneration" (82)." Elevated" levels" of" tau" and" s100b" have" been" detected" in" the" CSF" and"




or" s100b," either" in" CSF" or" serum." Given" the" high"molecular" weight" of" neurofilament" (NFl"
68kDa"and"NFh"190Z210"kDa)," it" is"not" likely"to"be"filtered"at"the"glomerulus"and"therefore"
urinary"levels"are"unlikely"to"be"useful."The"control"group"was"a"rather"heterogeneous"group,"
all"of"whom"were"undergoing"a"lumbar"puncture"for"diagnostic"and/or"therapeutic"purposes."




CCL7," CCL8" and" interleukin1Zα" in" the" serum" (84)." Although" neopterin" has" not" been"
previously"studied"in"this"patient"group,"it"may"be"that"neopterin"levels"are"increased"in"IIH.""
The"finding"that"the"control"patients"in"this"study"had"higher"than"expected"urinary"FLC"and"




inflammatory" demyelinating" polyneuropathy" (CIDP;" included" in" the" control" group" for" this"















develop" biomarkers" for" practical" use" in" MS" and" better" our" understanding" of" MS"
pathogenesis."Whilst" the"evidence"produced" in"this"smallZscale"study"does"not"support"the"

















until" the" time" at" which" the" criteria" for" the" diagnosis" of" a" disease" are" met" (86)." The"
constellation" of" symptoms" in" a" prodrome" tend" to" be" nonspecific," especially" in" the" early"
stages" (86)." This" concept" overlaps" with" that" of" the" endophenotype," where" the" disease"
spectrum" is" extended" to" those" at" risk" of" disease" development," allowing" the" study" of" the"
trajectory" of" changes" in" the" disease" process" from" genetic" risk" factors" to" clinical" diagnosis"
(86)." " The"endophenotype" is" associated"with" illness" in" the"population," is"more" common" in"
family"members"and"manifests" in"an"individual"whether"or"not"disease"is"active"(87)." It"can"
take"a"variety"of"forms,"and"may"be"thought"of"as"a"disease"“trait”"in"the"broadest"sense"of"
the" word." Those" at" higher" risk" of" demonstrating" the" disease" endophenotype" are" those"
carrying"genetic"risk"factors"for"a"given"disease,"such"as"first"degree"relatives"of"patients"with"
the"disease.""
Can" the" concept" of" an" endophenotype" be" applied" to"MS?" The" diagnosis" of"MS" remains" a"
clinical"one," supported"by"paraclinical" findings," and" confirmed"after" the"exclusion"of"other"
diseases" (88)." The" majority" of" patients" with" MS" initially" present" with" a" CIS," defined" as" a"
distinct"first"neurological"event"of"demyelination"which"can"potentially"affect"any"part"of"the"







the" context" of"MRI" being" performed" for" the" investigation" of" headache" syndromes." Some"
patients"who" are" thought" to" have" a" RIS" show" subclinical" cognitive" impairment" in" keeping"
with"that"seen"in"early"MS"(91),"highlighting"the"potential"prodromal"nature"of"the"condition."
Approximately" twoZthirds"of" persons"with"RIS" show" radiological" progression"and"oneZthird"
develop" neurological" symptoms" during" mean" followZup" times" of" up" to" five" years" (91)." A"
further" feature" in" support" of" an"MS" endophenotype" is" the" fact" that"MS" is"more" common"
among"members"of" the"same"family."Even" if"siblings"of"people"do"not"meet" the"diagnostic"
criteria"for"MS,"they"often"display"clinically"silent"changes"associated"with"MS"(92,"93)."""
Further"possible"endophenotypic"changes"that"may"be"seen"in"the"context"of"MS"include"CSF"
oligoclonal" bands," and" peripheral" markers" of" immune" abnormalities" that" have" previously"
bee"associated"with"MS."However,"whilst"many"such"changes"have"been"studied" in"people"
with"MS"compared"to"healthy"controls,"their"study"as"part"of"an"endophenotypic"construct"
has"not"been"performed" to"date."Through" the"development"of"a" tool" to" calculate"MS" risk,"




to" those"eventually" causing" the" symptoms"of"MS"develop"over"a"number"of"years"prior" to"
the"initial"clinical"presentation."An"excellent"illustration"of"this"can"be"seen"in"patients"who"





disease"pathogenesis"and"development."Through"the"study"of" the"pathways" leading" to" the"








There" is" considerable"evidence" that"MS"occurs" in"a"genetically" susceptible"population."The"
importance"of"genetic"factors"in"susceptibility"to"MS"has"been"demonstrated"by"genetic"and"
epidemiological" studies" (94)." Studies" assessing" the" risk" of"MS" in" relatives" of"MS" probands"
have"revealed"a"marked"familial"aggregation"of"the"disease."First"degree"relatives"generally"










only" the"strength"of" the"genetic" relationship,"but"also" the"nature"of" this" relationship"–" the"
“parent" of" origin”" effect." Compared" to" maternal" halfZsiblings," paternal" halfZsiblings" of"
73"
"
patients" with" MS" appear" to" have" a" significantly" reduced" risk" of" MS" (2.35%" vs." 1.31%"
respectively)," whereas" in" full" siblings" the" risk" is" comparable" (2.35%" vs." 3.11%)" (98)." The"












other" genetic" locus" for" MS" was" conclusively" identified" using" this" technique," and" there"
remained"much" to"be" learnt"about" the"genetic"basis"of"MS."Extensive" studies"have" shown"













sequencing" of" the" human" genome" in" 2003" to" more" recent" largeZscale" genomeZwide"
association" studies" (GWAS)." GWAS" involve" genotyping" thousands" of" single" nucleotide"
polymorphisms" (SNPs)" across" the" genome" in" hundreds" (or" thousands)" of" subjects" with" a"
given" disease," comparing" them" to" matched" controls." Through" this" technology," the" entire"
genome" can" be" scanned" simultaneously," and" genetic" variants" influencing" disease" risk"
established."
The"first"GWAS"in"MS"was"performed"in"2007."The"International"Multiple"Sclerosis"Genetics"
Consortium" published" the" results" of" an" international" collaboration" identifying" 17" SNPs"
strongly" associated" with" MS" (101)," with" further" data" generated" in" the" same" year" by" the"
Wellcome"Trust"Case"Control"Consortium" (102)."Outside"of" the"HLAZDRB1*1501"allele," the"
relative"risks"conferred"by"the"risk"SNPs"identified"were"relatively"modest,"with"odds"ratios"
(OR)"in"the"region"of"1.1Z1.3"(101)."A"followZup"GWAS"in"2011"(103)"built"on"this,"validating"
23" of" the" nonZMHC" SNPs" identified" in" the" original" GWAS" as" contributing" to" MS" risk,"
identifying" a" further" 29" nonZMHC" SNPs" as" significant" additional" contributors," and" finding"
strong"associations"between"five"additional"SNPs"and"MS.""
Additional"studies"have" identified"rare"mutations"with" larger"effect"sizes" (104)."These"rare,"
low"frequency"variants"are"not"present"on"current"SNP"genotyping"arrays,"meaning"that"they"





number" of" possible" explanations" for" the" lack" of" replication;" firstly," the" initial" study" could"




require" sequencing" of" genomes" in" large" patient" numbers."Whilst" this" is" rapidly" becoming"
affordable,"the"yield"is"highly"dependent"on"the"minor"allele"frequency,"which"is"the"primary"
unknown"variable."
It" is" possible" that" epigenetic" changes" explain" some" of" the" discordance" in" MS" seen" in"
genetically"identical"monozygotic"twins."If"GWAS"were"fully"able"to"predict"MS"susceptibility,"














MS"is"more"common" in" females" than" in"males,"with"an"estimated"relative"risk" (RR)"of"2.62"
(111)."A" similar" influence"of" sex" is" apparent" in"both"CIS" and"RIS" (112)," indicating" that" sexZ
specific" factors" play" a" role" in"MS"disease" development" at" an" early" stage."However,"GWAS"
have"failed"to"provide"any"convincing"support"for"MS"risk"being"conferred"by"genes"present"





demonstrated" this" phenomenon" (37," 114);" however" they" have" not" been" able" to" shed" any"
light"on" the"underlying"aetiology"of" this"change."This"change" in" the"sex" ratio"has"not"been"
demonstrated" in" all" countries"with" such" largeZscale" population" registries" –" a" recent" study"
originating" from" Sweden" demonstrated" a" remarkably" stable" sex" ratio" over" time" (111).""
Conversely," a" dramatic" change" in" the" sex" ratio" of" MS" has" been" seen" in" Iran," with" an"
exponential"increase"in"MS"prevalence"in"females"compared"to"a"relatively"stable"prevalence"
in"males"(116)."
The" potential" reasons" underlying" the" increase" in" prevalence" in" females" seen" in" certain"
countries" remain" opaque." Much" has" been" made" of" possible" trends" involving" decreasing"










One" theory"has"been" that" changes" in" the" sex" ratio"of" smoking,"which"mirrors" that" seen" in"
MS,"could"be"responsible."However,"whilst"the"changing"sex"ratio"in"MS"is"primarily"driven"by"
increasing" rates" of" MS" in" women," the" change" in" smoking" ratio" is" primarily" driven" by"
decreasing"rates"of"smoking"in"men"(119)."It"may"be"that"there"were"previously"differential"
access"to"healthcare"services"between"males"and"females,"with"males"more"likely"to"present"
to" healthcare" systems" (120)," and" this" difference" may" have" been" especially" marked" with"








Within" regions" of" temperate" climate," MS" incidence" and" prevalence" increases" as" latitude"
increases" (121)." A" recent" metaZanalysis" demonstrated" a" significant" but" weak" association"
between"prevalence"and"latitude"(figure"4.4)"(r2=0.045;"p=0.018;"regression"coefficient"1.29"
per" 100,000" per" degree" latitude)" (37)." More" complex" patterns" of" disease" distribution" do"
however" exist." In" Norway" for" example," MS" prevalence" does" not" increase" with" latitude:"
prevalence" here" correlates" with" proximity" to" coastal" fishing" areas" and" subsequent" fish"











‘critical" age’" has" been" hypothesized:" immigrants"who"migrate" before" adolescence" acquire"
the" risk"of" their"new"country,"while" those"who"migrate"after" retain" the" risk"of" their"home"
country"(126)."The"influence"of"place"of"birth"is"highlighted"by"the"fact"that"first"generation"



















adults" who" have" not" been" infected" with" EBV;" the" relative" risk" of"MS" in" an" EBV" negative"
individual"is"very"low"(OR=0.07;"95%CI"0.03Z0.16)"(130)."Furthermore,"MS"has"been"observed"
to"occur"only"after"EBV" infection,"as"demonstrated"during" longitudinal" followZup"of"a" large"
cohort" of" EBVZnegative" young" adults" (131)." People"with" high" titres" of" antiZEBV" antibodies"
have"a"higher"risk"of"developing"MS"compared"to"subjects"with"low"titres"(132,"133)."There"
appears" to" be" a" temporal" relationship" –" plasma" antibody" titres" against" the" EBV" nuclear"
antigenZ1" (EBNAZ1)" increase" several" years"prior" to" the"clinical"onset"of"MS" (132,"133)."The"
risk"of"MS"associated"with"the"presence"of"antiZEBNAZ1"IgG"antibodies"is"dependent"on"the"
technique" used" for" antibody" detection" –" indirect" immunofluorescence" has" a" far" higher"
sensitivity"for"antibody"detection"than"the"more"widelyZused"ELISA"technique"(130).""
Further" supporting" a" role" for" EBV" in" MS" is" the" finding" that" individuals" with" a" history" of"
infectious"mononucleosis"(IM)"have"an"increased"risk"of"developing"MS."A"systematic"review"
and"metaZanalysis"of"14"caseZcontrol"and"cohort"studies"reported"a"combined"conservative"
relative" risk" of"MS" after" IM"of" 2.3" (95%"CI" 1.7Z3.0)" (134)." This" risk" has" subsequently" been"
confirmed"in"large"population"based"studies"(135,"136)."
Whether"or"not"EBV"genotype"influences"MS"risk"remains"an"unanswered"question."A"study"
of" genetic" variability" in" EBV" strains" between" MS" patients" and" controls" did" not" provide"
evidence" of" specific" EBV" strains" associated" with" MS," although" it" did" show" differing"
frequencies"of"single"nucleotide"polymorphisms"in"the"EBNAZ1"and"BRRF2"genes"(137)."EBV"
can"be" typed"as" type"1"or" type"2,"according" to"polymorphisms" in" the"EBNA2"gene."Recent"










Sunlight" exposure" and" associated" serum" 25Zhydroxyvitamin" D" levels" represent" a" possible"
explanation" for" the" link" between" latitude" and" the" risk" of" MS" (139)." Levels" of" past" sun"
exposure" are" inversely" related" to" MS" susceptibility" (adjusted" OR" for" high" summer" sun"
exposure" (2Z3" hours" per" day)" during" childhood" and" adolescence=0.31" (95%" CI" 0.16Z0.59)"
(140))."Questionnaire"based"studies"are"prone"to"recall"bias,"but"confirmation"of"an"effect"of"
sun"exposure"on"MS"risk"was"seen"when"examining"actinic"damage,"an"objective"measure"of"
sun"exposure."Greater"actinic"damage" is"associated"with"a"decreased" risk"of"MS" (OR=0.32,"
95%"CI=0.11"to"0.88"for"grades"4Z6"of"damage),"however"the"timing"of"damage"could"not"be"
accurately" determined" in" this" retrospective" study." Additional" evidence" has" demonstrated"












A" prospective" cohort" study" found" that" taking" vitamin" supplementation" which" included"
vitamin"D"was"associated"with"an"approximate"40%"reduction" in"the"risk"of"developing"MS"
(143),"but"the"amounts"of"vitamin"D"taken"are"thought"to"be"insufficient"to"significantly"alter"
circulating" vitamin" D" levels" (144)." Additionally," the" effects" of" multivitamin" intake"may" be"
confounded"by"behavioural"differences.""There"is"some"evidence"that"UV"exposure"may"have"
a" protective" effect" on" overall" MS" risk" independent" of" serum" 25Zhydroxyvitamin" D" levels"
(145,"146),"and"these"findings"deserve"further"attention.""
The"best" evidence" for" a" role" for" vitamin"D" comes" from"a"prospective," nested" caseZcontrol"
study" of"military" personnel" in" the"United" States"with" stored" serum" samples." This" showed"
that" a" lower" risk" of" MS" was" associated" with" high" serum" 25Zhydroxyvitamin" D" levels" at"
enrolment"(147)."It"may"be"that"there"is"an"additional"link"between"vitamin"D"levels"and"MS"
relapses."Vitamin"D" levels"have"been" inversely" linked" to"MRI"markers"of"MS"activity" (148),"
and" this" is" supported" by" a" similar" relationship" between" vitamin" D" levels" and" relapse" rate"
(149)."However,"consumption"of"vitamin"D"during" immune"activation"seen" in"relapses"may"
provide" an" explanation" for" this," in" terms" of" reverse" causality" (150)." A" large"metaZanalysis"
found"an"excess"of"hospital"events"related"to"MS"in"the"spring"months,"with"a"nadir"in"winter"


















Recently," attention" has" shifted" towards" studying" the" interaction" between"MS" risk" factors."
These"studies"have"yielded"considerable"effect" sizes,"with"MS" risk" factors"appearing" to"act"




The" interaction" between" specific" risk" factors" measured" in" this" study" will" be" discussed" in"
more" detail" in" section" 4.3.3." However," one" point" that" deserves" particular" attention" is" the"




specific" relationships" between" defined" genetic" markers" and" environmental" exposures."
Additionally,"the"population"size"that"would"need"to"be"studied"to"examine"the" interaction"
between"two"risk"factors,"both"of"which"confer"a"relatively"small"(i.e."OR"in"the"region"of"1.2)"
effect" on" disease" risk" requires" prohibitively" large" studies." It" has" not" proved" possible" to"





HLAZDRB1*1501" and" the" absence" of" HLAZA*02" to" adjust" MS" risk" (156)." The" inclusion" of"
environmental" factors" has" been" shown" to" improve" a" putative" MS" risk" score" –" when" 16"
88"
"
genetic" variants" were" considered" in" isolation" the" area" under" a" receiver" operating"
characteristic"curve"(ROC"curve)"was"0.64;"including"gender"in"the"model"improved"the"area"
under" the"curve" (AUC)" to"0.72"and"the" inclusion"of"both"smoking"and" IgG"titres"against"an"
EBNAZ1,"an"EBV"antigen,"further"improved"the"AUC"from"0.64"to"0.68"(157)."Similarly,"geneZ
gene" interactions"may"be"modified"by"environmental" factors–"the" interaction"between"the"
HLAZDRB1*1501" risk" allele" and" the" absence" of" the" HLAZA*02" protective" allele" is" only"
significant"in"smokers"(OR"of"MS"in"smokers"13.5);"however"in"nonZsmokers"the"interaction"
disappears"and"the"OR"is"a"more"modest"4.9"(158)."
The" environment" clearly" has" a" highly" influential" role" in" the" development" of"MS," and" this"
must" be" considered" in" terms" of" both" exposure" and" potential" influence" on" preZexisting"
genetic"risk"when"modelling"MS"susceptibility."The"ultimate"aim"is"not"necessarily"to"predict"
an" individual’s" risk"but" to" identify" highZrisk" cohorts" that"will" enable" the"MS" community" to"
design"and"test"prevention"trials"that"will"economically"viable"and"readZout"in"a"reasonable"
period" of" time."Whilst" this" study" is" not" designed" or" able" to"measure"MS" susceptibility" in"
terms"of"disease"development"over"longitudinal"follow"up,"it"is"able"to"provide"an"indication"








The" longstanding" dogma" is" that" MS" is" primarily" a" CD4+" TZcell" mediated" disease" (159)."
Different"subpopulations"of"CD4+"T"cells"with"a"characteristic"cytokine"profile"exist,"namely"
proZinflammatory"TH1,"T"helper"TH2"and"TH17"cells"(159)."It"was"traditionally"thought"that"TH1"







has" not" been" replicated" (166)." MyelinZreactive" TH17" cells" are" able" to" efficiently" secrete"
cytokines"and" induce"CNS" inflammation" in"EAE," the"animal"model"of"MS" (167)." ILZ17" levels"
are" higher" in" early" MS" (duration" <2" years)" than" later" disease" (168)." ILZ17" stimulates"
macrophages" to" produce" ILZ6," TNFZα" and" ILZ1β," which" have" been" implicated" in" MS"
pathogenesis"(169)."
Another"subpopulation"of"CD4+"cells,"CD4+CD25high"T"cells"(Tregs)"have"been"shown"to"play"a"
role" in" immune"homeostasis" in"MS"(170)."The"subgroup"of"CD4+/CD25+" "cells" that"are"Tregs"
(i.e." CD25high)" are" difficult" to" detect" due" to" problems" differentiating" CD25high" from"
CD25intermediate."The"transcription"factor"Forkhead"Box"P3"(FoxP3)"can"be"used"as"an"additional"
marker" to" identify" these" cells" –" they" are" defined" as" CD4+/CD25+/FoxP3+." There" is" no"











The" dogma" of" exclusive" T" cell" pathology" in"MS" has" been" challenged" in" recent" years." The"
























mediation" of" T" cell" responses," through" their" role" in" antigen" presentation," cytokine"
production" and" germinal" centre" formation" (179)" (figure" 4.6)." It" has" been" recognised" for"
many"years"that"B"cells"are"present"in"the"inflammatory"plaques"that"characterise"MS"(180),"
but" until" recently" they" were" not" thought" to" play" a" major" role" in" plaque" formation" and"
propagation." However" this" viewpoint" has" shifted," with" the" discovery" of" B" cell" follicleZlike"
structures" in" the" brains" of" people" with" late" stage" secondary" progressive" MS" (181," 182)."
These" structures" exhibited" some" features" of" germinal" centres;" however," whether" they"
represent"a"true"germinal"centre"reaction"remains"unclear.""
It" has" been" postulated" that" the" establishment" of" these" areas" with" proliferating" B" cells,"




cell" follicleZlike" structures"with" severe" cortical" pathology" and"an" aggressive" clinical" course,"
further"reinforcing"their"role"in"disease"progression"(177)."Grey"matter"damage"in"the"brains"
of"people"with"MS"consists"of"both"demyelination"and"axonal"degeneration"(184)."Although"









present" in" CNS" infections" and" other" CNS" localised" autoimmune" diseases" such" as"
paraneoplastic"CNS"syndromes"(186)."These"bands,"which"represent" IgG"unique"to"the"CSF,"
are" a" marker" of" intrathecal" BZ" and" plasma" cell" activity." It" has" been" shown" that" clonally"
expanded"plasma"cells,"which"can"be"found"in"MS"lesions"and"in"the"CSF"of"people"with"MS,"
are" likely" to" be" at" least" one" of" the" sources" of" the" clonal" IgG" forming"OCBs," although" it" is"

























Tregs," correlating" with" suppressive" (regulatory)" function" (198)." However," whether" this" is" a"
direct" effect" of" vitamin" D" on" the" Treg" population" (198)," or" an" indirect" effect" through" the"
generation" of" tolerogenic" dendritic" cells" (199)" remains" unclear." Interestingly," high" dose"
vitamin"D" supplementation" appears" to" have" an" effect" on" the" TZcell" populations" of" people"
with"MS"(200)."

















described." It" is" possible" that" there" is" a" critical" age" of" action" for" at" least" some" of" these"
dynamic"factors,"as"demonstrated"by"the"influence"of"age"of"migration"and"the"changing"risk"
of"MS"with"age.""
However," the"order" in"which" these" factors" act" to" increase" risk" is" uncertain." They" certainly"
interact"with"static"risk"factors."As"an"individual"acquires"dynamic"risk"factors"over"time,"the"
probability" of" developing" MS" increases," until" a" biological" threshold" is" reached," and"
demyelinating" pathology" becomes" inevitable." At" this" point" MRI" changes" in" keeping" with"
demyelination" appear" (the" RIS)." Favourable" and" unfavourable" disease" modifying" factors"




population" based" studies" have" been" performed" (147," 204)," however," these" have" not"





only"4%"healthy"controls" (p=0.02)" (92)."Asymptomatic"MRI"abnormalities" suggestive"of"MS"
are"seen" in"approximately"10%"siblings"of"people"with"MS"(93,"205)"compared"to"0.06%"of"
the" general" population" (206)." Preliminary" evidence" suggests" MS" risk" in" those" with" MRI"
evidence"of"demyelination"but"without"any"clinical"correlate"may"be"as"high"as"30Z45%"at"60"
months" (207," 208)." This" indicates" that" siblings" of" people" with" MS" do" indeed" have" some"
endophenotypic"markers,"and"are"therefore"a"valid"population"to"study"in"order"to"examine"
the"MS"endophenotype."
"If"we" can" act" to"modify" some" of" the" dynamic" risk" factors" at" an" early" enough" stage" –" i.e."
before"point"(2)" in"figure"4.7,"when"biological"disease"becomes"inevitable,"then"we"may"be"
















assumption" that" the" presence" of" CSF" OCB" in" this" group" would" be" associated" with" other"
features"suggestive"of"an"endophenotypic"trait.""




with"MS" (209)."Using" these" figures,"76" siblings"are" required" to"give"a"power"of"0.8"and"an"
alpha" of" 0.05" to" detect" a" difference" in" the" prevalence" of" the" endophenotypic" fingerprint"
(210)." If" the" prevalence" of" the" endophenotypic" fingerprint" in" siblings" is" reduced" to" 15%"
(again,"4%"in"healthy"controls)"then"111"siblings"are"required"to"give"a"power"of"0.8"and"an"
alpha" of" 0.05" using" standard" power" calculations" (210)." Drawing" on" data" published" in" the"
psychiatric" literature,"most" exploratory" endophenotypic" studies" enroll" 25Z100" participants"
with"an"equal"number"of"siblings"and"controls"(211)."""
Given"that"the"study"design"requires"only"a"single"visit"for"the"majority"of"participants,"there"
was" no" need" to" factor" dropZout" rates" into" the" power" calculation." Only" a" minority" of"












All" participants"were" recruited" according" to" ICHZGCP" guidelines," and"within" to" the" ethical"
permission" that"was"granted" (see" section"4.2.2)." Full" informed"consent"was" taken" from"all"
participants.""
Participants" were" recruited" from" a" variety" of" sources." People" with" MS" attending" the"MS"
outpatient" clinic" at" the" Royal" London"Hospital"were" approached" regarding" the" study," and"
given" brief" written" information" regarding" the" study" to" share" with" their" siblings," together"
with"the"contact"information"for"myself."If"both"the"person"with"MS"and"their"siblings"were"
interested" in" participating" they" were" then" sent" the" participant" information" sheet" (see"
supplementary" appendices" 3aZc)" and" invited" to" book" a" visit." Additionally," information"







Various" charities" also" participated" in" the" recruitment" drive" for" this" study." The"MS" Society"








invited" to"attend"either" together"or" separately."All" visits" followed"a" standardised"protocol;"








personal" data" was" pseudoanonymised" and" stored" in" an" encrypted" form." All" patients" and"
siblings"were" examined" neurologically," and" the" Expanded" Disability" Status" Scale" (EDSS)" of"
participants" with" MS" was" calculated." All" biological" samples" were" taken" using" universal"
precautions"and"pseudoanonymised"at"the"time"of"collection."Urine"samples"were"tested"for"
the"presence"of"nitrites"at" the" time"of" sampling"using"widely"available"urine"dipsticks,"and"








BD"green" top" lithium/plasma" tubes" (catalogue"no." 368480)." Samples"were" stored" at" room"
temperature"until"processing,"which"was"performed"on"the"same"day"as"sample"collection,"
usually"within"1Z3"hours.""











Peripheral" blood" mononuclear" cells" were" separated" using" a" standard" technique" over" a"
lymphoprep" (Ficoll)" gradient." Peripheral" blood" was" collected" into" 3x" BD" green" top"
lithium/plasma" tubes" (catalogue" no." 368480)." 3" x" 1.5ml" cryovials" of" whole" blood" were"
removed" prior" to" any" further" processing" and" stored" at" Z80oc." The" remaining" blood" was 
transferred" into" a" sterile" 50ml" Falcon" tube" and" plasma" collected" (see" section" 3.2.5.1" for"
details)." Following" the" removal" of" 3ml" plasma," the" remaining" blood"was" diluted" to" a" final"
volume" of" 50ml" using" PBS" warmed" to" room" temperature." 15ml" lymphoprep" (warmed" to"















MidZstream" urine" samples"were" collected," reducing" the" risk" of" bacterial" contamination" of"
samples."As"detailed"above,"samples"were"tested"for"the"presence"of"nitrites"at"the"time"of"
sampling,"and"discarded" if"evidence"of"bacterial" infection"of" the"urinary" tract"was"present.""
Samples"were"divided"into"three"aliquots"prior"to"freezing"at"Z80oc."Care"was"taken"to"ensure"






A" number" of" techniques" have" been" developed" for" detecting" and" quantifying" antiZEBNAZ1"
IgG," of" which" the" gold" standard" is" indirect" immunofluorescence" (212)." However," this"
technique" is"not" readily" amenable" to" large" scale" testing," and"has" fallen"out"of"widespread"
use." The" DiaSorin" EBNAZ1" IgG" ELISA" (DiaSorin;" Salugia," Italy)" has" reasonable" sensitivity"
(87.5%)" and" specificity" (89.9%)," and" correlates" well" with" the" results" obtained" by" indirect"
immunofluorescence" (212)." Indeed," the" DiaSorin" platform" is" used" by" the" clinical"
microbiology"laboratory"at"the"Royal"London"Hospital"(personal"communication,"Dr"Duncan"
Clark).""
There"are"no" international"consensus"units" for"the"measurement"of"antiZEBNAZ1" IgG"titres,"
instead"manufacturers"define"arbitrary"units,"making" comparisons" complex."Rank"quintiles"
are" an" accepted"method"of" comparing" titres" between" groups"when"examining" continuous"
variables"and"this"technique"has"been"used"in"MS"epidemiology"(133,"147).""
Despite"the"fact"that"sensitivity"and"specificity"of"some"of"the"ELISA"kits"available"to"detect"
EBNAZ1" have" previously" been" demonstrated" to" be" variable" (212," 213)," no" quantitative"









120" serum" samples" (38" patients"with"MS," 50" siblings" of" patients"with"MS" and" 32" healthy"
controls,"HC)"were"used"in"this"preliminary"study."All"samples"were"assayed"in"duplicate.""
DiaSorin" EBNAZ1" IgG" ELISA" was" performed" according" to" the" manufacturer’s" instructions."
Prior" to" use" of" the" VirionSerion" EBNAZ1" IgG" ELISA," samples" were" diluted" 1:5" using" the"
dilution" buffer" provided" by" the" manufacturer" in" order" to" obtain" readings" within" range;"
otherwise"the"assay"was"performed"according"to"the"manufacturer’s"instructions.""
AntiZEBNAZ1" IgG" titres" for" each" sample" were" calculated" according" to" the" manufacturers’"
instructions." Samples" were" classified" as" positive" or" negative" using" the" cutZoff" values"
provided." Samples" with" titres" higher" than" the" upper" limit" of" detection" for" each" kit" were"
assigned" a" value" equal" to" the" upper" limit" of" detection." Repeat" analysis" on" borderline"







designated"as" the"gold"standard" for" the" reasons"discussed"above." In"all"other"analyses" the"
results" from" the" two" ELISA" kits" were" directly" compared." Analyses" were" performed" using"
Prism"v5"(GraphPad).""
The" kappa" coefficient" was" used" to" describe" the" correlation" between" the" rank" quintiles"
generated"by"the"two"ELISAs."The"agreement"between"the"two"methods"was"assessed"using"
a"BlandZAltman"plot" (214)." This"method"allows"a" visual"description"of"both" the"agreement"
between" ELISAs," in" addition" to" demonstrating" any" systematic" or" significant" proportional"
errors" between" the" two" sets" of" results" (214)." In" a" BlandZAltman" plot," the"mean" value" for"
each"sample" is"plotted"on"the"xZaxis,"with"the"difference"between"the"two"values"obtained"
for" each" sample" plotted"on" the" yZaxis." The"mean"difference"between" the" two" results" (the"






and" 12.7%" with" the" VirionSerion" ELISA." The" positive" predictive" value" of" the" VirionSerion"
ELISA" was" 99.1%," however" the" negative" predictive" value" was" 64.3%" when" calculated"
compared" to" the" DiaSorin" ELISA." Sensitivity" and" specificity" were" 95.5%" and" 90.0%"





used," there" was" a" poor" correlation" between" the" results" obtained" from" the" two" ELISAs,"
R2=0.49" (figure" 4.9a)." The" relationship" between" the" two" kits" appeared" exponential" rather"




the" decision"was" taken" not" to" examine" the"magnitude" of" the" error" in" this" study." Instead,"
information"regarding"the"positive"(99.1%)"and"negative"(64.3%)"predictive"values"should"be"
used"to"compare"those"samples."The" implication"of"these"values" is"that"whilst"the"DiaSorin"
and"Virion" ELISA" agree"on" those" samples" that"DiaSorin" calls" positive," there" is" a" significant"
overestimation"of"the"proportion"of"negative"samples"by"the"Virion"ELISA.""

























































































" 1' 2' 3' 4' 5'
1' 10" 5" 0" 0" 1"
2' 6" 7" 6" 4" 0"
3' 6" 3" 7" 4" 2"
























Both" ELISA" kits" used" in" this" study" employ" the" EBV" p72" antigen;" however" the"method" of" antigen"
production" differs." DiaSorin" use" a" synthetically" manufactured" version" of" the" antigen," whilst"
VirionSerion" employ" a" recombinant" antigen." It" is" unclear" as" to" whether" this" affects" overall" assay"
performance,"but"should"be"borne"in"mind"when"assessing"assays.""
The"decision"was"therefore"taken"to"employ"the"DiaSorin"ELISA,"rather"than"the"cheaper"VirionSerion"






antiPEBNAP1" IgG" titres." Samples" were" analysed" in" batches" on" 96Pwell" plates" according" to" the"
manufacturers’"protocol."Samples"were"thawed"on"the"day"of"analysis,"and"had"not"previously"been"
subject"to"repeated"freePthaw"cycles."Standards"were"analysed"on"each"plate,"and"the"values"used"to"
determine" the" IgG" titre" for" each" serum" sample." All" samples" were" assayed" in" duplicate." Quality"
control"samples"were"also"run"on"each"plate."Borderline"samples"(i.e."those"giving"values"within"10%"
of" the" positive/negative" cutoff" value)," and" samples" with" a" coefficient" of" variation" >10%" were"
repeated." In" the"case"of"borderline"samples," if"both"runs"gave"a"positive" IgG"titre" then"the"sample"
was"called"as"positive,"with"a"value"equal"to"the"mean"of"all" four"analyses."There"were"no"samples"
where"one"run"gave"a"positive"result"and"the"other"gave"a"negative"result.""""







Two" methods" were" used" to" define" smoking" status." Participants" were" directly" questioned" as" to"
whether" they"were" current"or"exPsmokers," and" if" so,"how"heavily" they" smoked."However," there" is"
evidence" that" replying" on" selfPreported" smoking" behavior"may" lead" to" an" underestimation" of" the"
true" prevalence" of" smoking" (215)." Biochemical" validation" of" smoking" status" is" commonly" used" to"




is" an" overlap" in" cotinine" values" between" less" intense" or" less" frequent" active" smokers," and"people"
heavily"exposed"to"secondhand"smoke"(i.e."those"living"with"heavy"smokers)."The"most"widely"used"
cutoff"point"for"discriminating"smokers"from"nonPsmokers" is"14ng/ml"(218)."However,"given"recent"






ELISA"was" performed" according" to" the"manufacturers’" instructions" on" samples" that" had" not" been"
previously" thawed."As"detailed"above,"a"value"of"3.08ng/ml"was"used"as" the"cutoff"value;" subjects"


















that" had"been" frozen"on" the"day" of" sampling" and"had"not" been"previously" thawed"or" exposed" to"
direct"light"for"extended"periods"of"time."Measurements"were"made"using"a"fully"automated"system,"
the" TECAN" EVO" 100," on" a"Walters" AcquityPQuattro" Premiere" XE" LCMSPMS" system." Samples" were"
analysed" in"batches"using"96Pwell"plates,"with"standards"and"quality"control"samples"run"alongside"







control" serum" samples" at" the" end" of" winter" (April" 2010)" and" end" of" summer" (September" 2010)."
There"was"a"highly"significant"difference"between"serum"25POHvD"levels"between"these"dates"in"an"
overlapping" cohort" of" individuals" (p=1.35x10^P8;" tPtest" on" log" values)" (figure" 4.11)." At" the" end" of"











In"order" to"validate" the"need" to"correct" for" seasonal" fluctuations" in"25POHvD," the"MS," sibling,"and"







OHvD" levels" in" the" nonPMS" population" are" plotted" over" the" year," and" figure" 4.12d," where" the"







January' 50.22"(27.93)" 12.24" 48.98"
February' 37.22"(16.28)" 0" 19.35"
March' 35.95"(24.78)" 10.00" 19.51"
April' 55.87"(33.77)" 26.67" 50.00"
May' 63.40"(21.59)" 20" 66.67"
June' 61.38"(21.13)" 31.25" 68.75"
July' 63.83"(19.44)" 33.33" 66.67"
August' 68.19"(26.97)" 40.63" 81.25"
September' 67.79"(23.02)" 47.37" 78.95"
October' 71.50"(30.52)" 43.75" 66.67"
November' 61.47"(25.08)" 34.21" 65.79"






















































A" regression" by" day" of" sampling" on" the" original" serum" 25POHvD" levels" was" therefore" performed"
(219)." The" serum" 25POHvD" level" for" each" individual" was" regressed" on" the" periodic" function" “—































4.2.9.4. Determining' whether' any' interaction' exists' between' treatment' with'
interferonBbeta'and'serum'25Bhydroxyvitamin'D'levels'
Some" authors" have" suggested" that" interferonPβ" used" to" treat" MS" acts" to" increase" 25POHvD"
production"by"the"skin"in"response"to"sunlight"(220)."If"this"was"the"case"in"this"study"cohort,"it"would"
have"the"potential"to"skew"the"25POHvD"levels"in"the"MS"population,"in"turn"affecting"the"overall"risk"
score" calculation." In" order" to" assess" whether" interferonPβ" usage" significantly" affected" serum" 25P
OHvD" levels" in" my" population," deseasonalised" 25POHvD" levels" were" compared" between" those"
people"with"MS"who"were"taking"interferonPβ"and"those"who"were"either"taking"other"therapies"or"
untreated.""
As" can" be" seen" in" figure" 4.15," there" is" no" significant" difference" in" deseasonalised" 25POHvD" levels"













DNA" isolation" was" performed" from" whole" blood" by" the" Genome" Centre," Queen"Mary" University"
London" using" the" BRIGHT" protocol" based" on" the" salting" out" procedure" published" by" Miller" et" al"
















to" the" protocols" supplied" by" Illumina." Briefly," following" DNA" denaturing," the" entire" genome" is"
amplified" overnight" prior" to" fragmentation." The" fragmented"DNA" is" precipitated" and" resuspended"
before" being" hybridised" to" the" bead" chip" supplied" by" Illumina." The" hybridized" gene" chip" is" then"
stained"and"read,"providing"the"results"for"all"196,524"polymorphisms.""
Using" immunobase" (http://www.immunobase.org)" the" Immunochip" markers" for" each" SNP" were"
determined." The" two"SNPs" that"were"not"on" the" immunochip"did"not"have"alternative"markers" in"




















rs1315388' HLAPDRB1*1501" " A" 3.1"
rs4648356' MMEL1" imm_1_2699024" C" 1.14"
rs11810217' EV15" 1kg_1_92920965" A" 1.15"
rs11581062' VCAM1" " G" 1.12"
rs1335532' CD58" imm_1_116902480" A" 1.22"
rs1323292' RGS1" imm_1_190807644" A" 1.12"
rs7522462' C1orf106(KIF21B)" imm_1_199148218" G" 1.11"
rs12466022' no"gene" 1kg_2_43212565" C" 1.11"
rs7595037' PLEK" imm_2_68500599" A" 1.11"
rs17174870' MERTK" " G" 1.11"
rs10201872' SP140" imm_2_230814968" A" 1.14"
rs11129295' EOMES" 1kg_3_27763784" A" 1.11"
rs669607' no"gene" 1kg_3_28046448" C" 1.13"
rs2028597' CBLB" " G" 1.13"
rs2293370' TMEM39A/CD80" imm_3_120702624" G" 1.13"
rs9282641' CD86" " G" 1.21"
rs2243123' IL12A" imm_3_161192345" G" 1.08"
rs228614' NFKB1" " G" 1.09"
rs6897932' IL7R" imm_5_35910332" G" 1.11"
rs4613763' PTGER4" imm_5_40428485" G" 1.2"
rs2546890' IL12B" imm_5_158692478" A" 1.11"
rs12212193' BACH2" imm_6_91053490" G" 1.09"
rs802734' THEMIS" imm_6_128320491" A" 1.1"
rs11154801' MYB/AHI1" " A" 1.13"
rs17066096' IL22RA2" " G" 1.14"
rs13192841' no"gene" imm_6_138008907" A" 1.1"
rs1738074' TAGAP" imm_6_159385965" G" 1.13"
rs354033' ZNF746" " G" 1.11"
rs1520333' IL7" " G" 1.1"
rs4410871' MYC" " G" 1.11"
rs2019960' PVT1" imm_8_129261453" G" 1.12"
rs3118470' IL2RA" imm_10_6141719" G" 1.12"
rs1250550' ZMIZ1" imm_10_80730323" A" 1.1"
rs7923837' HHEX" " G" 1.1"
rs650258' CD6" imm_11_60588858" G" 1.12"
rs630923*' CXCR5" " C" 1.12"
rs1800693' TNFRSF1A" imm_12_6310270" G" 1.12"
rs10466829' CLEC1" imm_12_9767358" A" 1.09"
rs12368653' CYP27B1" imm_12_56419523" A" 1.1"
rs949143' ARL6IP4" imm_12_122161116" G" 1.08"
rs4902647' ZFP36L1" imm_14_68323944" G" 1.11"
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rs2300603' BATF" " A" 1.11"
rs2119704' GALC/GPR65" " C" 1.22"
rs2744148' SOX8" " G" 1.12"
rs7200786' CLEC16A" imm_16_11085302" A" 1.15"
rs13333054' IRF8" imm_16_84568534" A" 1.11"
rs9891119' STAT3" imm_17_37761506" C" 1.11"
rs180515' RPS6KB1" " G" 1.09"
rs7238078' MALT1" " A" 1.12"
rs1077667' TNFRSF14" " G" 1.16"
rs8112449' TYK2/CDC37" imm_19_10381064" G" 1.08"
rs874628' MPV17L2" " A" 1.11"
rs2303759' DKKL1" " C" 1.11"
rs2425752' CD40" " A" 1.11"
rs2248359' CYP24A1" " G" 1.12"
rs6062314' ZBTB46/TNFRSF6B" " A" 1.16"
rs2283792' MAPK1" " C" 1.1"









HLA'haplotype' Associated'SNP' Risk'allele' Relative'risk'
associated'with'HLA'
haplotype'
HLABDRB1*1501' rs1315388" A" 3.1"
HLABDRB1*1303' rs2516049" C" 2.4"
HLABDRB1*0301' rs3129763" A" 1.26"










Free" light" chains" were" determined" on" urinary" samples" using" a" commercially" available" ELISA"
(BioVendor;"Brno,"Czech"Republic)."The"assay"was"carried"out"to"the"manufacturers’"instructions,"and"









Urinary" neopterin" levels" were" measured" using" a" commercially" available" ELISA" (IBL," Hamburg,"
Germany)" according" to" the" manufacturer’s" instructions," with" all" samples" assayed" in" duplicate."
Samples"were"not"been"exposed"to"light"for"prolonged"periods,"and"the"assay"was"performed"in"the"







Matrix" metalloproteinaseP9" (MMPP9)" is" one" of" a" family" of" zincPcontaining" and" calcium" requiring"
endopeptidases,"which"are"capable"of"remodeling"and"degrading"the"extracellular"matrix"(224)."Their"
activity" is" regulated" at" postPtranscriptional" level" by" the" suppressor" function" of" tissue" inhibitors" of"
metalloproteinases" (TIMPs)," which" bind" to" either" the" activated" MMPs" or" their" proforms" (224)."
Elevated" serum" concentrations" of"MMPP9" have" been" found" in" serum" and" CSF" of" people"with"MS"
(225," 226)," with" higher" levels" in" relapsing" remitting" MS" (225)." Increased" levels" have" also" been"
associated"with"MRI"evidence"of"inflammatory"disease"activity"(227,"228)."Conversely,"serum"and"CSF"
levels" of" TIMPP1" are" lower" in" people" with" MS" than" controls" (227," 228)." It" has" therefore" been"
proposed" that" the" MMPP9:TIMPP1" ratio" may" have" a" role" as" a" surrogate" marker" of" inflammatory"
disease"activity"in"MS"(228,"229).""






TIMPP2" (234)," increasing" the" concentration" of" TIMPP2" according" to" the" heparin" concentration."
















Previously" separated" peripheral" blood" mononuclear" cells" were" stored" in" liquid" nitrogen," before"
being" thawed," stimulated," stained" and" analysed" towards" the" end" of" the" study." The" samples" for"
analysis"were" selected"according" to" the"MS" risk" score"derived" for" each" individual."All" analysis"was"
performed" blinded" to" the" risk" score" associated" with" the" individual" whose" samples" were" being"
analysed." 8" participants" with"MS," 8" siblings"with" high"MS" risk" scores," 8" siblings"with" low"MS" risk"
scores"and"8"healthy"controls"were"selected"for"analysis"in"this"subPstudy.""
Intracellular"cytokine"staining"was"performed"for"ILP17"and"FoxP3."In"addition,"an"aliquot"of"the"cell"








































CD3Pv450" (catalogue" no" 560365;" BD" Biosciences)" and" 5µl" human" Th17/Treg" Phenotyping" Cocktail"







Flow" cytometry" analysis"was" performed"on" the"BD"Canto" II" flow" cytometer" in" the" flow" cytometry"
core"facility"at"the"Blizard"Institute."Prior"to"the"initial"data"collection,"appropriate"compensation"was"
performed"with"stained"compensation"beads"using"appropriate"techniques.""


































All"MR" imaging"was" performed" at" the"NMR"Research"Unit," Institute" of"Neurology,"Queen" Square."




Echo"train" length" (ETL)"="10," repetition"time"(TR)"="3500ms,"echo"time"(TE)"="19/85ms,"number"of"
excitations" (NEX)"="1"and" the" scan" time"="4"minutes."Other" images"were"obtained"during" the"MRI"











MS" risk" profile" of" any" of" the" participants." In" cases" of" dispute" between" the" two" independent"
assessors," a" third" assessor," a" consultant" neuroradiologist" (Dr" Jane" Evanson)" provided" a" further"
independent"opinion.""
MRI"scans"were"examined"for"the"presence"of"T2"hyperintense"lesions."Where"present,"lesions"were"
assessed" and" a" decision" made" whether" they" were" likely" to" represent" demyelination," alternative"
pathology"or"nonPspecific"T2"hyperintensities"using"internationally"accepted"guidelines"developed"by"
MAGIMS" (235," 236)." Lesions" were" identified" on" T2" FLAIR" weighted" images," corroborated" by" T2"
weighted" and" proton" density" images;" very" occasionally" sagittal" Phase" Sensitive" Inversion"
Recovery"(PSIR)"was" used" when" the" location" of" the" lesion" (periventricular/juxtacortical)" was" in"
question."
The" presence," absence" and" total" number" of" any" T2" weighted" hyperintensities" was" recorded,"










Females" have" an" increased" risk" of"MS" compared" to"males." There" is" no" recent" largePscale" analysis"
defining"the"sexPspecific"relative"risk"(RR)"of"MS"associated"with"being"female."Whilst"there"has"been"
much"interest"over"the"years"in"developing"markers"that"predict"development"of"CDMS"following"a"
CIS," there" has" been" little" work" examining" the" effect" of" gender" on" this" development." Many"





syndrome”," “multiple" sclerosis" AND" conversion”," “first" demyelinating" event”" and" “first"






Only" nonPinterventional" studies" were" selected." Studies" were" included" if" they" included" unselected"
patients" with" either"MS" or" a" CIS" (or" both," but" treated" as" separate" groups)," had" greater" than" 10"
participants," and"provided"data" regarding" the" gender" of" participants."When"examining" the" role" of"
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gender" in" the" development" of" CDMS" following" a" CIS," the" subgroup" of" nonPinterventional" studies"
giving" the" number" of" males" and" females" progressing" to" CDMS" were" selected." For" those" studies"
examining"RIS,"original"observational" accounts"only"were"used."Papers"used"were" limited" to" those"
that"used"accepted"MRI"criteria"(Barkhof)"for"the"radiological"diagnosis."










published" from" 2000" onwards" were" hand" searched." Those" papers" giving" information" on" the"
prevalence" of" MS" according" to" either" the" MacDonald" or" Poser" criteria," and" providing" some"
information"regarding"gender"were"selected"for"inclusion."Where"raw"data"regarding"the"number"of"
males"and" females"with"MS"were"not"provided," corresponding"authors"were" contacted" to"provide"
data."763"studies"were"retrieved"from"PubMed"using"the"term"“clinically"isolated"syndrome”,"254"for"
“multiple" sclerosis" AND" conversion”" and" 91" for" the" term" “first" demyelinating" event”." There" was"
considerable"overlap"between"results,"and"duplicate"results"were"manually"identified"and"removed.""
69"studies"meeting"the"inclusion"criteria"gave"information"regarding"the"sex"ratio"of"MS"(see"figure"
4.17" and" appendix" 5)." 33" gave" information" regarding" the" sex" ratio" of" CIS" (see" figure" 4.18a" and"
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appendix" 5)," 9" provided" information" regarding" sex" and" the" development" of" CDMS" following" a" CIS"













2.12" (95%" CI" 1.94P2.32)" compared" to" males" (figure" 4.18a)." There" was" significant" between" study"
heterogeneity;" I2=69%," p<0.00001." Effect" sizes" of" individual" studies" appeared" to" be" uniformly"
distributed" around" the" metaPanalysis" effect" size" on" a" funnel" plot," suggesting" no" large" degree" of"
publication"or"selection"bias"(figure"4.18b)."
The"majority"of"publications"did"not"differentiate"between"forms"of"CIS."However,"three"publications"
selected" patients" with" transverse" myelitis" as" a" presenting" feature" (237P239)." When" analysed"
separately"to"other"studies"these"gave"a"RR"in"females"of"2.96"(95%"CI"1.72P5.10)"compared"to"males."





















following"a"CIS"was"1.20" (95%"CI"0.98P1.46)"compared" to"males" (figure"4.19)."There"was"moderate"
betweenPstudy"heterogeneity:"I2=46%,"p=0.06.""Although"one"study"appeared"to"give"a"much"higher"
relative"risk,"this"study"was"given"little"weight"(1.0%"in"the"generic" inverse"variance"model),"and"so"


















included" 51" studies," with" a" total" of" 58,489" subjects" (40,926" female," 17,423" male)." This" gave" an"
overall" RR" of" MS" in" females" of" 2.22" (95%CI" 2.08P2.38)" (data" not" shown)." BetweenPstudy"









same" for" both" the" overall" and" conservative" analyses." This" is" similar" to" the" RR" of" CIS" in" females"













those"born" in"the"spring"have"an" increased"risk,"has"been"interpreted"as" indicating"a"prePnatal"role"
for" vitamin" D" in"modulating"MS" risk" (243)." The"month" of" birth" effect" was" first" described" in" 1987"
(244)," and" the" first" largePscale" study" by" Willer" et" al" (245)" was" performed" in" 2005." A" number" of"
studies"examining"the"variation"in"MS"risk"associated"with"an"individual’s"month"of"birth"have"been"
performed." These"have"enrolled" varying"numbers"of"participants," although"more" recently"national"
MS"registers"have"facilitated"largePscale"populationPbased"studies"(245P248).""
Studies" have" been" performed" at" a" range" of" latitudes," meaning" that" there" is" a" large" interPstudy"
variation" in" the" change" in" UV" light" exposure" between" seasons." At" latitudes" greater" than"
approximately"52o"from"the"equator," insufficient"UV"light"of"the"correct"wavelength"(UVB;"290P315"
nm)"reaches"the"skin"between"October"and"March"to"enable"vitamin"D"synthesis"during"the"winter"






PubMed" and"Web" of" Science"were" searched" using" the" terms" “multiple" sclerosis”" AND" “month" of"
birth”,"“multiple"sclerosis”"AND"“month”"and"“multiple"sclerosis”"AND"“season”."Papers"were"then"
evaluated" using" the" inclusion" criteria" described" below." Additionally," the" references" of" evaluated"







































A" populationPconservative" analysis" excluded" additional" papers" where" there" was" a" reasonable"






























45.2oN" 2,737" April"(1.17;"1.02P1.32)" October"(0.88;"0.76P0.99)"












































Excluded" 4,834" Nil" Nil"
Sadovnick'
2007'(257)'
Canada" 56.8oN" 14,799" June"(0.95;"0.90P1.00)" November"(0.90;"0.84P0.95)"
Canada" 56.8oN" 17,874" Nil" November"(0.91;"0.85P0.97)"Willer'2005''




Sicily" 37.6oN" 965" Nil" Nil"
 
A"geographicallyPconservative"analysis"examined" the"effect"of"month"of"birth" in" those"populations"
with"a"clear"and"consistent"difference"in"UV"radiation"between"months."This"analysis"selected"those"
studies" where" the" latitude" associated"with" the" population"was" greater" than" 52o." Included" papers"
were" those" by"Menni" et" al" (247)" (Danish" data" only),"Willer" et" al" (245)," Saastamoinen" et" al" (246),"
Disanto"et"al"(248),"and"Salzer"et"al"(255)."Ramagopalan"et"al"(256)"was"excluded"from"this"analysis,"
as" it"was"not"possible" to"estimate" the" latitude"of" the"population,"as" samples" from"three"countries"
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"
were"used" in" the" study."Additionally," Sadovnick"et" al" (257)"was"excluded" from" this" analysis" as" the"
authors"state"that"the"dataset"used"was"previously"used"by"Willer"et"al"(245)."The"figure"of"52o"was"
chosen"because"at"latitudes"of"about"52o"and"above,"there"is"no"UV"light"of"appropriate"wavelength"
for" the" cutaneous" synthesis" of" vitamin" D" during" October" –" March" (249)." People" living" at" these"







Nine"studies"gave" information"on"month"of"birth"and"subsequent"MS" risk" (245P248,"254P258)."The"





































































































































































only#month# in#which# there#was#a#significant#deviation#of#MS#births# from#expected#was#November,#
where#there#were#significantly#fewer#MS#births#than#expected##(O:E=0.93,#p=0.04)#(table#4.7).##
When# the#geographicallyAconservative#analysis#was#performed,# the#effect#of#UV#variation#over# the#
course#of#the#year#was#highlighted.#There#were#significantly#more#observed#MS#births# in#April#than#
expected#(O:E=1.08,#p=0.001),#May#(O:E#1.11,#p=0.007)#and#June#(O:E=1.06,#p=0.05),#and#significantly#
fewer# in# October# (O:E=0.94,# p=0.006)# and# November# (O:E=0.89,# p=0.004)# (table# 4.7).# Conversely,#
when#only#those#studies#performed#at#<52oN#were#selected#(Menni#et#al#(Italian#data)#(247),#Givon#et#









population# included# in# the# sibling# study#were# almost# entirely# born# in# the#UK,# the# associated# risks#
generated#by# the#population#and#geographically#conservative#analysis#are# the#most#appropriate# to#
be#used#in#the#final#analysis.##
Through#combining#existing#datasets# for#month#of#birth#and#subsequent#MS#risk,# this#provides# the#
most# robust# evidence# to# date# that# the# month# of# birth# effect# is# a# genuine# one.# Whilst# this# has#




Susceptibility# to#Multiple#Sclerosis# (CCPGSMS),#used#by# (245,#256,#257).#Whilst# the# latitudinal#data#












When# the# studies# that#were# performed# at# a# latitude#of# <52oN#were# excluded,# the#month# of# birth#
effect#once#again#became#apparent.#There#was#a#highly#significant#increase#in#MS#births#in#both#April#
and#May,#and#a#reduction#in#October#and#November.#Only#one#study#(248)#has#previously#shown#a#
significant# reduction# in#all#of# these#months.#This# finding#was#complemented#by# the#demonstration#
that# the# month# of# birth# effect# is# almost# entirely# lost# when# selecting# those# studies# performed# at#
<52oN.#However,#it#must#be#noted#that#the#geographically#conservative#analysis#has#the#potential#to#
overestimate# some# populationAspecific# risks,# due# to# the# high# probability# of# duplicate# data# in# the#
analysis.#Any#deviation#present#in#these#datasets#will#therefore#be#exaggerated#in#this#analysis.#
No#studies#from#the#Southern#hemisphere#were#included#in#this#analysis.#This#was#not#a#deliberate#
selection# criterion,# but# instead# reflects# the# imbalance# in# the# origin# of# such# studies.#Whilst# studies#




be# used# in# this# analysis.# There# remains# a# need# for# further# studies# in# the# Southern# hemisphere# in#
order# to#confirm# if# the#reversal# in# the#month#of#birth#effect#noted#by#Staples#et#al.,# (260)#exists# in#
other#countries.##
The#overall#conservative#analysis#had#the#least#number#of#participants,#78,488.#However,# it# is# likely#
to# be# the# most# appropriate# analysis,# as# both# potential# duplicate# datasets# and# those# studies#
performed# in# areas#with# low# variation# in#UV# exposure# during# the# year#were# excluded.# The# highly#
significant#increase#in#MS#risk#in#those#born#in#April#and#May#remains#clear,#as#does#the#reduction#in#
risk# in# those#born# in#October#and#November.#By#pooling#data#and#performing#a#metaAanalysis,# the#
month# of# birth# effect# can# be# extended# from# that# previously# described.# This# effect# is# highlighted#
when#looking#at#the#differences#in#MS#risk#stratified#by#season#of#birth.##
However,# it#must#be#borne# in#mind# that# this# is#a#metaAanalysis#of#existing#data,#and# therefore#has#
weaknesses#in#keeping#with#this#methodology.#Publication#and#selection#bias#are#potential#problems,#
although# studies# showing# both# no# effect# and# significant# effects# were# included,# and# there#was# no#
evidence# of# bias# in# funnel# plots.# Additionally,# although# steps# were# taken# to# attempt# to# exclude#
duplicate# data,# it# may# be# that# some# remains,# influencing# the# results.# The# lack# of# Southern#
hemisphere# studies# is# a# significant# limitation,# as# a# demonstration# of# the# reversal# of# the#month# of#
birth# effect# would# strengthen# confidence# in# this# finding# considerably.# Combining# the# data# from#
individual#months#into#seasons#(as#defined#by#the#UK#Met#Office)#may#have#introduced#bias#into#the#
























The# relative# risk# of# those# with# a# previous# history# of# infectious# mononucleosis# (IM)# (symptomatic#
primary#infection#with#EpsteinABarr#virus)#has#recently#been#determined#in#an#updated#metaAanalysis#
(262).# By# examining# 19390# reported# cases,# the# authors# were# able# to# demonstrate# a# strong#







Barr# virus# nuclear# antigenA1# (EBNAA1)# –# the# reduction# in# risk# associated# with# negative# antibody#
status,# and# the# increasing# risk# associated#with# higher# titres# of# IgG# (133).# The# single# largest# study#
examining#this#used#a#nested#caseAcontrol#study#design#examining#3#million#US#army#recruits,#83#of#
whom# subsequently# developed# MS.# AntiAEBNAA1# IgG# titres# were# divided# into# quintiles,# and# the#
relative# risk#of#MS#associated#with#each#quintile# calculated# (133).#The# relative# risk#associated#with#















metaAanalysis# examined# the# odds# ratio# of#MS# associated#with# EBNAA1# negativity,# as#measured# by#








caseAcontrol# nested# study# of# US# army# recruits# demonstrated# a# change# in# odds# ratio# for# the#




























In# the# recent# genomeAwide# association# study,# possession# of# the# HLAADRB1*1501# haplotype# was#
associated#with#a#relative#risk#of#3.1#(95%#CI#2.9A3.3)#of#developing#MS#(103).#This#relative#risk#relates#

















published# to# date# have# been# contradictory.# Particular# areas# of# interest# have# surrounded# the#
interaction#between#combinations#of#smoking,#HLAADRB1*1501#haplotype#and#antiAEBNAA1#IgG#titre.#
In#order#to#detect# interactions#between#factors#with#relatively#small#effect#sizes# in#a#relatively#rare#
illness# such# as# MS,# studies# of# supraApopulation# size# are# required.# LargeAscale# populationAbased#
studies# have# only# recently# become# feasible;# however# to# gain# adequate# power# to# fully# examine#
potential# interactions# international# collaborations# are# needed.# There# are# some# indications# of#




control# study# of# 109# MS# patients# and# 212# controls,# HLAADRB1*1501# positive# controls# had,# on#
average,#higher#antiAEBNAA1#IgG#titres#than#HLAADRB1*1501#negative#controls.#There#appeared#to#be#
an#additional#interaction#in#those#with#midArange#antiAEBNAA1#IgG#titres;#there#was#an#increased#risk#
of#MS# in# those#with# titres# in# this# range#who#were#HLAADRB1*1501# positive# but# not# in# those#who#
were# HLAADRB1*1501# negative.# They#were# also# able# to# demonstrate# some# interaction# in# a# larger#
study#(264),#with#an# interaction#present#on#an#additive#scale#but#not#on#a#multiplicative#scale.#This#
interaction# was# found# to# be# present# when# IgG# titres# against# the# EBNAA1# fragment# 385A420# were#
studied#(156),#with#IgG#directed#against#this#fragment#appearing#to#be#a#risk#factor# independent#of#
conventionally#measured#antiAEBNAA1# IgG#titres.#However,# these#findings#have#not#been#replicated#




Similarly# conflicting# results# exist# when# looking# for# any# interaction# between# smoking# and# HLAA
DRB1*1501# haplotype.# Neither# Simon# et# al# not# Sundqvist# et# al# were# able# to# demonstrate# any#
interaction# (264,# 265).# However,# Hedstrom# et# al# (158)# were# able# to# demonstrate# an# interaction#
between#smoking#and#HLAADRB1*1501#haplotype,#albeit#only#in#those#subjects#lacking#the#protective#
HLA#allele,#HLAAA*02.##
A# potential# interaction# between# smoking# and# antiAEBNAA1# IgG# titres# appears# to# have# a# plausible#
biological# basis.# EBV# activation# and# nicotine# metabolism# have# been# shown# to# share# molecular#





Another# area# where# there# appears# to# be# a# biological# basis# for# an# interaction# is# the# possible#
interaction#between#vitamin#D#and#presence#of# the#HLAADRB1*1501#haplotype.# It#has#been#shown#
that#there#is#a#biologically#active#vitamin#D#response#element#(VDRE)#in#the#promoter#region#of#HLAA





demonstrate# conclusively.# Emerging# evidence# suggests# that# this# may# be# the# case.# TAcell# receptor#
excision#circles#(TRECS),#which#can#be#measured#by#PCR#in#TAcells#isolated#from#cord#blood,#provide#a#









A# finding# that# requires# replication# is# a# potential# interaction# between# month# of# birth# and# HLAA
DRB1*1501#haplotype.# Ramagopalan# et# al# (256)# demonstrated# that# there#were# significantly# fewer#
patients#with#MS#born# in#November#who# carried# the#HLAADRB1*1501# allele# compared# to#patients#
not#carrying#the#allele;#conversely#patients#with#MS#carrying#HLAADRB1*1501#had#a#higher#number#of#











be# included# in# the# latitudinal# analysis,# papers# had# to# provide# information# about# the# geographical#
location#of#the#population#studied.#The#geographical#location#of#the#population#used#in#each#of#the#
included#papers#was#extracted#from#the#original#paper.#Google#maps#(www.maps.google.com)#were#
then# used# to# determine# the# latitude.# In# those# papers#where# databases# from# a# large# geographical#
area# (such#as#an#entire#country)#were#used# to#determine#population#characteristics,# the#midApoint#
latitude# of# the# geographical# area# was# used# in# the# analysis.# In# those# papers# where# two# or# more#
geographically# distinct# regions# were# studied# (i.e.# different# countries/continents)# (245,# 247)# and#
separate# population# figures# were# given# for# the# distinct# regions,# these# were# analysed# as# separate#
datasets.# # The# Italian# cohort# studied#by#Menni# et# al# (247)#originates# from# three# separate# areas#of#
Italy,# and# in# this# case# the# latitude#of# the# central# region#of# the# three#was#used# in# the#analysis.# The#
single#paper#(256)#where#the#datasets#from#three#countries#were#combined#into#a#single#analysis#was#
excluded# from# the# latitudinal# analysis.# In# one# paper# (247),# data# were# given# covering# the# entire#
geographical#area#of#the#United#States#of#America#(USA).#This#data#was#excluded#from#the#latitudinal#
analysis# due# to# the# large# area# covered# –# the# latitude# of# the# USA# ranges# from# 18.5oN# (Hawaii)# to#







above.# The# dependent# variable#was#O:E#MS# births/month,# and# the# independent# variable# latitude,#










was# lost.# Given# that# the# three# southernmost# studies# were# also# the# three# smallest# studies,# it# is#
therefore#difficult#to#know#whether#the#latitudinal#interaction#is#a#function#of#study#size,#or#is#indeed#
a#genuine#effect.#It#must#also#be#taken#into#account#when#interpreting#this#data#that#latitude#may#not#
act#as#a# linear#variable# in# terms#of# its#effect#on#month#of#birth,#but# there#were# insufficient#studies#
available#to#investigate#this.##







Given# the# uncertainty# currently# regarding# any# potential# interaction# between# risk# factors,# and# the#






Interaction# analysis# was# performed# using# a# liner# regression# model# where# both# risk# factors# were#
linear#(serum#25Ahydroxyvitamin#D,#IgG#titre#against#EBNAA1)#and#a#logistic#regression#model#where#
one#variable#was#binary#(smoking#status,#HLAADRB1*1501#haplotype)#in#PASW#v18#(SPSS).##Given#that#







Interaction# testing#was#not#performed# for# the#genetic# risk# factors# (other# than# the#HLAADRB1*1501#
haplotype)#in#this#cohort.#Given#the#number#of#nonAMHC#SNPs#tested,#this#study#did#not#come#close#














The# overall# risk# score#was# constructed# by# pooling# all# of# the# available# data# regarding# relative# risks#
described# above# to# create# an#overall# “risk# score”.# This# score#was#not# conceived#of# as# an# absolute#
score,# instead# an# indication# of# the# relative# risk# of#MS# in# an# individual.# There# have# been# previous#
attempts#to#generate#such#a#score,#the#most#extensive#of#which#was#that#by#de#Jager#et#al#(157).##
This# score,# which# was# developed# prior# to# the# most# recent# GWAS# in# MS,# attempted# to# assign#
individuals#both#a#genetic#risk#score,#and#then#to#integrate#selected#environmental#factors#in#order#to#
improve# the# score.# Using# 16# SNPs# (2#MHC,# 14# nonAMHC),# the# authors# argued# for# a#weighted# risk#
score,#as#the#relative#risks#associated#with#the#SNPs#selected#showed#considerable#variability.#They#
calculated# their# “weighed#genetic# risk# score”#by# first# calculating# the#weight# assigned# to# each# SNP,#
equal# to# the#natural# log#of# the#OR# for#each#allele.#The#authors# then#multiplied# the#number#of# risk#





risk# score# (category# 4# encompassing# the# mean),# a# significant# difference# in# MS# risk# according# to#




for# cumulative# genetic# risk#was# taken# to# be# one# in#which# risk# increases#multiplicatively#with# each#
174#
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score# (275).#A#potential#problem#with# this# is# that# the# risks#associated#with# the#SNPs#may#be#overA
inflated#in#the#population#studied.##
Given# the# readily#available# information#provided#by# the# recent#MS#GWAS# (103),# together#with# the#
relatively#small# sample#size# in# the#sibling#study,# the#decision#was# taken#to#use# the#OR#given# in# the#
GWAS,#with#the#logAodds#risk#additive#model#proposed#by#de#Jager#et#al#(157).##The#weighting#given#
to#each#of#the#nonAgenetic#risk#factors#and#possession#of#the#HLAADRB1*1501#allele#is#given#in#table#
















































significant# difference# in# the# average# age# between# both# patients# with# MS# and# their# siblings# and#
healthy# controls# (see# table# 5.1),# with# healthy# controls# significantly# younger# than# the# other#
participants.#However,#the#age#range#was#similar#between#the#three#groups.####
Table!5.1:!Demographic#details#of#study#participants#
! MS! Unaffected!siblings! Healthy!controls!
Number! 78# 121# 103#
Age!(mean;!SD;!range)! 47.26#(11.74;#20A74)# 47.24#(12.55;#18A75)# 41.22#(11.33;#21A72)a#

















Treatment!(n;!%)! 37#(47.4%)c# # #















between# MS# probands# and# healthy# controls# (p=0.002)# and# the# siblings# of# people# with# MS# and#
healthy#controls#(p=0.001).#There#was#no#significant#difference#in#the#age#group#distribution#between#





MS# and# 7# (9.0%)# primary# progressive# MS# (table# 5.1).# # 37# (47.4%)# participants# with# MS# were# on#
disease# modifying# treatment.# 3# people# with# MS# were# taking# Avonex,# 2# Betaferon,# 14# Rebif,# 14#
Copaxone,# 4#Natalizumab# and# 2#Mitoxantrone.# Both# patients# on#Mitoxantrone# had# received# their#
last#dose#>4#months#ago.#No#patients#had#received#steroid#treatment#for#their#MS#within#the#three#
months#prior#to#the#samples#being#taken.#The#EDSS#range#of#the#people#with#MS#was#0A8.5,#with#a#
mean# EDSS# of# 3.79# (table# 5.1).# However,# the# distribution# of# the# EDSS# of# the# people# with# MS#






































There# was# an# overall# significant# difference# between# the# proportion# of# participants# in# each# group#
reporting# a# personal# history# of# infectious#mononucleosis# (p=0.037,# Chi# square# test)# (table# 5.2).# In#
postAhoc#analysis#using#a#Fisher’s#exact#test,#the#significant#difference#was#found#to#lie#between#the#
proportion# of# people# with# MS# (17/78,# 21.8%)# and# healthy# controls# (10/103,# 9.8%)# reporting# a#
personal#history#of#infectious#mononucleosis#(p=0.0345,#Fisher’s#exact#test)#(table#5.2).#There#was#no#









































































based# studies# (276).# In# a# study# using# a# large# Canadian# database,# 699/14,362# (4.9%)#MS# probands#
reported# a# history# of# infectious# mononucleosis# compared# to# 165/7,671# (2.2%)# spousal# controls#
(276).#Using#these#figures,#there#is#a#significantly#different#rate#of#infectious#mononucleosis#between#
the#two#MS#cohorts,#and#also#when#the#spousal#and#sibling#cohorts#are#compared#(p<0.0001#for#both#
comparisons,# Chi# square# test).# The# reason# for# this# difference# may# well# be# selection# bias# –# large#
populationAbased# studies# include# as# close# as# possible# to# all# patients# diagnosed# with# MS# in# a#
particular#geographical#area,#minimising#as#far#as#possible#selection#(or#volunteer)#bias.#In#contrast,#
the#endophenotype#study#asked#for#a#relatively#small#number#of#volunteers# from#a#relatively# large#




a# role# in# the# finding#of#higher# than#expected# rates#of# infectious#mononucleosis# in#people#with#MS#
and#their#siblings#–#however,#family#members#were#seen#together#where#possible# in#an#attempt#to#




The# fact# that# the# rate# of# infectious#mononucleosis# in# the# sibling# cohort# did# not# differ# significantly#
from#either# the# cohort#with#MS#or# the#healthy# cohort# does#not#necessarily#mean# that# the# rate#of#
infectious#mononucleosis#in#siblings#is#midway#between#that#of#people#with#MS#and#healthy#controls.#
Rather,# the#rate#of# infectious#mononucleosis# in#siblings#may#be#the#same#as# in#people#with#MS,#or#
















reach# significance# (Fisher’s# exact# test),# although# the#difference# between# the# proportion# of# people#
with#MS#and#healthy#controls#with#undetectable#IgG#titres#approached#significance#(p=0.061,#Fisher’s#
exact#test).#
The# proportion# of# people#with#MS#who# have# undetectable# titres# of# IgG# against# EBNAA1# has# been#
shown#to#vary#according#to#the#technique#used#to#detect#IgG#(130).#This#study#was#performed#using#
ELISA,#which#has#a# lower#sensitivity#than#the#accepted#gold#standard,# indirect# immunofluorescence#
(130).# However,# indirect# immunofluorescence# is# rarely# used# in# practice,# as# it# is# relatively# labour#
intensive# compared# with# more# modern# technologies.# Indeed,# even# the# national# reference#
laboratories# in# the#UK#have# switched# to#using#platformAbased# technologies,#provided#by# the# same#
manufacturer#as#the#ELISA#kit#used#in#this#study#(Dr#Duncan#Clark;#Consultant#Clinical#Scientist#Royal#
London#Hospital,#personal#communication).#It#is#therefore#possible,#if#not#likely,#that#a#proportion#of#
subjects#who#are#regarded#as#antiAEBNAA1#IgG#negative# in#this#study#do# in#fact#have#extremely# low#
positive#IgG#titres#against#EBNAA1.##
5.1.2.4.2. Direct!comparison!of!IgG!titres!between!groups!
A# comparison# of# the# absolute# antiAEBNAA1# IgG# titres# obtained# by# using# the# DiaSorin# ELISA# was#




Although# the# IgG# titres# against# EBNAA1# for# people# with# MS# were# found# to# follow# a# normal#
distribution# when# those# samples# with# undetectable# titres# were# excluded# (ShapiroAWilk# test),# the#
distribution#of#the# IgG#titres#for#both#the#siblings#of#people#with#MS#and#healthy#controls#deviated#
significantly# from# a# normal# distribution# (siblings# p=0.001,# healthy# controls# p=0.047,# ShapiroAWilk#
test).#It#proved#impossible#to#normalise#these#distributions,#and#therefore#nonAparametric#statistical#
tests#were#used#in#the#comparison#analysis.##
There# was# a# significant# overall# difference# in# antiAEBNAA1# IgG# titres# between# the# three# groups#
(p<0.0005,# KruskalAWallis# test).# On# postAhoc# analysis# with# a# MannAWhitney# U# test,# there# was# a#
significant# difference# between# the# antiAEBNAA1# IgG# titres# between# people# with# MS# and# their#














this# analysis#was# to#define# the#quintiles,#which#was#done#using# the#assay# and#population# that# the#
analysis#was#being#performed#on,# rather# than# taking#values# from#existing# literature.#This#approach#









(2x5# table).# The# number# of# participants# in# the# extreme# quintiles# (Q1# and# Q5)# were# compared#
between# the# three# groups# using# Chi# square# (3x2# table)# with# postAhoc# analysis# between# pairs# of#




all# five#quintiles#was#compared# (p=0.0388,#Chi# square).#This# significance#was#maintained#when#the#
quintile# distribution# of# people#with#MS#was# compared# to# the# distribution# of# their# healthy# siblings#








































The#reported#rates#of#“ever#smoking”# in#each#group#are#given# in# table#5.3.#As#described# in#section#
4.2.8,# a# cotinine# cutAoff# of# 3.08ng/ml# was# used# to# define# biochemical# current# smokers# (216).#
Although#more#participants#in#each#of#the#three#groups#had#cotinine#levels#meeting#the#definition#of#
“biochemical#current#smoking”#than#the#number#who#reported#current#smoking,# the#proportion#of#
participants# classified# as# “current# smokers”# did# not# differ# significantly# based# on# the#method# (selfA
report#vs.#biochemical#classification)#used#to#define#“current#smoking”.#All#of#those#participants#who#
did# not# report# a# history# of# “current# smoking”# but# who# were# classified# as# “biochemical# smokers”#
reported#a#history#of#previous#smoking.#For#the#purposes#of#this#study,#those#participants#who#had#a#





! MS!(n=78)! Siblings!(n=121)! Healthy!controls!
(n=103)!
Ever!smoking!(reported;!n,!%)! 41#(52.6%)# 54#(44.6%)# 28#(27.2%)#






was# a# clear# distinction# between# “biochemical# smokers”# and# “nonAsmokers”,# with# no# participants#
having# a# cotinine# level#within# ±1ng/ml# of# the# cutAoff# level.# Those# participants#who#had# a# cotinine#
level#±2ng/ml#within# the#cutAoff# level# (i.e.#1.08–5.08ng/ml)#had# their# serum#samples# reAassayed#as#
described# in# the# methods# section.# All# of# those# participants# who# had# samples# reAassayed#





There#was# an#overall# significant# difference# in# the#proportion#of# participants# reporting# a# history# of#
“ever#smoking”#in#the#three#groups#(p=0.0014,#Chi#square#2x3#table).#PostAhoc#analysis#using#Fisher’s#
exact#test#revealed#that#significant#differences#in#the#proportion#of#participants#reporting#a#smoking#
history# lay# between# people# with# both# MS# and# healthy# controls# (p=0.0007),# and# the# unaffected#
siblings#of#people#with#MS#and#healthy# controls# (p=0.0082).#There#was#no# significant#difference# in#
the#proportion#of#people#with#MS#and#their#unaffected#siblings#reporting#a#history#of#“ever#smoking”.##
When# a# similar# analysis#was# performed#with# the# proportion# of# participants# reporting# a# history# of#
“current#smoking”,#there#was#no#overall#significant#difference#between#the#three#groups#(Chi#square#
2x3#table).#PostAhoc#analysis#between#pairs#of#groups#revealed#no#significant#differences.##
Finally,# an# analysis# was# performed# using# the# proportion# of# subjects# in# each# group# who# were#
classified# as# “biochemical# current# smokers”,# i.e.# those# with# a# serum# cotinine# level# >3.08ng/ml.#




with#MS# have# similar# rates# of# smoking# to# people#with#MS# is# not# necessarily# a# surprise# –# there# is#











norms# regarding# attitudes# to# smoking# are# the# strongest# predictor# of# smoking# status# (280).# It# is#
therefore# likely# that# the# siblings# of# the# healthy# control# cohort# would# display# smoking# behaviours#
similar#to#the#healthy#controls#studied.#Unfortunately,#in#the#context#of#this#study,#such#behavioural#
transmission#is#almost#impossible#to#control#for#in#a#practical#sense.#It#is#therefore#difficult#to#come#








The# raw# serum# 25AOHvD# levels# were# initially# tested# for# normality# using# the# ShapiroAWilk# test.#
Although#the#distribution#of#the#serum#25AOHvD#levels#in#people#with#MS#did#not#differ#significantly#
from#a#normal#distribution#(p=0.06),#the#distributions#in#both#the#sibling#and#healthy#control#groups#
were# significantly# different# from# normal# (p<0.0005# for# both).# Although# a# natural# logarithmic#
transformation#was#able#to#successfully#normalise#the#distributions#of#serum#25AOHvD#for#both#the#
sibling#(p=0.222)#and#healthy#control#(p=0.357)#groups,#it#resulted#in#the#serum#25AOHvD#results#for#
the# MS# group# significantly# deviating# from# a# normal# distribution# (p<0.0005).# NonAparametric#
statistical#tests#were#therefore#used#in#the#analysis#of#the#raw#serum#25AOHvD#values.##
When# the# three# groups# were# compared# using# a# KruskalAWallis# test,# there# was# a# nonAsignificant#
difference# between# the# three# groups# overall# (p=0.093).# Similarly,# when# the#medians# of# the# three#
groups# were# compared# there# was# no# significant# difference# between# the# three# groups# (p=0.173).#
However,#when#pairwise#comparisons#between#the#serum#25AOHvD#levels#were#performed,#people#
with# MS# had# significantly# higher# serum# 25AOHvD# levels# than# healthy# controls# (p=0.048,# Mann#
Whitney# U# test)# (table# 5.4# and# figure# 5.6).# There# was# a# trend# towards# a# significant# difference#
between#the#people#with#MS#and#their#unaffected#siblings#(p=0.061)#(table#5.4#and#figure#5.6).#There#
















































































As# previously# described# in# section# 4.2.9,# the# serum# values# 25AOHvD# for# each# individual# were#
matched#to#the#relevant#quintile#described#by#Munger#et#al#(147),#and#that#quintile#assigned#to#the#
individual#concerned.#The#serum#levels#of#25AOHvD#used#to#define#each#of#the#quintiles#are#given#in#



















hoc# pairwise# analysis# was# performed# using# Fisher’s# exact# test,# there# was# a# highly# significant#





with# MS# and# their# unaffected# siblings# compared# to# healthy# controls,# there# was# no# significant#
196#
#
increase# or# decrease# in# the# chance# of# being# in# any# quintile# in# either# group# (data# not# shown).#









There# was# an# unexpected# significant# increase# in# the# proportion# of# people# with# MS# being# in# the#
highest# quintile# of# serum# 25AOHvD.# This# finding#was# in# contrast# to#multiple# previous# publications#
associating#MS#with# a# low# serum#25AOHvD# (281).# It# seems#plausible# that# this# increase#was#due# to#
postAdiagnosis#behavioural#modification#in#the#MS#group,#with#people#with#MS#being#more#likely#to#
take#vitamin#D#supplements# regularly,#especially#given# the# increasing#awareness#of# the#prevalence#
and#potential#effects#of#vitamin#D#deficiency.##
15/78#people#with#MS#reported#regularly#taking#vitamin#D#supplementation#(>3x/week),#compared#
to# 4/121#of# their# siblings# and#5/103#healthy# controls# (table#5.4).# This# difference# in# the#proportion#
197#
#
supplementing# between# the# groups# was# highly# statistically# significant# (p<0.0001,# Chi# square# 3x2#
table).#On#postAhoc#pairwise#analysis#there#was#a#significant#difference# in#the#proportion#of#people#
with#MS#and#their#unaffected#siblings#regularly#supplementing#(p=0.0003,#Fisher’s#exact#test)#and#the#
proportion# of# people# with# MS# and# healthy# controls# regularly# supplementing# (p=0.0033,# Fisher’s#







serum# vitamin# D# levels# therefore# remains# unexplained# to# some# degree.# Given# the# fact# that# postA
diagnosis#behavioural#modification#therefore#cannot#be#assumed#to#account#for#the#observed#bulge#
in# the# highest# quintile# of# serum# vitamin#D,# the# samples# giving# these# unexpected# results#were# not#
removed#from#the#cohort#when#calculating#the#overall#MS#risk#score.##
5.1.2.6.4. Historical!serum!25Hhydroxyvitamin!D!levels!in!people!with!MS!
To# further# test# the# hypothesis# that# the# increased# proportion# of# patients#with#MS#with# serum# 25A
OHvD#levels#in#the#highest#quintile#was#a#result#of#behavioural#modification,#those#subjects#with#MS#
who# had# previously# had# serum# 25AOHvD# levels# measured# at# the# Royal# London# Hospital# were#
identified.# There# were# 10# subjects# who# had# serum# 25AOHvD# levels# recorded# prior# to# 2011.#
Deseasonalised#values#were#used#in#this#comparison.#Results#for#each#participant#are#given#in#table#
4.15.# 8/10# patients# had# an# increase# in# serum# 25AOHvD# following# the# initial# measurement# of# the#


































the#MS#and#unaffected# sibling#groups.#However,# the#evidence# that# this#postAdiagnosis#behavioural#
effect# is# solely# responsible# for# the# relatively# high# vitamin#D# levels# in# this# study# is#weak.#Not# all# of#
those#supplementing#have#very#high#vitamin#D#levels,#and#not#all#of#those#with#high#vitamin#D#levels#
report# regularly#supplementing.#There# is# little#evidence#to#support#a# theory#that#a#diagnosis#of#MS#
























MS!(n=64)! 4#(6.3%)# 33#(51.6%)# 27#(42.2%)a#
Sibling!(n=92)! 4#(4.3%)# 40#(43.5%)# 48#(52.2%)#




There# was# a# highly# significant# difference# overall# regarding# the# rate# of# HLAADRB1*1501# carriage#
(p<0.0001,#Chi# square#3x2# table).# There#was#a#nonAsignificant#difference#between#people#with#MS#
and#their#unaffected#siblings#with#respect#to#HLAADRB1*1501#carriage.#There#was#a#highly#significant#
difference#between#healthy# controls# and#both#people#with#MS# (p=0.0001,# Fisher’s# exact# test)# and#









SNPs# in# the# three# populations# studied.# In# the# MS# population,# 9# SNPs# were# seen# at# significantly#
different# frequency# than# would# be# expected.# In# the# sibling# population# 5# SNPs# were# seen# at#
significantly#different#frequency#than#expected,#and#5#were#seen#at#significantly#different#frequency#




countries# including# Finland,# Sweden,# Norway,# Denmark,# Poland,# Spain# and# Italy.# Background#
expected#genotype#frequencies#were#not#available#divided#by#country#of#origin,#and#it#may#well#be#
that#the#frequencies#of#some#variants#differ#considerably#between,#for#example,#Spain#and#the#UK.##
Clearly#with# a# relatively# small# sample# size,# differences# in# the# observed:expected# ratios#would# not#





















the# risk# scores# generated.# In# a# ROC# curve# true# positives# (sensitivity)# are# plotted# against# false#




of# the# difference# in# scores# between# the# two# groups# (MS# and# HC).# The# confidence# interval# is# the#
range#in#which#you#can#be#95%#certain#that#the#true#AUC#resides.##
In# order# to# assess# the# potential# clinical# utility# of# the# putative#MS# risk# score,# the# overall# risk# score#
distribution#was#partitioned#using#the#healthy#control#risk#score#distribution,#and#the#risk#of#MS#for#














The# initial#MS# risk# score# was# generated# using# the# genetic# information# regarding# carriage# of# HLAA
DRB1*1501#only.#The#distribution#of#the#MS#risk#score#was#Gaussian#for#people#with#MS,#unaffected#
siblings# and# healthy# controls;# therefore# parametric# statistical# tests# were# used# to# compare# the#
groups.#Details#regarding#the#MS#risk#scores#obtained#by#each#group#are#given#in#table#5.7.#There#was#
a#significant#difference#in#the#MS#risk#scores#between#the#three#groups#(p<0.0005;#oneAway#ANOVA)#
(table# 5.7# and# figure# 5.10).# PostAhoc# testing# using# a# Bonferroni# correction# revealed# significant#
differences#between#all#three#groups#(table#5.7#and#figure#5.10).#People#with#MS#had#a#significantly#
higher#MS#risk#score#than#both#their#unaffected#siblings#(p<0.0005)#and#healthy#controls#(p<0.0005).#
There#was#also#a# significant#difference#between#mean#MS# risk# scores#of# the#unaffected# siblings#of#
people#with#MS#and#the#healthy#controls#(p=0.042)#(table#5.7#and#figure#5.10).##
A#receiver#operating#characteristic#(ROC)#curve#comparing#people#with#MS#with#healthy#controls#(i.e.#





























































score,# according# to# the# methods# described# by# de# Jager# et# al# (157).# The# seven# categories# were#
defined# as# +/A# 0p25,# 0p75,# and# 1p25# standard# deviations# from# the# mean;# the# extreme# categories#
(categories#1#and#7)#were# less#than#1p25#or#greater#than#1p25#SD#from#the#mean#respectively,#with#
category# 1# representing# the# lowest# risk# score,# and# category# 7# the#highest.# By#partitioning# the# risk#
scores# in# this# way,# a# direct# comparison# of# the# proportion# of# participants# obtaining# extreme# risk#
scores#between#groups#was#possible.#An#initial#calculation#compared#the#proportion#of#people#with#



















































There#was#a# significant# increase# in# the#odds# ratio#of#people#with#MS#being# in# the# two#highest# risk#
score# categories#when# compared# to# healthy# controls# (OR#2.18# and#6.29,# p=0.02# and#p<0.0001# for#
highest# two# categories# respectively)# (table# 5.9# and# figure# 5.12a).# There# was# also# a# significant#
increase#in#the#odds#ratio#of#the#unaffected#siblings#of#people#with#MS#being#in#the#highest#risk#score#
category# when# compared# to# healthy# controls# # (OR# 2.46,# p=0.04)# (table# 5.9# and# figure# 5.12b).# A#
regression#model# was# used# to# assess# the# trend# across# the# groups;# the# OR# was# assumed# to# be# a#
continuous# variable# for# the# purposes# of# this# model.# Models# were# created# for# linear,# logarithmic,#
quadratic,# and# exponential# models,# and# the# p# values# for# the# trends# compared.# There# was# a#
significant#trend#across#groups#when#the#quadratic#and#exponential#models#were#used#(p=0.019#and#





















































































significantly# increased# odds# ratio# of# having# MS# compared# to# being# a# healthy# control# (OR# 10.56,#
95%CI#3.4441A32.3936;#p<0.0001)#and#also#a#significantly#increased#odds#ratio#of#being#a#sibling#of#a#
person#with#MS#(OR#5.64,#95%CI#1.7538A18.1417;#p=0.004).#This#highlights#the#potential#utility#of#this#
risk# score,# as# those# with# a# low# risk# score# are# significantly# less# likely# than# chance# to# have# MS;#





































The#odds# ratio#of#being# in# the#highest#category#of# the# risk# score# (i.e.# category#7)# compared# to# the#
lowest# category# of# the# risk# score# (i.e.# category# 1)# was# then# calculated# for# each# of# the# three#
categories# (MS,# unaffected# siblings# and# healthy# controls).# People# with# MS# had# a# significantly#
increased#risk#of#being#in#the#highest#category#(OR#169.00;#95%#CI#22.11A1291.87;#p<0.00001),#where#
the#odds#of#being#in#the#lowest#category#of#the#risk#score#was#taken#as#the#reference#category.#There#
















way# ANOVA)# (table# 5.8# and# figure# 5.16).# PostAhoc# testing# showed# that# there# were# significant#
differences#between#all#pairwise#combinations# (table#5.8#and# figure#5.16).#The#difference#between#
the#mean#MS#risk#score#of#people#with#MS#and#their#unaffected#siblings#was#highly#significant,#as#was#



















full# genetic# information#was#partitioned# into# seven# categories#using# the#distribution#and# values#of#
the#healthy#control#population.#As#previously,# the#seven#categories#were#defined#as#+/A#0p25,#0p75,#





























































































































Finally,# the# odds# ratio# of# being# in# the# highest# category# of# the# risk# score# compared# to# the# lowest#
category#of#the#risk#score#was#calculated.#People#with#MS#had#a#significantly#increased#risk#of#being#













Given# the# potential# for# postAdiagnosis# behavioural# modification# in# terms# of# vitamin# D#
supplementation# in# the# MS# group# (discussed# in# section# 5.1.2.6),# a# comparison# of# the# risk# scores#
excluding#the#contribution#from#serum#25AOHvD#levels#were#also#performed.##
When#the#MS#risk#score#calculated#with#the#genetic#contribution#from#HLAADRB1*1501#only#had#the#
contribution# from# serum#25AOHvD# levels# excluded,# the# scores# remained# normally# distributed.# The#
overall#significant#difference#between#the#risk#scores#remained#(p<0.0005,#oneAway#ANOVA)#(figure#
5.20#and#table#5.8).#However,#whilst#on#postAhoc#testing#the#significant#difference#between#people#
with# MS# and# their# unaffected# siblings# (p<0.0005)# and# healthy# controls# (p<0.0005)# remained,# the#


















Partitioning# the# risk# score# into#seven#categories#gave#similar# results# to# those#described#previously.#
There# was# a# significantly# reduced# odds# of# people# with# MS# being# in# categories# 1# and# 4,# with# a#
borderline#significant#reduction#in#the#risk#of#being#in#category#3.#There#was#a#significantly#increased#
























































probability# of# being# a# healthy# control# subject# for# the# subjects# in# each#MS# risk# score# category#was#
then#calculated#and#expressed#as#an#odds#ratio##(table#5.17#and#figure#5.22).##There#was#a#significant#
exponential# trend# across# the# OR# for# the# groups# (p=0.006# and# p=0.052# for# people# with# MS# and#
unaffected#siblings#respectively)#(table#5.18).#Those#participants# in#the#lowest#MS#risk#score#groups#










































































5.2.5. Effect! of! excluding! serum! 25Hhydroxyvitamin! D! from! calculations! including! full!
genetic!data.!!
When# the# MS# risk# score# with# all# genetic# information# had# the# contribution# from# serum# 25AOHvD#
levels#excluded,#the#MS#risk#scores#of#the#three#groups#remained#normally#distributed.#There#was#a#
significant# difference# overall# between# the#MS# risk# scores# of# the# three# groups# (p<0.0005,# oneAway#
ANOVA)# (table# 5.8# and# figure# 5.24).# PostAhoc# testing# showed# that# the#differences#were# significant#
between#all#pairwise#combinations#(table#5.8#and#figure#5.24).#The#difference#between#the#mean#MS#






























(table# 5.23# and# figure# 5.27).# Again,# the# exponential#model# showed# the# best# relationship#with# the#
trend# for# the# OR# over# the# categories# (p=0.009# for# people# with# MS# and# p=0.003# for# unaffected#















































































































5.2.6. Effect! of! excluding! serum! 25Hhydroxyvitamin! D! levels! on! MS! risk! scores! of!
unaffected!siblings!






In# order# to# attempt# to# explore# the# potential# effect# of# excluding# serum# 25AOHvD# levels# from# the#
model,#a#number#of#postAhoc#analyses#were#performed.#The#MS#risk#score#calculated#using#genetic#
information# from# HLAADRB1*1501# only# was# used# in# this# analysis,# in# order# to# ensure# that# the#
contribution#from#serum#25AOHvD#levels#towards#the#final#score#was#the#largest#possible#proportion#




56.11nmol/l,# compared# to# 56.22nmol/l# for# those# siblings# in# the# higher# MS# risk# score# cohort#
(difference# not# significant)# (figure# 5.28a).# In# order# to# ensure# that# the# lack# of# difference# was# not#
caused# by# subjects# with#MS# risk# scores# around# the#median,# the# serum# 25AOHvD# levels# of# the# 20#




levels# in# each# category# of# the# MS# risk# score# (i.e.# categories# 1A7)# were# compared.# There# was# no#
234#
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A# final# analysis# was# performed# whereby# the# individuals# with# the# 20# highest# and# lowest# MS# risk#
scores#were#determined#both#with# serum#25AOHvD# levels# included#and#excluded# from#the#MS# risk#
score# calculation.# The# individuals# identified# using# each# method# were# then# compared# in# order# to#
assess#the#overlap#in#individuals#identified#using#each#method.#18/20#individuals#for#both#the#lowest#
and# highest# MS# risk# scores# were# the# same# regardless# of# whether# serum# 25AOHvD# levels# were#
included# in# the# risk# score# calculation#or#not.# The# similarity#between# the# two#groups#highlights# the#













approaching#clinical#utility#–#0.818.#This# is# far#superior# to#previous#attempts# to#develop#such#a#risk#
score,#which#were#able#to#achieve#an#AUC#of#0.69#(275)#and#0.72#(157).#A#value#of#0.85#is#generally#
taken#as#the#level#at#which#a#test#becomes#potentially#clinically#useful#(157).#It#is#not#clear#whether#
inclusion# of# serum# 25AOHvD# levels# in# a# population# that# had# not# undergone# postAdiagnosis#
behavioural#modification#would# improve# the#AUC# further;# it# could#be# supposed# that# this#might#be#




the# region# of# 10,# regardless# of# the# risk# score# calculated.# Similarly,# for# those# with# the# lowest# risk#
score,#the#risk#of#MS#was#significantly#reduced.#This#highlights#the#potential#utility#of#the#risk#score#
from#a# clinical#point#of# view#–#whilst# it# is#more#difficult# to# interpret#an# intermediate# score,# a#high#
score#is#associated#with#a#far#higher#risk#of#MS.#The#most#robust#trend#of#the#odds#ratios#with#respect#











Clearly# further#work# is# required# to# validate# the# suggested#MS# risk# score.# Firstly,# a# larger# cohort#of#

















The# study# of# the# risk# of# additional# autoimmune# diseases# both# in# people#with#MS,# and# their# firstA
degree#relatives#has#been#pursued#over#many#years,#with#studies#employing#a#variety#of#designs#and#
yielding#conflicting#results#(282).#As#part#of#this#sibling#study,#both#people#with#MS#and#their#siblings#
were# questioned# about# coAmorbidities,# including# autoimmune# diseases.# Whilst# this# represents# a#
relatively#smallAscale#contribution#to#the#literature#on#autoimmune#disease#in#MS,#the#opportunity#to#
directly# question# siblings# of# people#with#MS# regarding# their# comorbidities# provided# an# interesting#
avenue#of#study.##
The# most# recent# largeAscale# study# to# attempt# to# address# this# question# (283)# used# the# Swedish#




seen# in#MS#may# be# a# result# of# the# increased# contact# that# people# with#MS# have# with# healthcare#
professionals,# implies# that# there#may# be# either# surveillance# or# reporting# bias# underlying# previous#
reports#of#an#increased#risk#of#additional#diagnoses.##
However,# this# study# (283)# is# not# the# only# one# using# a# national# database# in# order# to# attempt# to#








of# the#most# commonly# used# databases# in# the# UK,# the# Hospital# Episodes# Statistics# (HES)# database#
carry# a# considerable# risk# of# overestimating# the# population# risk.# The#HES# database# uses# data# from#
hospital# inpatients# only,# and# so# does# not# capture# those# members# of# the# population# who# do# not#




Another# important# consideration# is# that# rates# of# autoimmune# disease# may# differ# considerably#
between#males# and# females.# Overall# population# rates#merely# provide# an# average# rate,# and#when#
comparing# populations# where# the# gender# distribution# is# not# identical# between# the# populations#
under# study# (as# in# this# cohort),# genderAspecific# disease# rates# must# be# used# where# there# is# a#
difference#in#male#and#female#rates#of#the#disease#in#question.##
Overall# and#genderAspecific#disease# rates#were# therefore#established# from#the#published# literature#
for# a# variety#of# autoimmune#and#other#diseases.# The#nonAautoimmune#diseases#examined# (type#2#
diabetes# and# seizures)# were# included# as# it# was# felt# important# to# have# a# comparator# to# the#
autoimmune# diseases.# Hypothyroidism# was# used# as# a# surrogate# marker# for# autoimmune# thyroid#







if# they# had# any# past# medical# history# of# thyroid# disorders,# diabetes,# arthritis,# lupus,# psoriasis,#
gastrointestinal# problems# or# if# they# had# ever# had# a# seizure.# If# they# answered# yes# to# any# of# these#
questions,# further# questions# were# asked# regarding# both# the# precise# diagnosis# (if# known),# the#
investigations# that# they#had#undergone,# and#any# treatment# that# they#had# received.# In# the# case#of#
diabetes,#participants#were#questioned#regarding#the#use#of#insulin#and#oral#therapies,#together#with#
the#age#of#diagnosis.#From#this#information,#it#was#possible#to#infer#a#diagnosis#for#those#participants#
who# were# unsure# as# to# their# precise# diagnostic# label.# In# addition,# participants# were# all# asked# to#
provide#a#full#list#of#medication.#If#any#participants#were#taking#medications#such#as#thyroxine,#they#
































Hashimotos/hypothyroidism! 80# 170# 20# (290A293)#
Type!1!diabetes! 34# 34# 34# (291,#292,#
294,#295)#
Type!2!diabetes! 450# 340# 430# (296)#
Rheumatoid!arthritis! 55# 107# 47# (291,#292,#
297)#




2.7# 4.8# 0.5# (291,#292,#
298,#299)#
Psoriasis! 150# 150# 150# (300)#
Coeliac!disease! 5# 5.4# 4.7# (297)#
Inflammatory!bowel!disease! 26# 26# 26# (301)#







a# number# of# disease# in# both# the# MS# and# the# sibling# population.# These# are# mainly# autoimmune#
diseases:#Hashimotos#disease,#pernicious#anaemia,#celiac#disease#and#inflammatory#bowel#disease#all#
















Hashimotos/hypothyroidism# N/A# 2.52#(0.82F7.70)# 62.5&(9.49>411.6)& N/A# 6.38&(3.38>12.03)& 13.16#(1.81F
95.58)#
Type#1#diabetes# No#cases# No#cases# No#cases# 2.43#(0.34F17.61)# 3.54#(0.49F25.58)# No#cases#
Type#2#diabetes# N/A# 0.42#(0.06F3.02)# No#cases# N/A# 1.06#(0.33F3.39)# No#cases#
Rheumatoid#arthritis# No#cases# No#cases# No#cases# N/A# 1.13#(0.16F7.97)# No#cases#
Pernicious#anaemia# 19.72&(4.53>
85.95)&
21.98&(5.05>95.59)& No#cases# 12.71&(2.90>55.74)& 18.54&(4.25>80.85)& No#cases#
Systemic#lupus#
erythematosus#(SLE)#
N/A# No#cases# No#cases# N/A# 50.20&(12.40>203.17)& No#cases#
Psoriasis# No#cases# No#cases# No#cases# 1.10#(0.26F4.76)# 0.80#(0.11F6.01)# 1.75#(0.24F12.94)#
Coeliac#disease# N/A# 26.46&(3.71>188.58)& No#cases# N/A# 22.31&(3.12>159.40)& No#cases#
Inflammatory#bowel#disease# 9.86&(2.38>40.84)& 10.99&(2.66>45.41)& No#cases# 6.36&(1.53>26.49)& 9.27&(2.24>38.42)& 20.24&(4.98>
82.29)&







As$ discussed$ above,$ there$ is$ therefore$ a$ large$ amount$ of$ information$ available$ examining$ the$
frequency$of$autoimmune$disease$both$in$people$with$MS$and$their$first@degree$relatives.$I$set$out$
to$ perform$ a$ systematic$ review$ of$ the$ frequency$ of$ selected$ autoimmune$ diseases$ (autoimmune$
thyroid$ disease,$ type$ 1$ diabetes$ mellitus,$ inflammatory$ bowel$ disease,$ psoriasis,$ systemic$ lupus$
erythematosus$ and$ rheumatoid$ arthritis)$ in$ both$ people$ with$MS$ and$ their$ first@degree$ relatives.$







which$ gave$ figures$ for$ the$ prevalence$ of$ specified$ autoimmune$ diseases$ in$ both$MS$ and$ healthy$
control$populations.$The$control$population$had$to$be$matched$to$the$MS$population$in$terms$of$age$
and$ sex,$ or$ alternatively$ a$ precise$ local$ population$ prevalence$ of$ autoimmune$ disease$ had$ to$ be$
given$ (approximations$ of$ overall$ population$ rates$ were$ not$ felt$ to$ be$ sufficiently$ precise).$ The$






PubMed$ and$Web$ of$ Science$ were$ searched$ using$ the$ terms$ “multiple$ sclerosis”$ AND$ “thyroid”,$
“multiple$ sclerosis”$ AND$ “diabetes”,$ “multiple$ sclerosis”$ AND$ “Crohn’s”,$ “multiple$ sclerosis”$ AND$
“Crohns”$“multiple$sclerosis”$AND$“ulcerative$colitis”,$“multiple$sclerosis”$AND$“inflammatory$bowel$
disease”,$“multiple$sclerosis”$AND$“psoriasis”,$“multiple$sclerosis”$AND$“lupus”,$“multiple$sclerosis”$
AND$ “SLE”,$ “multiple$ sclerosis”$ AND$ “rheumatoid”$ and$ “multiple$ sclerosis”$ AND$ “arthritis”.$ The$







A$ generic$ inverse$ variance$ fixed$ or$ random$ effects$model$ was$ used$ for$ the$ statistical$ analysis$ as$
appropriate.$A$random$effects$model$was$applied$unless$I2$was$≤$25%;$in$which$case$a$fixed$effects$
model$ was$ used$ (15).$ $ Between@study$ heterogeneity$ was$ assessed$ for$ each$ calculation$ using$
Cochran's$Q$chi@square$test$and$I2$(16).$$Where$present,$heterogeneity$was$explored$using$subgroup$
analysis.$ Risks$ were$ reported$ as$ pooled$ OR$ and$ 95%$ confidence$ intervals$ (CI).$ Bias$ was$ assessed$
using$ visual$ inspection$ of$ funnel$ plots;$ and$where$ >10$ studies$were$ included,$ quantified$ using$ an$









same$ cohorts$ were$ used$ in$ later$ published$ articles.$ 41$ unique$ papers$ were$ initially$ selected$ for$


































(TPO$and$Tg)$ $ $ 11$(8.5)$(Tg)$ 11$(3.9)$ $ $
AIT$ Matched$families$ 571/375/$
2124/1315$
$ $ 263$(12.4)$ 71$(3.3)$
SLE$ $ $ $ $ 13$(0.6)$ 0$(0)$
T1DM$ $ $ $ $ 47$(2.2)$ 18$(1.4)$
Psoriasis$ $ $ $ $ 195$(9.2)$ 87$(6.6)$










DM$ Stroke$patients$ 146/198$ 6$(4.1)$ 23$(11.6)$ $ $
Hypothyroidism$ OND$ 828/100$ 4$(0.5)$ 1$(1.0)$ $ $
T1DM$ $ $ 4$(0.5)$ 1$(1.0)$ $ $
UC$ $ $ 2$(0.2)$ 0$(0)$ $ $
Notes$review$
Cross$sectional$
RA$ $ $ 5$(0.6)$ 1$(1.0)$ $ $
Thyroid$
autoantibodies$$





CaseAcontrol$ ANA$ $ $ 20$(19.0)$ 8$(7.6)$ $ $
AIT$ HC$ 891/355/$
3112/1580$
$ $ 258$(8.3)$ 52$(3.3)$
SLE$ $ $ $ $ 20$(0.6)$ 9$(0.6)$
IDDM$ $ $ $ $ 37$(1.2)$ 6$(0.4)$
Psoriasis$ $ $ $ $ 33$(1.1)$ 9$(0.6)$






















Blood$donors$ 156/437$ 9$(5.8)$ 16$(3.7)$ $ $
AIT$$ Local$population$ 658/2779$ 21$(3.2)$ 50$(1.8)$ $ $
T1DM$ $ 658/252538$ 6$(0.9)$ 128$(0.1)$ $ $
Psoriasis$ $ $ 9$(1.4)$ 1836$(0.7)$ $ $
RA$ $ $ 2$(0.3)$ 824$(0.3)$ $ $










6$(5.1)$ 15$(6.8)$ 12$(1.7)$ 11$(0.7)$
Hypothyroidism$ $ $ 3$(2.6)$ 8$(3.6)$ $ $
SLE$ $ $ 2$(1.7)$ 1$(0.5)$ 6$(0.8)$ 7$(0.4)$
T1DM$ $ $ 1$(0.9)$ 2$(1.0)$ 5$(0.7)$ 4$(0.3)$
Psoriasis$ $ $ 6$(5.1)$ 7$(3.2)$ 9$(1.2)$ 17$(1.1)$


































$ $ 0$(0)$ 0$(0)$ $ $
Kang&2010& Database$ Hypothyroidism$ HC$ 898/4490$ 15$(1.7)$ 24$(0.5)$ $ $
252$
$
Hypothyroidism$ HC$ 898/4490$ 15$(1.7)$ 24$(0.5)$ $ $
SLE$ $ $ 26$(2.9)$ 5$(0.1)$ $ $
T1DM$ $ $ 3$(0.3)$ 1$(0.0)$ $ $
(288)& CaseAcontrol$
























HC$ 5296/26478$ 9$(0.2)$ 47$(0.2)$ $ $
SLE$ $ $ 20$(0.4)$ 75$(0.3)$ $ $
T1DM$ $ $ 45$(0.8)$ 240$(0.9)$ $ $
Psoriasis$ $ $ 70$(1.3)$ 319$(1.2)$ $ $





RA$ $ $ 44$(0.8)$ 228$(0.9)$ $ $
AIT$ HC$ 245/245/$
984/1002$
9$(3.7)$ 7$(2.9)$ 13$(1.3)$ 10$(1.0)$
DM$prior$to$age$
20$
$ $ 9$(3.7)$ 1$(0.4)$ 8$(0.8)$ 3$(0.3)$



















28$(2.6)$ 194$(0.5)$ 53$(1.0)$ 194$(0.5)$
Goitre$ Hospital$
inpatients$




DM$ $ $ 0$(0)$ 0$(0)$ 25$(3.5)$ 21$(2.1)$
253$
$
Psoriasis$ $ $ 12$(7.7)$ 8$(4.0)$ 12$(1.7)$ 23$(2.3)$& $




















$ $ 11$(11.8)$ 10$(2.5)$ $ $
Clinical$review$
CaseAcontrol$















HC$ x/x/14771/14771$ $ $ 56$(0.4)$ 39$(0.3)$
Hashimoto$ HC$ 10596/10596/$
20800/20800$
0$(0)$ 0$(0)$ 0$(0)$ 0$(0)$
SLE$ $ $ 2$(0.0)$ 4$(0.0)$ 9$(0.1)$ 7$(0.1)$
Psoriasis$ $ $ 18$(0.2)$ 12$(0.1)$ 16$(0.1)$ 22$(0.1)$
UC$ $ $ 29$(0.3)$ 15$(0.$1)$ 51$(0.2)$ 39$(0.2)$





















based$cohort$ SLE$ $ $ 28$(0.6)$ 7$(0.3)$ $ $
254$
$
T1DM$ $ $ 19$(0.4)$ 14$(0.5)$ 112$(0.4)$ 14$(0.5)$
Psoriasis$ $ $ 293$(5.8)$ 146$(5.4)$ $ $
UC$ $ $ 9$(0.2)$ 4$(0.1)$ 88$(0.3)$ 4$(0.1)$
Crohn’s$ $ $ 11$(0.2)$ 4$(0.1)$ 57$(0.2)$ 4$(0.1)$
& $
RA$ $ $ 153$(3.0)$ 66$(2.4)$ 529$(1.7)$ 66$(2.4)$
T1DM$ HC$ 20276/203951/$
23242/251423$
966$(4.8)$ 8611$(4.2)$ 1730$(7.4)$ 18558$(7.4)$
Psoriasis$ $ $ 122$(0.6)$ 800$(0.3)$ 119$(0.5)$ 1126$(0.4)$
UC$ $ $ 113$(0.6)$ 819$(0.4)$ 82$(0.4)$ 821$(0.3)$




























AIT$ OND$ 491/532$ 41$(8.4)$ 14$(2.6)$ $ $
Hypothyroidism$ HC$ 4332/4332$ 61$(1.4)$ 42$(1.0)$ $ $





based$cohort$ RA$ $ $ 30$(0.7)$ 38$(0.9)$ $ $
Clinical$thyroid$
dysfunction$









































































T1DM$ HC$ 334/334$ 3$(1.0)$ 0$(0)$ $ $





T1DM$ $ $ 9$(4.7)$ 6$(3.1)$ $ $
$
OND:$Other$nonAinflammatory$neurological$diseases$ $ $ $ $ HC:$healthy$controls,$without$evidence$of$MS$
AIT:$all$autoimmune$thyroid$disease$ $ $ $ $ $ SLE:$systemic$lupus$erythematosus$
T1DM:$type$1$diabetes$mellitus$ $ $ $ $ $ $ DM:$diabetes$mellitus$
UC:$ulcerative$colitis$ $ $ $ $ $ $ $ IBD:$inflammatory$bowel$disease$
RA:$rheumatoid$arthritis$ $ $ $ $ $ $ TMA:$thyroid$microsomal$antibodies$
TPO:$thyroid$peroxidase$antibodies$ $ $ $ $ $ Tg:$antiAthyroglobulin$antibodies$









cannot$ be$ said$ of$ hyperthyroidism.$ Some$ studies$ therefore$ used$ hypothyroidism$ as$ a$ surrogate$
diagnosis$ for$ autoimmune$ thyroid$ dysfunction.$Nineteen$ studies$ examined$ thyroid$ function$ in$MS$
(285@288,$308,$312,$313,$316@318,$321,$323,$324,$326@329,$331,$334).$ In$ five$of$ these$studies$ (285,$
316,$ 323,$ 329,$ 331)$ there$were$ no$ cases$ of$ thyroid$ dysfunction$ in$ either$MS$patients$ or$ controls,$
therefore$these$could$not$be$included$in$the$analysis.$The$remaining$fourteen$studies$gave$an$overall$
increased$ risk$ of$ thyroid$ dysfunction$ in$ people$ with$ MS$ (OR$ 1.66,$ 95%CI$ 1.35@2.05,$ p<0.00001),$
without$ between@study$ heterogeneity$ (Cochran's$ Q$ p=0.16,$ I2=27%)$ (figure$ 6.2a).$ A$ funnel$ plot$
demonstrated$no$significant$publication$bias$(figure$6.3a),$with$an$Egger$p@value$of$0.76.$When$those$
studies$using$hypothyroidism$as$a$marker$of$autoimmune$thyroid$disease$were$selected$(286,$288,$
308,$313,$317),$ there$was$an$ increased$ risk$ in$people$with$MS$ (OR$1.72,$95%CI$1.00@2.97,$p=0.05)$
with$no$heterogeneity.$A$similar$effect$was$seen$when$only$ those$studies$specifying$“autoimmune$
thyroid$disease”$were$selected$(312,$318,$324,$326,$328,$334)$(OR$1.72,$95%CI$1.46@2.04,$p<0.00001).$
When$ cases$ of$ Hashimoto’s$ thyroiditis$ were$ analysed$ separately$ (287,$ 318,$ 328)$ there$ was$ no$
increased$risk$in$people$with$MS$(OR$1.42,$95%CI$0.72@2.79,$p=0.31).$























































































































































Ten$ studies$ examined$ thyroid$ autoantibodies$ in$MS$ (306,$ 308,$ 311,$ 315,$ 316,$ 323,$ 324,$ 327,$ 329,$
332).$ One$ study$ (316)$ did$ not$ detect$ any$ antibodies$ in$ either$ MS$ patients$ or$ controls,$ and$ was$
excluded$from$the$analysis.$There$was$an$overall$increased$rate$of$thyroid$autoantibodies$in$patients$
with$ MS$ compared$ to$ healthy$ controls$ (OR$ 2.36,$ 95%CI$ 1.32Q4.20,$ p=0.004)$ but$ with$ significant$
heterogeneity$(Cochran's$Q$p=0.0001,$I2=74%).$There$was$no$evidence$of$publication$bias$(Egger$pQ
value=0.56).$ $ Heterogeneity$ was$ explored$ by$ examining$ each$ thyroid$ autoantibody$ individually,$
however$each$attempt$at$subgroup$analysis$resulted$in$a$small$number$of$studies$being$examined.$
No$ studies$ gave$ data$ regarding$ the$ rate$ of$ thyroid$ autoantibodies$ in$ relatives$ of$ MS$ patients$
compared$to$healthy$controls.$$
6.1.4.5.2. Type'1'diabetes'mellitus'
Seventeen$ studies$ (283,$ 286Q288,$ 307,$ 308,$ 312,$ 313,$ 318Q321,$ 326,$ 333Q336)$ gave$data$ regarding$
the$ number$ of$ people$ with$MS$ and$ coQexisting$ diabetes.$ One$ study$ (321)$ contained$ no$ cases$ of$
diabetes$ in$ either$people$with$MS$or$ controls.$ There$was$an$ increased$ risk$of$diabetes$ associated$
with$MS$overall$(OR$2.02,$95%CI$1.22Q3.40,$p=0.006)$(figure$6.4a).$However,$this$was$associated$with$




with$ stroke$ as$ the$ control$ group$ was$ also$ excluded$ (307),$ given$ the$ association$ of$ stroke$ with$
diabetes.$This$strengthened$the$relationship$between$MS$and$diabetes$(OR$2.69,$95%CI$1.43Q5.04),$
but$ heterogeneity$ remained$ (Cochran's$ Q$ p<0.00001,$ I2=94%).$ Separating$ studies$ using$ large$












291,$ 309,$ 313,$ 318,$ 320,$ 321,$ 326,$ 335,$ 336).$ There$ was$ an$ overall$ increased$ risk$ of$ diabetes$ in$












(OR$ 1.13,$ 95%CI$ 0.82Q1.57),$ with$ no$ significant$ heterogeneity$ and$ insufficient$ studies$ to$ assess$
publication$bias$ (figure$ 6.5c).$ Interestingly,$when$ those$ studies$ using$ a$ questionnaire$ design$were$
used$ (291,$309,$313,$318,$320,$321,$326),$ there$did$appear$ to$be$an$ increase$ in$ the$ risk$of$ type$1$






























MS$for$ inflammatory$bowel$disease$was$calculated.$This$showed$an$ increased$risk$of$ inflammatory$
bowel$disease$with$MS$(OR$1.56,$95%$CI$1.28Q1.90,$p<0.0001)$(figure$6.6a).$No$increase$in$risk$was$
seen$ in$ relatives$of$people$with$MS$ (OR$1.29,$95%$CI$0.92Q1.82,$p=0.14)$ (283,$285,$291,$309,$313,$


























Eight$ studies$examined$ the$ risk$of$psoriasis$ in$people$with$MS$ (283,$285,$287,$312,$313,$318,$321,$
326)$(figure$6.8).$There$was$a$significant$increase$in$the$risk$of$psoriasis$in$people$with$MS$(OR$1.31,$
95%CI$ 1.09Q1.57,$ p<0.0001).$ There$ was$ no$ significant$ betweenQstudy$ heterogeneity$ (Cochran's$ Q$
p=0.16,$I2=34%).$Six$studies$examined$the$risk$of$psoriasis$in$firstQdegree$relatives$of$people$with$MS$
(283,$285,$291,$309,$313,$321).$There$was$no$ increased$ risk$of$psoriasis$ in$ firstQdegree$ relatives$of$





























using$ a$ questionnaire$ design$ were$ selected$ (312,$ 313,$ 318,$ 321,$ 326),$ the$ lack$ of$ association$










On$ a$ population$ level,$ the$ only$ autoimmune$ diseases$ showing$ an$ increased$ rate$ in$ relatives$ of$
people$with$MS$are$thyroid$disease$and$type$1$diabetes.$Thyroid$disease$is$relatively$common$in$the$
general$ population.$ The$ symptoms$ of$ thyroid$ disease$ tend$ to$ be$ nonQspecific$ and$ progress$
insidiously.$The$finding$that$there$is$a$consistent$increase$in$the$rate$of$thyroid$disease$both$in$the$
MS$population$and$in$their$relatives$should$prompt$the$consideration$of$baseline$testing$of$thyroid$




function,$ with$ the$ prevalence$ of$ thyroid$ peroxidase$ antibodies$ reported$ to$ be$ as$ high$ as$ 12%$ in$
some$series$of$healthy$individuals$(337).$$











When$ thinking$ about$ the$ findings$ of$ the$ metaQanalysis,$ it$ is$ important$ to$ bear$ in$ mind$ that$ the$
accuracy$of$the$results$are$limited$by$the$quality$of$the$studies$informing$it.$Despite$the$best$efforts$
of$the$authors$of$the$studies$included$here,$it$is$highly$likely$that$diseases$are$misclassified$within$the$
studies$ included$ here.$When$ comparing$ selfQreport$ to$ GP$ verified$ diagnosis,$ Broadley$ et$ al$ (291)$
found$ that$ the$ positive$ predictive$ value$ of$ a$ patient$ reportedQcondition$ varied$ from$ 32%$ for$
rheumatoid$arthritis$ to$85%$ for$ thyroid$disease$ (291).$ This$ is$ a$major$ limitation$ for$questionnaireQ
based$ studies.$ Similarly,$ reporting$ bias$ may$ have$ led$ to$ overQestimation$ of$ autoimmune$ disease$
prevalence$amongst$people$with$MS$and$their$relatives.$This$is$particularly$apparent$in$those$studies$
examining$the$frequency$of$diabetes$in$relatives$of$people$with$MS,$where$there$is$clear$evidence$of$
publication$ bias.$ However,$ the$ majority$ of$ the$ more$ recent$ studies$ use$ largeQscale$ databases,$
potentially$minimising$ these$ sources$of$ bias.$ Interestingly,$ in$ the$ case$of$diabetes$ in$ relatives,$ the$
effect$ of$ MS$ disappears$ when$ studies$ using$ databases$ are$ analysed$ in$ isolation,$ highlighting$ the$
benefits$of$such$studies.$$
This$ work$ does$ not$ address$ the$ potential$ cause(s)$ of$ the$ increased$ rate$ of$ autoimmune$ diseases$
demonstrated$ in$ both$ people$with$MS$ and$ their$ siblings.$ This$ is$ likely$ to$ be$multifactorial,$ as$ the$
diseases$ studied$ have$ differing$ underlying$ aetiologies$ and$ pathogenesis.$ Common$ factors$ in$ the$
development$ of$MS$ and$ these$ diseases$ include$both$ genetic$ and$ environmental$ factors,$ including$
smoking$ and$ vitamin$ D$ deficiency.$ The$ conditions$ studied$ do$ not$ have$ a$ single$ underlying$
pathogenesis,$and$as$such$it$is$difficult$to$use$this$study$to$shed$light$on$the$mechanisms$underlying$








One$aim$of$ this$ study$was$ to$ validate$ the$MS$ risk$ score$ generated$ for$ siblings$of$ people$with$MS$
using$serological$and$urinary$markers$known$to$be$increased$in$people$with$MS.$One$of$the$markers$
selected$for$further$study$was$urinary$free$light$chains$(FLC).$FLC$are$known$to$be$increased$in$the$
CSF$of$people$with$MS,$ and$ their$presence$ is$ strongly$associated$with$OCBs$ (see$ chapter$3).$ They$
have$also$been$detected$at$increased$concentrations$in$the$urine$of$people$with$MS$(41,$43,$192).$$
A$hypothesis$of$this$study$was$that$some$siblings$of$people$with$MS$would$also$have$increased$FLC$in$




Urinary$ FLC$were$ therefore$ examined$ in$ all$ participants$ in$ this$ study$who$provided$ suitable$ urine$















ShapiroQWilk$ test.$ As$ the$ urinary$ FLC:protein$ measurements$ $ were$ not$ normally$ distributed,$ an$
attempt$ was$ made$ to$ normalise$ them$ using$ a$ natural$ logarithmic$ transformation.$ However,$ this$
proved$ unsuccessful.$ The$ groups$ were$ therefore$ compared$ using$ nonQparametric$ statistical$
methods.$A$KruskalQWallis$Analysis$of$Variance$was$used$to$compare$the$three$groups.$The$medians$
of$ the$ FLC:protein$measurements$were$ compared$using$ the$ Independent$ Samples$Median$ Test$ (k$
test).$ $ PostQhoc$ analysis$ using$ the$MannQWhitney$ U$ Test$was$ performed$ to$ determine$where$ the$
significant$differences$lay.$$
A$ possible$ correlation$ between$ the$ risk$ score$ and$ urinary$ FLC$ was$ assessed$ using$ the$ standard$
correlation$coefficient,$which$does$not$make$any$assumption$regarding$the$distribution$of$the$data.$
Initially$the$risk$score$with$genetic$contribution$from$HLAQDRB1*1501$was$used$in$this$analysis,$prior$
to$ a$ second$ analysis$ using$ the$ risk$ score$ with$ full$ genetic$ information.$ In$ order$ to$ compare$ the$
urinary$FLC$measurements$between$the$20$highest$risk$siblings$and$the$20$ lowest$risk$siblings,$the$
measurements$ for$ these$ samples$ were$ determined$ and$ then$ tested$ for$ normality.$ Again,$ the$
distribution$ of$ the$ urinary$ FLC:protein$ values$ was$ found$ to$ differ$ significantly$ from$ a$ Gaussian$
distribution$and$attempts$ to$normalise$ this$were$unsuccessful.$The$values$ for$ those$siblings$ in$ the$










results$ for$ these$samples$were$not$normally$distributed.$They$were$ therefore$compared$using$ the$







As$ stated$ above,$ the$ values$ for$ the$ FLC:protein$ ratios$ for$ people$ with$ MS,$ siblings$ and$ healthy$
controls$could$not$be$normalised.$NonQparametric$statistical$analysis$was$therefore$performed.$$
There$ was$ a$ significant$ difference$ between$ the$ groups$ overall$ for$ kappa$ FLC:protein$ (p=0.005),$
lambda$FLC:protein$ (p=0.002)$and$total$FLC:protein$ (p=0.004)$ (KruskalQWallis$Analysis$of$Variance).$
There$ was$ also$ a$ significant$ difference$ between$ the$medians$ for$ each$ group$ (kappa$ FLC:$ protein$




























MS$and$ their$ siblings$with$ respect$ to$ kappa$ FLC:protein$ (p=0.002),$ lambda$ FLC:protein$ (p<0.0005)$
and$total$FLC:protein$(p=0.001).$There$was$a$similar$difference$between$people$with$MS$and$healthy$
controls$ (kappa$ FLC:protein$ p=0.05,$ lambda$ FLC:protein$ p=0.015,$ total$ FLC:protein$ p=0.05).$ There$
was$ no$ significant$ difference$ between$ the$ siblings$ of$ people$ with$ MS$ and$ healthy$ controls$ with$
respect$to$any$of$the$FLC:protein$measures$(figures$6.10aQc;$table$6.4).$$
6.2.1.2.2. Comparison' between' siblings' with' high' MS' risk' score' and' low' MS' risk'
score'














risk$ score,$ there$was$no$difference$between$ the$groups$ (MannQWhitney$U$ test)$or$ the$medians$of$
the$groups$(Independent$Samples$Median$Test)$(figure$6.12aQc,$data$shown$for$risk$score$using$HLAQ
DRB1*1501$only,$similar$ results$were$obtained$for$ risk$score$using$ full$genetic$ information).$When$
the$sibling$group$was$bisected$around$the$median$MS$risk$score$and$the$urinary$FLC:protein$ratios$
compared$between$ those$with$MS$risk$ scores$above$ the$median$and$ those$with$ risk$ scores$below$
the$median$MS$risk$score,$there$was$no$significant$difference$between$the$groups$(figure$6.12d;$data$































extremes$are$selected,$or$whether$ the$entire$sibling$cohort$ is$considered$ (i.e.$bisected$around$the$
median).$ Similarly,$ when$ all$ siblings$ are$ considered,$ no$ relationship$ between$ MS$ risk$ score$ and$
urinary$FLC:protein$could$be$observed.$$
As$discussed$in$chapter$3,$the$hypothesised$relationship$between$urinary$FLC:protein$and$CSF$OCBs$
could$ not$ be$ confirmed.$ This$was$ thought$ to$ be$ due$ to$ confounding$ by$ the$ possible$ presence$ of$


















ShapiroQWilk$ test.$ As$ the$ raw$ urinary$ neopterin:creatinine$ results$ $ were$ not$ normally$ distributed,$
they$ were$ normalised$ using$ a$ natural$ logarithmic$ transformation.$ Parametric$ statistical$ methods$
were$used$on$the$log$transformed$data.$$





















was$possible$ to$ convert$ them$ to$ a$normal$distribution$using$ a$natural$ logarithmic$ transformation.$
Parametric$statistical$tests$were$therefore$used$in$the$analysis.$$
One$way$analysis$of$variance$(ANOVA)$was$used$to$compare$urinary$neopterin:creatinine$between$
people$ with$ MS,$ their$ unaffected$ siblings$ and$ healthy$ controls.$ There$ was$ an$ overall$ significant$
difference$between$the$three$groups$(p<0.0005,$figure$6.13).$When$postQhoc$analysis$was$performed$
to$ determine$ where$ the$ significant$ difference$ lay,$ there$ was$ a$ significant$ differences$ between$
















When$ the$ 20$ siblings$ with$ the$ highest$MS$ risk$ score$ were$ compared$ to$ the$ 20$ siblings$ with$ the$







































It$ is$ interesting$ to$ note$ that$ whilst$ people$ with$ MS$ appear$ to$ have$ increased$ urinary$








those$ with$ a$ low$MS$ risk$ score.$ However,$ one$ analysis,$ that$ comparing$ the$ 20$ siblings$ with$ the$
highest$MS$risk$score$to$those$with$the$lowest$MS$risk$score$determined$using$all$genetic$data,$did$
show$ a$ significant$ result.$ This$ analysis$ appeared$ to$ show$ that$ urinary$ neopterin:creatinine$ levels$
were$higher$in$those$siblings$with$a$low$MS$risk$score$compared$to$those$with$a$high$MS$risk$score.$
This$finding,$which$is$in$the$opposite$direction$to$that$hypothesised,$is$somewhat$difficult$to$explain.$

























The$original$ publication$describing$ increased$ an$ significantly$ increased$MMPQ9:TIMPQ1$ ratio$ in$ the$





















ShapiroQWilk$ test.$ As$ the$ raw$ MMPQ9:TIMPQ1$ ratios$ $ were$ not$ normally$ distributed,$ they$ were$
normalised$using$a$natural$logarithmic$transformation.$Parametric$statistical$methods$were$used$on$
the$log$transformed$data.$$
An$ initial$ comparison$ of$MMPQ9:TIMPQ1$ ratios$ between$ the$MS$ samples,$ healthy$ control$ samples$






















confirmed$ in$ this$ study.$ In$ addition,$ there$was$no$ appreciable$difference$between$MMPQ9:TIMPQ1$





does$ not$ appear$ a$ correlation$ between$ the$ two$ (338).$ Additionally,$ not$ all$ studies$ have$ used$ the$
MMPQ9:TIMPQ1$ratio$as$a$marker$of$“active$MMPQ9”,$with$others$using$alternative$techniques$(339).$
The$existing$ literature$ is$ therefore$ inconsistent$ in$ terms$of$methodology,$which$ leaves$ the$ results$
generated$difficult$to$interpret.$.$$
A$ further$possibility$ is$ that$ the$use$of$ serum$samples$adversely$affected$ the$ results.$As$previously$
stated$(section$4.2.12.2)$(338),$there$is$no$consensus$as$to$whether$serum$or$plasma$should$be$used$
for$ MMPQ9$ measurement.$ In$ the$ samples$ collected$ as$ part$ of$ this$ study,$ it$ was$ not$ possible$ to$
measure$ plasma$MMPQ9:TIMPQ1$ ratios$ as$ the$ plasma$ samples$ were$ collected$ in$ lithium$ heparin,$
which$affects$the$concentration$of$TIMPQ2$(234),$and$therefore$is$quite$likely$to$affect$TIMPQ1.$$
Further$ work$ is$ therefore$ needed$ both$ to$ determine$ the$ optimal$ biological$ fluid$ for$ the$
















intracellular$ ILQ17$ and$ FoxP3$ was$ determined.$ The$ proportion$ of$ cells$ demonstrating$ positive$
staining$ was$ determined$ both$ prior$ to$ stimulation$ and$ following$ stimulation$ with$ PMA$ and$





between$ unstimulated$ and$ stimulated$ cells$ were$ found$ to$ be$ normally$ distributed.$ Parametric$
statistical$methods$were$therefore$used.$The$four$groups$were$compared$using$a$oneQway$ANOVA,$
and$postQhoc$pairwise$analysis$was$performed$with$a$Bonferonni$correction.$$
The$ raw$ results$ for$ ILQ17$measured$ in$ the$ cell$ culture$ supernatant$were$ not$ normally$ distributed.$
However,$ they$ were$ normalised$ using$ a$ natural$ logarithmic$ transformation;$ therefore$ parametric$












































































































































It$ can$ therefore$ be$ seen$ that$whilst$ there$ does$ not$ appear$ to$ be$ a$ significant$ difference$or$ trend$
between$ the$MS$ risk$ score$ groups$ in$ the$ number$ of$ cells$ expressing$ intracellular$ ILQ17$ or$ FoxP3,$
there$does$appear$ to$be$a$ trend$ in$ the$ ILQ17$ levels$ in$ the$cell$ culture$supernatant.$The$number$of$




However,$ the$ cell$ culture$ ILQ17$ results$ are$ more$ convincing.$ Whilst$ the$ differences$ between$ the$
groups$are$sufficiently$small$as$to$render$the$absolute$differences$nonQsignificant,$the$trend$across$









The$MRI$ imaging$ substudy$was$ performed$ as$ a$ pilot$ study$within$ the$ overall$ study.$ Extrapolating$
from$ existing$ data$ on$ the$ proportion$ of$ siblings$ who$ would$ be$ expected$ to$ demonstrate$ MRI$
abnormalities$in$keeping$with$demyelination,$approximately$10%$of$the$siblings$enrolled$in$this$study$
would$ be$ expected$ to$ demonstrate$ these$ changes$ (93,$ 205).$ This$ equates$ to$ approximately$ 10$
unaffected$siblings$with$MRI$evidence$of$demyelination.$ If$ the$MS$risk$score$ is$ indeed$a$marker$of$












A$ total$of$22$ siblings$ (12$with$high$MS$ risk$ score$and$10$with$ low$MS$ risk$ score)$had$MR$ imaging$
performed$ at$ the$ Institute$ of$ Neurology.$ Details$ of$ scan$ acquisition$ and$ image$ interpretation$ are$
given$ in$section$4.2.14.$One$additional$sibling$with$ low$MS$risk$score$was$able$to$provide$a$recent$




































































Although$ the$MRI$ results$were$not$ statistically$ significant,$ it$ is$ entirely$possible$ that$ this$ is$due$ to$
statistical$underpowering$of$this$part$of$the$study.$A$total$of$3$siblings$selected$for$imaging$studies$































more$ important$ now$ than$ ever$ before.$ If$ an$MS$ risk$ score$ can$ be$ integrated$ into$ the$ diagnostic$
pathway$alongside$the$existing$clinical$diagnosis$then$both$accuracy$of$diagnosis$and$potential$early$
access$to$treatments$may$improve.$$




early$ treatment$ is$ likely$ to$have$ longQterm$effects$on$disability$outcomes.$An$MS$risk$ score,$which$
could$provide$additional$risk$stratification$to$MRI$and$CSF$findings$for$those$presenting$with$CIS,$may$










underpinning$ of$ this$ complex$ disease.$ Through$ the$ development$ of$ this$ risk$ score,$ and$ the$
comparison$to$other$similar$scores$which$include$fewer$genetic$variants,$it$can$be$seen$that$the$AUC$
steadily$ improves$as$ increasing$numbers$of$SNPs$ that$have$been$associated$with$MS$are$ included.$
However,$given$the$relatively$modest$improvement$in$the$AUC$with$the$inclusion$of$a$large$number$
of$ additional$ SNPs$ it$ seems$ unlikely$ that$ expanding$ the$ genetic$ contribution$ to$ the$ score$ will$
eventually$result$in$a$“perfect”$score.$Instead,$it$is$likely$that$further$refinement$of$the$influence$of$
the$ environment,$ which$ is$ influenced$ by$ the$ genetic$ makeup$ of$ an$ individual$ will$ result$ in$
meaningful$ improvement$in$such$a$score.$From$the$results$obtained$in$this$study,$ it$seems$unlikely$




across$ reducing$ levels$ of$ risk$ score.$ It$must$ be$ noted$ that$ this$ subQstudy$was$ performed$ in$ a$ low$
number$ of$ participants,$ and$ these$ findings$ require$ replication.$ Despite$ the$ caution$ regarding$ the$
preliminary$nature$of$these$findings,$this$novel$discovery$potentially$sheds$light$on$early$peripheral$
changes$that$may$be$associated$with$MS.$Th17$cells$are$a$relatively$recent$avenue$of$interest$in$the$
field$of$MS,$with$ increased$ levels$of$ ILQ17$ seen$ in$MS,$particularly$ in$ the$ context$of$ relapses$ (161,$
162,$163).$ Indeed,$on$a$microscopic$ level,$ transcripts$encoding$ ILQ17$were$ found$ to$be$elevated$ in$
MS$ plaques$ when$ compared$ to$ control$ brains$ (370).$ ILQ17$ acts$ as$ a$ potent$ proQinflammatory$
cytokine,$upregulating$the$production$of$other$cytokines$including$ILQ1$and$ILQ6$(169),$thus$placing$ILQ
17$in$a$potentially$ important$place$ in$the$cascade$of$ inflammation$that$appears$to$result$ in$clinical$
disease.$However,$it$is$unlikely$that$ILQ17$is$the$only$part$of$the$jigsaw$–$mice$treated$with$antiQILQ17$
antibodies$demonstrate$a$delayed$disease$onset$and/or$a$reduction$ in$the$severity$of$EAE$(371Q2),$






widespread$ subclinical$ inflammation$ is$ unlikely$ to$ be$ part$ of$ the$ endophenotype.$ This$ does$ not$
completely$ exclude$ such$ changes$ in$ individuals$with$ early$ (i.e.$ asymptomatic)$ demyelination;$ this$
study$was$not$sufficiently$powered$to$study$this,$and$a$larger$study$focussing$purely$on$individuals$
with$ MRI$ evidence$ of$ active$ demyelination$ would$ be$ required.$ These$ changes$ may$ be$ relatively$
downstream$ of$ the$ early$ immunological$ endophenotype$ possibly$ typified$ by$ increased$ ILQ17$
secretion$in$response$to$Th17$cell$stimulation.$$
The$ fact$ that$ there$ were$ no$ statistically$ significant$ differences$ between$ the$ two$ cohorts$ who$
underwent$MRI$does$not$mean$that$the$endophenotype$concept$is$not$applicable$to$MS.$A$relatively$
small$number$of$participants$were$imaged,$and$it$may$be$that$imaging$the$entire$cohort$is$needed$to$
fully$ assess$ the$ distribution$ of$ risk.$ Hyperintense$ lesions$ seen$ on$ T2$ MRI$ are$ the$ hallmark$ of$
demyelination,$ and$ underpin$ our$ understanding$ of$ MS.$ These$ lesions$ represent$ focal$ areas$ of$
demyelination,$and$follow$a$characteristic$pattern$in$MS.$In$relapsing$remitting$MS,$new$T2$lesions$
are$the$best$indication$of$subclinical$active$disease$that$we$have,$and$such$changes$are$widely$used$
as$the$outcome$measures$ in$clinical$ trials$of$disease$modifying$therapy.$ In$patients$with$CIS,$ those$
with$MRI$ changes$ in$keeping$with$MS$at$ the$ time$of$presentation$demonstrated$a$hazard$ ratio$of$
either$6.1$ (patients$with$1$or$2$Barkhof$ criteria)$or$17.0$ (patients$with$3$or$4$Barkhof$ criteria)$ for$
conversion$to$CDMS$compared$to$those$with$no$lesions$within$a$median$of$7$years$(373).$










approximately$ a$ third$of$ patients$with$RIS$ appear$ to$ go$on$ to$develop$ clinical$ symptoms$ (i.e.$ CIS)$
within$about$2$years;$a$proportion$of$these$then$develop$a$second$clinically$apparent$demyelinating$
event$ and$ are$ diagnosed$ with$ clinically$ definite$ MS$ (367).$ The$ group$ with$ asymptomatic$ MRI$
changes$in$keeping$with$demyelination$provide$an$ideal$cohort$for$further$investigation$of$both$the$






Another$ limitation$ of$ the$MRI$ step$was$ the$ number$ of$ participants$who$ underwent$ imaging.$MRI$
imaging$ of$ asymptomatic$ siblings$ is$ not$ without$ ethical$ and$ practical$ concerns.$ Whilst$ no$
asymptomatic$ clinically$ significant$ abnormalities$ (outside$ of$ demyelination)$ were$ discovered,$ the$
risk$ of$ uncovering$ such$ abnormalities$ is$ estimated$ to$ be$ around$ 1.7Q4.3%,$ depending$ on$ the$
resolution$and$sequences$performed$(206).$The$cost$and$practicalities$of$ imaging$large$numbers$of$
participants$ are$ also$ a$ limiting$ step,$ and$ hence$ the$ decision$was$ taken$ to$ only$ perform$MRI$ on$ a$
subgroup$of$siblings.$Clearly$the$power$of$this$part$of$the$study$could$be$improved$by$increasing$the$
number$of$participants$undergoing$imaging$studies.$$
One$ question$ that$ it$ is$ important$ to$ answer$ is$ whether$ OCB$ negative$MS$ is$ truly$MS.$ In$ primary$
progressive$MS,$the$presence$of$OCBs$is$enshrined$within$the$diagnostic$criteria;$the$same$is$not$true$
of$relapsing$remitting$MS.$OCBs$have$had$a$somewhat$chequered$history,$with$interQassay$variability$






within$ the$past$ year$ indicates$ the$need$ for$ robust$diagnostic$ criteria,$ and$a$ reQexamination$of$ the$
clinical$ phenotype$ of$ the$ “OCB$ negative$ MS”$ is$ required.$ A$ significant$ proportion$ of$ this$ group$
almost$certainly$do$not$have$MS,$and$whether$the$remainder$convert$ to$being$OCB$positive$ is$not$








potentially$ important$contributor$ to$MS$risk$ that$ is$not$detected$by$GWAS$ is$ relatively$ rare$alleles$
associated$ with$ large$ effect$ sizes.$ These$ low$ frequency$ variants$ are$ not$ present$ on$ current$ SNP$
genotyping$arrays.$It$is$becoming$increasingly$clear$that$rare$variants$are$more$common$than$initially$
thought$ (105),$ suggesting$ that$ individual$ disease$ risk$may$be$ influenced$by$ rare$or$ indeed$private$
(confined$to$one$individual/family)$mutations.$Examples$of$these$in$MS$have$recently$been$described$
and$ it$ is$ extremely$ likely$ that$more$will$ follow$ (104,$ 106).$ Discovering$ these$ variants$ will$ require$
genome$sequencing$in$large$patient$numbers;$whilst$this$is$rapidly$becoming$affordable,$it$is$unclear$









GWAS.$ The$ effect$ of$ geneQenvironment$ interactions$ on$ the$ strength$ of$ genetic$ contribution$ to$
disease$ is$ difficult$ to$ estimate$ outside$ studies$ examining$ specific$ relationships$ between$ defined$




implied$ a$ marked$ potential$ effect$ of$ such$ interactions$ on$ the$ OR$ calculated$ by$ GWAS,$ with$ an$
increase$in$the$OR$of$up$to$16.8$from$a$GWAS$estimated$OR$of$1.3$(344).$This$model$does$not$take$
account$of$ the$magnitude$of$ the$effect$of$any$environmental$exposure,$ instead$assuming$a$binary$
relationship,$ limiting$ the$ direct$ applicability$ of$ the$ results.$Whilst$ it$ seems$ highly$ likely$ that$ such$
interactions$ play$ a$ significant$ role$ in$ modulating$ disease$ risk,$ studying$ this$ through$ a$ purely$
epidemiological$ approach$ has$ severe$ limitations,$ and$ alternative$ approaches$ such$ as$ epigenetic$
correlations$will$need$to$be$used.$$
Environmental$ influences$ on$ genetic$ risk,$ many$ of$ which$ are$ likely$ to$ be$ mediated$ through$
epigenetic$ mechanisms,$ are$ complex$ to$ include$ into$ such$ a$ prediction$ algorithm.$ The$ parentQofQ
origin$ effect$ in$ MS$ (98),$ which$ has$ been$ highlighted$ as$ a$ demonstration$ of$ potential$ unknown$
influences$ on$ genetic$ risk,$ is$ well$ described,$ and$ discussed$ in$ section$ 4.1.2.2.$ The$ precise$
mechanisms$ underlying$ this$ apparent$ differential$ transmission$ of$ risk$ remain$ speculative,$ but$ are$
likely$to$involve$epigenetic$changes,$which$are$likely$to$at$least$partly$explain$the$discordance$in$MS$
seen$in$genetically$identical$monozygotic$twins.$If$GWAS$were$fully$able$to$predict$MS$susceptibility,$
MZ$ twin$ concordance$ rates$would$ approach$100%;$however,$ it$ is$ around$25%$ (3).$Outside$of$MS,$
epigenetic$differences$between$MZ$ twins$have$been$demonstrated$ (109).$ To$date,$only$one$ study$
has$examined$methylation$status$in$MZ$twins$discordant$for$MS$(110),$and$this$did$not$uncover$any$




















If$ it$ is$ indeed$possible$ to$ define$MS$ risk$ according$ to$ the$MS$ risk$ score$ described$ above,$ then$ an$




that$ the$ siblings$ of$ people$ with$MS$ represent$ a$ population$ loaded$ with$ genetic$ risk$ for$MS.$ The$






We$ live$ in$ a$ world$ where$ vitamin$ D$ deficiency$ has$ become$ the$ norm.$ Changes$ in$ lifestyle$ and$
behaviour$in$the$developed$world$have$led$to$what$has$been$described$as$an$“epidemic$of$vitamin$D$




indoors,$ glued$ to$ computer$ screens.$ Despite$ this,$ the$ recommended$ daily$ allowance$ (RDA)$ for$
vitamin$D$has$not$changed$its$inception.$$
The$ first$ attempt$ to$develop$ recommended$ values$ for$ dietary$ vitamin$D$ intakes$was$ in$ 1941.$ The$
value$of$400$IU/day$(10ug)$was$chosen;$derived$by$measuring$the$amount$of$vitamin$D$in$a$teaspoon$





the$ Institute$ of$ Medicine$ (IOM)$ in$ the$ USA$ state$ that$ a$ serum$ level$ of$ 25(OH)vD$ of$ 12.5$ ng/ml$
(30nmol/l)$is$sufficient$to$maintain$bone$health$(348,$349).$The$acceptable$intake$(AI;$equivalent$to$


















































fairly$ standard$ techniques:$ gathering$ a$ diverse$ population,$ measuring$ serum$ vitamin$ D$ levels,$
plotting$the$data$and$defining$a$reference$range$against$a$Gaussian$distribution$(351).$In$generating$
the$ data$ for$ this$ study,$ “normal”$ individuals$ were$ compared$ to$ a$ group$ of$ lifeguards,$ who$ had$
circulating$25(OH)vD$ levels$2.5$ times$higher$ than$ the$ reference$population$ (351).$ It$has$previously$
been$assumed$ that$ the$ lifeguards$had$abnormally$high$serum$ levels$of$25(OH)vD,$propagating$ the$
normal$ranges$espoused.$$
However,$ it$ has$ been$ argued$ that$ the$ lifeguards$ are$ actually$ the$ population$ with$ normal$ (i.e.$
physiologically$ healthy)$ serum$ 25(OH)vD$ levels,$ and$ the$ “normal”$ population$ were$ all$ 25(OH)vD$
deficient$ (352).$ An$ evolutionary$ perspective$ would$ support$ this$ theory.$ Skin$ depigmentation$ in$
response$to$migration$patterns$50,000$years$ago$is$thought$to$indicate$an$evolutionary$response$to$
maximise$ the$ absorption$ of$ UVB$ from$ limited$ sunlight$ in$ Northern$ areas$ –$ vitamin$ D$ deficiency$
leading$ to$ rickets$ would$ be$ a$ clear$ selection$ pressure$ causing$ death$ in$ childbirth$ in$ woman$with$
rickety$pelvises$ (352).$ Indeed,$ in$populations$where$sun$exposure$ is$maximal,$circulating$25(OH)vD$
levels$have$been$reported$to$range$from$135Q225nmol/l$(54Q90ug/l)$(352,$353).$$
Attempts$ to$ define$ physiologically$ normal$ 25(OH)vD$ levels$ have$ been$ made.$ At$ 25(OH)vD$ levels$
below$75nmol/l$(30ug/l),$calcium$absorption$by$the$gut$is$suboptimal$(354).$In$the$elderly,$secondary$








25(OH)vD$ levels$ should$ certainly$not$be$ judged$ to$be$ vitamin$D$ replete.$ In$ addition$ to$ the$ flawed$
way$in$which$the$reference$ranges$have$been$developed,$determining$optimal$vitamin$D$levels$in$the$










redefine$ the$ RDA$ for$ vitamin$ D$ and$ enable$ physiological$ levels$ of$ supplementation.$ There$ is$ no$
convincing$evidence$of$serious$adverse$events$resulting$ from$relatively$high$dose$supplementation$
(in$ the$ region$ of$ 5,000Q10,000$ IU/day)$ (350),$ and$ the$ longQterm$ effects$ from$ chronic$ vitamin$ D$
insufficiency$in$the$population$are$not$to$be$underestimated.$Trials$of$high$dose$vitamin$D$are$being$
performed$ in$ people$ with$ MS$ (356),$ but$ this$ intervention$ is$ clearly$ too$ late$ to$ prevent$ disease$
development.$$
Vaccination$against$infection$by$EpsteinQBarr$virus$is$another$potential$strategy.$An$EBV$vaccine$has$
been$ developed,$ and$ there$ has$ been$ a$ placebo$ controlled$ phase$ 2$ clinical$ trial$ in$ 181$ EBV$
seronegative$ volunteers$ (357).$ The$ vaccine$ is$ directed$ against$ the$ viral$ capsid$ glycoprotein$ 350$
(gp350),$which$mediates$ viral$ entry$ into$BQcells.$ The$ vaccine$had$ considerable$ success$ in$ terms$of$
both$ seroconversion$against$gp350$ (98.7%$developed$antiQgp350$antibodies$ (95%$CI$85.5%Q97.9%)$
and$ preventing$ the$ development$ of$ infectious$ mononucleosis$(mean$ efficacy$ rate$ 78.0%$ [95%$ CI$






vaccine$ has$ no$ use$ in$ preventing$ MS.$ Infectious$ mononucleosis$ appears$ to$ influence$ MS$ risk$
independently$of$antiQEBNAQ1$titres,$and$so$ this$vaccine$may$have$a$ role$ in$modifying$at$ least$one$
EBVQrelated$ risk$ factor$ for$MS$development.$Additionally,$ the$effect$of$vaccination$on$antiQEBNAQ1$
titres$has$not$been$studied.$$
Smoking$cessation$strategies$are$now$widespread,$and$the$subject$of$major$public$health$campaigns.$
However,$ 20.6%$UK$women$and$22.8%$UK$males$ still$ smoke$ (358).$ There$ is$ a$wealth$of$ literature$
evaluating$the$success$(or$ lack$of)$smoking$prevention$and$cessation$strategies$(359Q364).$Smoking$
prevention$ is$clearly$a$priority$ for$public$health$ in$the$21st$Century,$and$hopefully$this$will$have$an$
impact$on$MS$development.$In$terms$of$MS$prevention,$trials$in$this$arena$would$not$be$ethical$nor$
feasible$ –$ interventions$ that$ are$ proven$ to$ reduce$ smoking$ rates$ should$ clearly$ be$ aimed$ at$ the$
population$as$a$whole,$not$merely$a$proportion$of$those$thought$to$be$at$high$MS$risk.$$
Studies$ to$prevent$MS$would$have$ to$be$ largeQscale$and$ longQterm.$The$modifiable$environmental$
factors$discussed$above$have$influences$on$a$number$of$diseases$other$than$MS.$ It$ is$ important$to$
ensure$that$longitudinal$studies$are$set$up$with$sufficient$care$taken$to$ensure$that$the$large$number$
of$potential$confounding$factors$do$not$render$them$ultimately$uninformative.$There$remains$much$













with$ a$ RIS$ develop$ clinical$ attacks$ in$ keeping$ with$ demyelination$ at$ longitudinal$ followQup.$ This$
proportion$appears$ to$be$ relatively$ constant$across$a$number$of$ studies$ (207,$208,$365,$366).$The$
only$consistent$prognostic$feature$for$conversion$to$clinically$apparent$demyelination$appears$to$be$
gadolinium$ enhancement$ on$ the$ baseline$MRI$ (367);$ however$ only$ a$ limited$ number$ of$ analyses$






followQup$ period$ of$ greater$ than$ 2$ years.$ It$ may$ be$ that$ with$ a$ follow$ up$ of$ a$ sufficiently$ long$
duration$all$patients$eventually$convert$to$CIS.$If$this$is$indeed$the$case,$this$would$be$important$to$
know.$ Such$a$ study$ could$allow$ the$determination$of$ factors$ that$ appear$ to$ influence$ the$ time$ to$
clinical$conversion,$enabling$patients$to$make$lifestyle$changes,$such$as$stopping$smoking,$that$may$
influence$their$risk$of$future$disease.$$
An$ additional$ future$ study$ would$ involve$ calculating$ the$ baseline$ MS$ risk$ score$ of$ a$ cohort$ of$
unaffected$siblings$of$people$with$MS,$ followed$by$ longitudinal$ followQup$over$a$number$of$years.$
This$ would$ enable$ an$ assessment$ of$ conversion$ rates,$ which$ could$ then$ be$ related$ back$ to$ the$
baseline$MS$ risk$ score.$However,$ the$ followQup$ time$ required$ in$ such$ a$ study$would$be$high,$ and$
thousands$ of$ siblings$ would$ be$ required$ to$ adequately$ power$ the$ study.$ Such$ a$ study$ would$ be$
considerably$affected$by$confounding$factors$such$as$dropQout$rates$and$behavioural$changes,$such$





seem$ to$ be$ sensible$ to$ combine$ such$ a$ longitudinal$ study$with$ a$ placeboQcontrolled$ intervention,$
such$ as$ high$ dose$ vitamin$ D$ supplementation,$ in$ order$ to$ assess$ whether$ this$ had$ any$ effect$ on$
conversion$rates.$$
Is$an$MS$prevention$study$a$realistic$goal?$There$are$two$strands$to$answering$this$question.$The$first$




provides$ a$ useful$ predictive$ tool,$ then$ it$ could$ be$ used$ to$ inform$ a$ prevention$ study.$ In$ terms$ of$
interventions$within$a$preventative$study,$options$are$limited.$We$cannot$change$the$multifactorial$
genetic$ risk$ underpinning$ an$ individuals’$ MS$ risk$ at$ birth.$ As$ discussed$ above,$ a$ vitamin$ D$
supplementation$study$is$likely$to$be$of$value,$not$just$for$MS$but$for$a$variety$of$diseases$associated$
with$low$serum$vitamin$D.$$Vaccination$against$the$EpsteinQBarr$virus$is$likely$to$have$some$effect$on$
MS$ risk.$ However,$ as$ discussed$ above,$ whilst$ this$ protects$ against$ symptomatic$ infectious$
mononucleosis,$ it$ does$ not$ prevent$ asymptomatic$ seroconversion.$ The$ expected$ effect$ of$
vaccination$ on$MS$ risk$ is$ therefore$ unclear,$ as$ it$ may$ only$ affect$ the$ risk$ associated$ with$ IM,$ or$
potentially$the$risk$associated$with$any$EBV$infection.$Care$would$need$to$be$taken$to$ensure$such$a$
study$was$well$powered$to$demonstrate$a$potentially$relatively$small$effect$on$overall$risk.$$
The$ secret$ to$ MS$ prevention$ may$ well$ be$ preQnatal$ intervention.$ This$ adds$ a$ further$ level$ of$
complexity$to$already$challenging$prevention$studies.$At$the$present$time,$ it$ is$unlikely$that$such$a$









With$ increasing$ knowledge$ surrounding$ epigenetics$ and$ the$ transmission$ of$ risk$ through$
generations,$awareness$ is$growing$of$ the$ importance$of$prenatal$ factors$ in$modifying$disease$ risk.$
Coming$ full$ circle,$and$once$again$ taking$ inspiration$ from$the$psychiatric$ literature,$ the$challenges$
inherent$ in$ studying$ such$ diseases$ become$ apparent.$ Novel$ methods$ are$ required$ to$ study$ the$
effects$of$ prenatal$ influences$on$ complex$disease$development$ (368),$which$ require$development$
and$validation.$$
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Patient information sheet (for people with MS) 
Towards an endophenotype in multiple sclerosis 
 
We would like to invite you to help us with a research project studying multiple sclerosis (MS), looking at both 
people with multiple sclerosis and their siblings (brothers and sisters).  Please read the following information 
carefully, which explains why the research is being done and what your participation would involve.  Please ask 
us about anything which is unclear or if you would like further information.  
 
What is the purpose of the study? 
We are studying proteins, immune signal molecules (antibodies) and white blood cells in the blood and urine of 
patients with multiple sclerosis and their siblings. We are looking for a common virus called the Epstein-Barr 
virus (the virus that causes glandular fever) in the saliva. We also want to examine the genetic code in people 
with MS and their siblings, to examine further whether this influences who gets the disease. We hope that 
through this research we can begin to understand why the relatives of people with MS have a higher risk of MS 
than other members of the population, and improve our understanding if the disease. We also hope that this 
research will help us to design new treatments and/or ideas about preventing MS.  
 
Why have I been chosen? 
We have approached you because you are someone who has been diagnosed with a multiple sclerosis and have a 
brother or sister who does not have MS and may be able to take part in this research.  
We would like to take a blood sample from you, as well as a urine sample, a sample of cheek cells and a saliva 
sample. We would also like to have permission to inspect your medical notes.   
 
Do I have to take part? 
Your participation would be entirely voluntary.  If you do decide to take part, we would ask you to sign a 
consent form.  A copy of the signed consent form and patient information sheet would be given to you to keep.  
If you do not wish to take part, you do not have to give any reason, and this would not in any way affect the 
treatment or care that either you or any family members who agree to take part in this study receive in hospital or 
in the outpatient clinic. 
 
What will happen to me if I take part? 
If you decide to take part, we would ask you to contact your sibling(s) in order to see if they would be happy to 
take part in this study. If they are happy to take part, then we would be able to see you either together or at 
separate times, at your convenience.  
 
We would take approximately 3 tablespoons (45ml) of your blood from a vein in your arm, which we would try 
to do at the same time as any other blood tests you might be having. We would also ask you to provide a urine 
sample, a cheek swab and a saliva sample on the same day as having the blood test. One of the blood tests being 
taken is to allow researchers to carry out certain genetic tests. These genetic tests do not currently allow us to 
predict disease. The results of these genetic tests will remain anonymous, will not be linked to my healthcare 
records in any way, and will only be used for research purposes. 
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What are the possible disadvantages and risks of taking part? 
The only risks of taking part are the normal risks associated with having blood taken, such as slight bruising to 
the arm. There are no risks associated with providing the urine or saliva samples.  
 
What are the possible benefits of taking part? 
Your participation may help in advancing scientific knowledge about the potential causes of multiple sclerosis, 
although there may be no direct benefit to yourself. 
 
Will my taking part in this study be kept confidential? 
Restricted access to your medical records would be required by the research team to help interpret the results.  
All information which is collected about you during the course of the research would be kept strictly 
confidential. Any information about you which leaves the hospital would have your name and address removed 
so that you can not be recognised from it. Your personal data will be stored under a code rather than under your 
name. Only named researchers will have access to the coding sheets, which will be kept in a locked cabinet. 
Your GP will be informed of your participation in this study.  
 
What will happen to the results of the research study? 
We do not anticipate that the research will reveal information of immediate clinical relevance regarding any 
individual participant’s medical care, and so we do not plan to give feedback to individuals regarding their own 
results.  However, updates on the general progress of the research project may be given at the department’s 
regular ‘patient information days’, and findings may be published in scientific academic journals within the next 
few years. Individual participants will not be able to be identified from any publications in scientific journals. 
 
Who is organising and funding the research? 
This research is being carried out by research doctors and scientists under the direction of Professor Gavin 
Giovannoni.  Sections of this research are being carried out as part of PhD by Dr Dobson. The research and 
research workers are paid for from a variety of sources including the Medical Research Council, the Multiple 
Sclerosis Society of Great Britain and Northern Ireland, the NHS and funds from Queen Mary University 
London. 
 
Who has reviewed the study? 
Approval for this project has been granted by the East London Research Ethics Committee 2. 
  
Storage and further use of your blood or cerebrospinal fluid samples 
It is possible that not all of the blood, urine or saliva samples which you donate will be fully used up in this 
project.  If this occurs, in order to avoid wastage of valuable samples, we might like to use them for other 
research projects to be undertaken in the future. Surplus samples will be transferred to a licensed human tissue 
storage bank, where they will be stored. Stored samples will be anonymised, but details such as age, gender, and 
the date on which the sample was taken will be stored. We will always maintain the confidentiality of your 
personal and medical information. 
 
Future projects might include further studies on the role of antibodies or other molecules in neurological 
diseases.  These projects may be carried out by members of Professor Giovannoni’s research team, or by 
members of other research teams or other research institutions. All such projects will have to have been 
approved by research ethics committees, and the use of samples from the tissue bank is at the discretion of the 
custodian of that tissue bank.   
 
Contact for further information 
Further information can be obtained by contacting our research team, including our research manager Maria 
Espasandin, in the Neurology Clinical Trials Unit (020 7377 7000 and ext 3303). 
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Patient information sheet (for siblings of people with MS) 
Towards an endophenotype in multiple sclerosis 
 
We would like to invite you to help us with a research project studying multiple sclerosis (MS), looking at both 
people with multiple sclerosis and their siblings (brothers and sisters).  Please read the following information 
carefully, which explains why the research is being done and what your participation would involve.  Please ask 
us about anything which is unclear or if you would like further information.  
 
What is the purpose of the study? 
We are studying proteins, immune signal molecules (antibodies) and white blood cells in the blood and urine of 
patients with multiple sclerosis and their siblings. We are looking for a common virus called the Epstein-Barr 
virus (the virus that causes glandular fever) in the saliva. We also want to examine the genetic code in people 
with MS and their siblings, to examine further whether this influences who gets the disease. We hope that 
through this research we can begin to understand why the relatives of people with MS have a higher risk of MS 
than other members of the population, and improve our understanding if the disease. We also hope that this 
research will help us to design new treatments and/or ideas about preventing MS.  
 
Why have I been chosen? 
We have approached you because you have a brother or sister who has been diagnosed with a multiple sclerosis, 
and they have indicated that you may be willing to take part in this research. In order to carry out this research 
we need to have siblings from the same family, one of whom has MS.  
We would like to take a blood sample from you, as well as urine and saliva samples and a sample of cheek cells. 
We will need to meet you in order to discuss your medical history, and carry out a brief examination of the 
nervous system.   
 
Do I have to take part? 
Your participation would be entirely voluntary.  If you do decide to take part, we would ask you to sign a 
consent form.  A copy of the signed consent form and information sheet would be given to you to keep.  If you 
do not wish to take part, you do not have to give any reason, and this would not in any way affect the treatment 
or care that either you or any family members who agree to take part in this study receive in hospital or in the 
outpatient clinic. 
 
What will happen to me if I take part? 
If you decide to take part, then we would be able to see you either together with your sibling(s) or at separate 
times, at your convenience. We would take approximately 3 tablespoons (45ml) of your blood from a vein in 
your arm, which we would try to do at the same time as any other blood tests you might be having. We would 
also ask you to provide both a urine sample and a saliva sample on the same day as having the blood test. One of 
the blood tests being taken is to allow researchers to carry out certain genetic tests. These genetic tests do not 
currently allow us to predict disease. The results of these genetic tests will remain anonymous, will not be linked 
to my healthcare records in any way, and will only be used for research purposes. 
 
We would also ask for your permission to be contacted at a future time in order to have an MRI brain scan. If  
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you were to agree to the scan, we would provide you with further information regarding it at that time. You 
would be free not to have the scan if you do not wish to have this done. We will only be scanning one-fifth of the 
participants in this study, so we will not necessarily be contacting you. If you do not wish to be contacted in the 
future, but still wish to take part in this research, please let one of the researchers know.  
 
What are the possible disadvantages and risks of taking part? 
The only risks of taking part are the normal risks associated with having blood taken, such as slight bruising to 
the arm. There are no risks associated with providing the urine or saliva samples. Those participants selected to 
have MRI brain scans will have the procedure explained to them in greater detail nearer the time of the scan. 
  
What are the possible benefits of taking part? 
Your participation may help in advancing scientific knowledge about the potential causes of multiple sclerosis, 
although there may be no direct benefit to yourself. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research would be kept strictly 
confidential. Any information about you would have your name and address removed so that you can not be 
recognised from it. Your personal data will be stored under a code rather than under your name. Only named 
researchers will have access to the coding sheets, which will be kept in a locked cabinet. Your GP will be 
informed of your participation in this study. 
 
What will happen to the results of the research study? 
We do not anticipate that the research will reveal information of immediate clinical relevance regarding any 
individual participant’s medical care, and so we do not plan to give feedback to individuals regarding their own 
results.  However, updates on the general progress of the research project may be given at the department’s 
regular ‘patient information days’, and findings may be published in scientific academic journals within the next 
few years. Individual participants will not be able to be identified from any publications in scientific journals. 
 
Who is organising and funding the research? 
This research is being carried out by research doctors and scientists under the direction of Professor Gavin 
Giovannoni.  Sections of this research are being carried out as part of PhD by Dr Dobson. The research and 
research workers are paid for from a variety of sources including the Multiple Sclerosis Society of Great Britain 
and Northern Ireland, the NHS and funds from Queen Mary University London. 
 
Who has reviewed the study? 
Approval for this project has been granted by the East London Research Ethics Committee 2. 
 
Storage and further use of your blood or cerebrospinal fluid samples 
It is possible that not all of the blood, urine or saliva samples which you donate will be fully used up in this 
project.  If this occurs, in order to avoid wastage of valuable samples, we might like to use them for other 
research projects to be undertaken in the future. Surplus samples will be transferred to a licensed human tissue 
storage bank, where they will be stored. Stored samples will be anonymised, but details such as age, gender, and 
the date on which the sample was taken will be stored. We will always maintain the confidentiality of your 
personal and medical information. Future projects might include further studies on the role of antibodies or other 
molecules in neurological diseases.  These projects may be carried out by members of Professor Giovannoni’s 
research team, or by members of other research teams or other research institutions. All such projects will have 
to have been approved by research ethics committees, and the use of samples from the tissue bank is at the 
discretion of the custodian of that tissue bank.   
 
Contact for further information 
Further information can be obtained by contacting our research team, including our research manager Maria 
Espasandin, in the Neurology Clinical Trials Unit (020 7377 7000 and ext 3303). 




Neurology Clinical Trials Unit 
Surgery & Anaesthesia  
Department of Neurology 
Barts and the London NHS Trust 
4th Floor, Holland Wing 
The Royal London Hospital 
Whitechapel, London 
E1 1BB 
Tel ext: 3303 
Main switchboard: 020 7377 7000 
Fax: 020 7377 7033 
www.bartsandthelondon.nhs.uk 
Barts and The London NHS Trust, The Royal London Hospital    
St Bartholomew’s Hospital and The London Chest Hospital 









Subject Initials:  
 




Patient information sheet (MRI) 
Towards an endophenotype in multiple sclerosis 
 
We would like to invite you to help us with a research project studying multiple sclerosis (MS), looking at both 
people with multiple sclerosis and their siblings (brothers and sisters).  Please read the following information 
carefully, which explains why the research is being done and what your participation would involve.  Please ask 
us about anything which is unclear or if you would like further information. You have already provided blood, 
urine and saliva studies, and we would like to perform an MRI brain scan on you as well.  
 
What is the purpose of the study? 
We hope that through this research we can begin to understand why the relatives of people with MS have a 
higher risk of MS than other members of the population, and improve our understanding if the disease. We also 
hope that this research will help us to design new treatments and/or ideas about preventing MS. Through looking 
at the MRI scans of the brain in people with MS and their siblings, we are hoping that we can detect very subtle 
changes that may help us to work out how the disease begins.  
 
Why have I been chosen? 
We have approached you because you have already taken part in the first part of this study.  
 
Do I have to take part? 
Your participation would be entirely voluntary.  If you do decide to take part, we would ask you to sign a 
consent form.  A copy of the signed consent form and information sheet would be given to you to keep.  If you 
do not wish to take part, you do not have to give any reason, and this would not in any way affect the treatment 
or care that either you or any family members who agree to take part in this study receive in hospital or in the 
outpatient clinic. 
 
What will happen to me if I take part? 
 The MRI brain scans will be done at the NMR Research Unit at the Institute of Neurology, Queen Square. MRI 
scans are widely used in medicine and are a safe procedure that does not involve any radiation. During the 
examination you will lie comfortably on a moveable table that slides into a cylinder and you will hear some 
knocking noise that can be reduced with earplugs. You will be able to communicate with the technicians 
performing the study at all times and the examination can be interrupted at any time should you feel 
uncomfortable.   
 
What are the possible disadvantages and risks of taking part? 
MRI is very safe and used daily in clinical routine. MRI cannot be used if you have large bits of metal inside you 
(such as after brain surgery, or certain joint replacements), a cardiac pacemaker or if you are claustrophobic.   
Although unlikely, there is a small possibility that the MRI scan may show up abnormalities within the brain that 
have not caused any symptoms yet. An example of this could be a small brain tumour, or changes within the 
blood vessels that make them more likely to bleed. Should we discover any abnormalities which have the 
potential to go on to cause problems in the future we would contact you, and offer you an appointment in the 
neurology outpatient clinic to discuss the findings and potential treatment. If the MRI brain scan does not show  
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any such abnormalities then we will not routinely contact you.  
 
What are the possible benefits of taking part? 
Your participation may help in advancing scientific knowledge about the potential causes of multiple sclerosis, 
although there may be no direct benefit to yourself. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research would be kept strictly 
confidential.  Any information about you would have your name and address removed so that you can not be 
recognised from it. Your personal data will be stored under a code rather than under your name. Only named 
researchers will have access to the coding sheets, which will be kept in a locked cabinet. Your GP will be 
informed of your participation in this study. 
 
What will happen to the results of the research study? 
We do not anticipate that the research will reveal information of immediate clinical relevance regarding any 
individual participant’s medical care, and so we do not plan to give feedback to individuals regarding their own 
results.  However, updates on the general progress of the research project may be given at the department’s 
regular ‘patient information days’, and findings may be published in scientific academic journals within the next 
few years. Individual participants will not be able to be identified from any publications in scientific journals. 
 
Who is organising and funding the research? 
This research is being carried out by research doctors and scientists under the direction of Professor Gavin 
Giovannoni. Sections of this research are being carried out as part of PhD by Dr Dobson.  The research and 
research workers are paid for from a variety of sources including the Multiple Sclerosis Society of Great Britain 
and Northern Ireland, the NHS and funds from Queen Mary University London. 
 
Who has reviewed the study? 
Approval for this project has been granted by the East London Research Ethics Committee 2. 
 
Contact for further information 
Further information can be obtained by contacting our research team, including our research manager Maria 
Espasandin, in the Neurology Clinical Trials Unit (020 7377 7000 and ext 3303). 
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Extraction of DNA from 9ml of whole blood 
 
Recording and Reporting of Results 
This form should be printed, completed steps ticked off and any deviations from 




BRIGHT protocol- based on salting out procedure published by miller et al 1988 
 
Related Procedures 
GC003501 Booking in of blood samples for DNA extraction 
GC003502 Printing of barcode labels 
GC003503 Preparation of Blood extraction solutions 
GC003504 DNA Extraction from 9 ml whole blood 
AF003501 DNA Extraction Batch Sheet 
 
Specimen Requirements 




Name Supplier Part Number Location  
Sodium Hypochlorite solution GPR  
(Approx.12%w/vavailablechlorine) VWR 301696 Flammables cupboard  
96%Ethanol VWR 104766 Flammables cupboard 
18MOhmdistilleddeionisedwater Millipore N/A MilliQ water purifier 
500mgofProteinaseKfromTritrachiumAlbum Sigma P6556 Freezer1 inpost PCR room 




See the SOP called “preparation of blood extraction solutions” for other reagents used in this protocol 
 
Equipment 
50ml screw cap tubes 










Day 1 of this protocol should be carried out in the class 2 cabinet situated in the RNA room. Day 2 and 3 should be carried out in the 
pre-pcr room  
 
Protocol     
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Make up the following solutions before starting: 
 
Proteinase K (20 mg/ml) 
 
Total mass of Proteinase K in bottle: 500 mg  
 
1. To make up a final concentration of 20 mg/ml you have to add 25 ml of 18MΩ.cm MilliQ water 
2. Since the bottle of proteinase K is small, it is not possible to add 25 ml straight away. So, first add 5 ml to the brown bottle of 
proteinase K.  
3. Mix by swirling the bottle and leave to stand for a little while before transferring it to a 50 ml falcon tube. 
4. Make up the volume to 25 ml. 





1. Take a 1L glass bottle and a 1L measuring cylinder 
2. Measure 729 ml of 96 % ethanol in the measuring cylinder 
3. Make the volume up to 1L with 18MΩ.cm MilliQ water 
4. Transfer volume into 1L glass bottle 
5. Store the bottle in freezer 1 in the pre pcr room. 
 
 
1 x TE (pH 7.5) 
 
1. Take a 50 ml falcon tube 
2. Add 4 ml of 100 x TE (pH 7.5) 
3. Add 36 ml of 18MΩ.cm MilliQ water. That makes a 10 x TE (pH 7.5) dilution! 
4. Take another 50 ml falcon tube 
5. Add 4 ml of 10 x TE (pH 7.5) 











• Fill out a DNA extraction batch sheet for every batch you are extracting (AF003501 DNA Extraction Batch Sheet).  
• Print out 5 replicate labels for sample tubes containing sample number and box position of where DNA will be stored after 
extraction 
• Cool the tube centrifuge to 4°C 
• Fill a large polystyrene box with ice 
• Fill a 1L glass bottle with 18MΩ.cm MilliQ water 
• Fill two dispojars with approximately 100 ml of sodium hypochlorite each 
• Defrost proteinase K (1 tube for 16 extractions and 2 tubes for 32 extractions) 
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1. Defrost blood tubes in fridge o/n or for 10 min at 37°C in the water bath (The blood had been transferred into 50 ml falcon 
tubes upon receipt. Blood sample volumes above 9-10 ml were split in two equal volumes by pouring half of the volume into 
another 50ml falcon tube with identical labeling). 
2. Mix the samples to resuspend the thick viscous blood. 
3. Add milliQ water to make up the volume to 40ml. Vortex briefly. 
4. Incubate samples on ice for 2min. 
5. Centrifuge at 3000 RPM for 20min at 4°C. 
6. Remove the supernatant by pouring gently to leave around 5ml. The supernatant is poured off into a dispojar containing 
approx. 100ml of sodium hypochlorite. 
7. Add solution 1 to make up a final volume of 40ml. 
8. Vortex to disperse the pellet. Do not proceed to the next step unless all the large pellets are dispersed. (This stage results in 
cell lysis). 
9. Incubate samples on ice for 2min. 
10. Centrifuge at 3000 RPM at 4°C for 15min. 
11. Remove supernatant by pouring gently and save pellet.  
12. Repeat steps 8 -11 using only 30ml of solution 1. 
13. Gently vortex the pellet. 
14. Resuspend the pellet in 11ml of solution 2. 
15. Add 55µl of proteinase K (20mg/ml) to the supernatant to yield a final concentration of 100µg/ml. 
16. Incubate tubes in water bath at 37°C overnight.  
 
Important: Clean out centrifuge buckets, tube holders, class 2 cabinet and general surfaces used with Virkon which is located on the 
bench closest to the dishwasher on the first shelf  
 




• Label the lid and the side of 50 ml falcon tubes 




17. Take tubes out of water bath. 
18. Add 4ml of solution 3. 
19. Mix by inverting several times. 
20. Centrifuge at 3500 RPM for 20min at 4°C (The SDS in solution 2 forms a complex with the protein, which precipitates out 
once NaCl is added). 
21. Transfer supernatant using a 3ml Pasteur pipette to a sterile 50ml conical tube, which is correctly labeled. There are usually 
around 15 to 25ml of supernatant. 
22. If the transferred supernatant is cloudy repeat centrifugation at 3500 RPM for 20min at 4°C. Transfer supernatant using a 3ml 
Pasteur pipette into a new sterile labeled 50ml conical tube. 
23. Precipitate DNA by adding 96% ethanol to the supernatant up to a volume of 50ml.  
24. Invert the tube at least 5 times to precipitate the DNA. 
25. Store the tube at –20°C overnight. 
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Important: Empty sodium hypochlorite-filled blood dispojars left in hood overnight by flushing contents down the sink and flushing 









26. Take 50 ml tubes out of the freezer. 
27. Spin tubes at 3100 RPM at 4°C for 15min to pellet DNA. 
28. Decant off supernatant. 
29. Add 15 ml ice-cold 70% EtOH per 50ml tube, invert 3 times, 
30. Spin sample tubes containing pptDNA/70% EtOH at 3100 RPM at 4°C for 10min. 
31. Decant off supernatant. 
32. Invert the tube on tissue paper and air dry for approx. 3hrs. Mark the DNA pellet location on the outside of tube if the pellet 
isn’t located at the base of the tube.  
33. Re-suspend DNA pellet in 500µl 1xTE pH 7.5 (Resuspend the DNA in a smaller volume if you can’t see a pellet or if the pellet 
is very small, record the volume if you add less than 500µl). Leave the tube at RT during those 48 hours.  
 
Important: Clean out centrifuge buckets and tube holders with virkon and wipe down general surfaces used. 
After DNA has dissolved 
 
Important: NEVER vortex genomic DNA as the DNA will shear!!! 
 
34. Quick spin 50 ml tubes to collect sample at the bottom of the tubes 
35. Transfer DNA from 50 ml tubes into labeled 1.5 ml cryo-nunc tubes. 
36. Rotate the nunc tubes on the rocker in the cold-room for 48 hrs before nanodropping the DNA. 
 
 
Expected Results  
Pure DNA for downstream analysis 
 
Recording and Reporting of Results 
The nanodrop data should be saved to a USB, and then saved in the appropriate project file in the DNA extraction from blood folder 
located in shares.  
 




The member of staff performing the protocol is responsible 
 
Internal Quality Assessment 
N/A 
 
Internal Quality Control 
N/A 
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Equipment at Risk 
Current control 
measures 





    
Ethanol- flammable 
 











Protection, Gloves & 










Biohazard     






Operator Standard laboratory 
practice- Gloves & 
lab coat to be worn 
 
Work carried out in 











Class 2 cabinet 
training 
Task Associated     
None 
 




    
     
 
  
 # See material safety data sheets in office filing cabinet 2C for further hazard information 
*A = Death or Major Injury, B= Injury resulting in >3 days Sick, C = minor Injury or minor damage 
1 = very likely to occur, 2 = likely to occur, 3 = could occur 
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